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Abbreviations
2AB 2-aminobenzamide
[3H] Tritium
ABC ATP-binding cassette
CDP cytidine diphosphate
CFU colony forming unit
CID collisionally induced dissociation
CPS capsular polysaccharide
CTAB hexadecyltrimethylammonium bromide
CV column volume
Dol-P dolichyl phosphate
Dol-PP dolichyl pyrophosphate
ECA enterobacterial common antigen
ELISA enzyme-linked immunosorbent assay
EPA exotoxin A of Pseudomonas aeruginosa
EPI Expanded Program on Immunization
GalNAcA N-acetylgalactosaminuronate
GalNAcAN N-acetylgalactosaminuronamide
GlcNAc N-acetylglucosamine
HPLC high-performance liquid chromatography
Ig immunoglobulin
IPTG isopropyl ȕ-D-1-thiogalactopyranoside
Kdo 2-Keto-3-deoxy-D-mannooctonic acid
LLO lipid-linked oligosaccharide
LPS lipopolysaccharide
MALDI matrix-assisted laser desorption/ionization
MDR multi-drug resistant
MS mass spectrometry
m/z mass-to-charge ratio
NTS nontyphoidal Salmonella
OD optical density
OPX outer membrane polysaccharide export
O-SP O specific polysaccharide (O antigen)
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  OST oligosaccharyltransferase
PAMPs pathogen-associated molecular patterns
PBS phasphate buffered saline
PCP polysaccharide copolymerase
RT room temperature
RU repeating unit
SCV Salmonella containing vacuole
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
Sn supernatant
SPI Salmonella pathogenicity island
TEM transmission electron microscopy
TTSS type three secretion system
UDP uridine diphosphate
Und-P undecaprenyl phosphate
Und-PP undecaprenyl pyrophosphate
VAERS Vaccine Adverse Event Reporting System
Wc whole cell
WHO World Health Organization 
7Abstract
Abstract
Various Salmonella enterica serovars can cause human diseases that 
range in severity from a mild gastroenteritis to a severe systemic 
infection known as typhoid fever. The emergence of antibiotic re-
sistance in S. enterica strains poses a major problem in treatment 
of patients in many regions of the world. Currently, two licensed 
vaccines exist, conferring protection against S. enterica serovar Ty-
phi, the causative agent of human typhoid. Unfortunately, these 
typhoid vaccines are only moderately immunogenic in infants 
and young children and revaccination is required every few years. 
Therefore, new vaccines are needed, which not only confer long-
term protection against S. Typhi but also other harmful S. enterica 
serovars.
 Conjugate vaccines are among the most effective and safe vac-
cines against bacterial diseases and have been used in humans 
for over 30 years. They are composed of an antigenic cell surface 
polysaccharide, purified from the pathogen, chemically coupled 
to a carrier protein. Several clinical trials have shown that glyco-
conjugates are promising vaccine candidates to prevent Salmonella 
infections. However, manufacturing of conjugate vaccines is a 
complex, multi-step process. An alternative approach to produce 
glycoconjugates is based on the bacterial N-linked protein glyco-
sylation system first described in Campylobacter jejuni. This pro-
tein modification system was functionally transferred into E. coli, 
enabling production of customized recombinant glycoproteins in 
vivo. In this dissertation, the possibilities of using the in vivo con-
jugation technology for production of conjugate vaccines against 
various S. enterica serovars causing human diseases were explored.
 Chemical coupling of the purified capsular polysaccharide of 
S. Typhi, known as Vi antigen, to a protein carrier resulted in a 
vaccine candidate that can be used for administration to infants 
as part of their routine immunization in endemic areas. Several 
key aspects of Vi capsule biosynthesis and its accessibility to the 
8Development of Novel Conjugate Vaccines Against Salmonella 
bacterial oligosaccharyltransferase PglB, the key enzyme forming 
the N-glycosidic linkage, remain unresolved. Therefore, a mo-
lecular characterization of the viaB locus, encoding the biosyn-
thetic machinery for Vi capsule formation, has been conducted. 
The study provides a comprehensive phenotypic analysis of single 
gene transposon insertion mutants using diverse microscopic and 
biochemical techniques. There were no indications that the Vi anti-
gen is assembled on the lipid carrier undecaprenyl pyrophosphate 
(Und-PP) and no periplasmic intermediates exist, which are both 
prerequisites for being a substrate of PglB. Therefore, polysac-
charide structures that fulfill these requirements and mimic the Vi 
were evaluated for their potential use as a typhoid vaccine com-
ponent. The E. coli O121 O antigen cluster was genetically engi-
neered, resulting in expression of an O specific polysaccharide re-
active with antibodies raised against the Vi antigen. The structure 
of the recombinantly expressed O antigen was elucidated using a 
novel HPLC and mass spectrometry based method for purified 
Und-PP-linked glycans. Glycoconjugates were produced using the 
bacterial N-glycosylation system and their immunogenicity was 
evaluated in mice. 
 Expression of the Vi capsule is largely restricted to S. Typhi. 
Other harmful S. enterica serovars express O antigens, which have 
been used as components of conjugate vaccine candidates against 
S. Paratyphi A or S. Typhimurium. These O specific polysaccha-
rides have a galactose at the reducing end in common. It has been 
reported that such glycan structures do not serve as substrates 
for PglB, because the reducing end saccharide should contain an 
acetamido group at C-2, thought to be essentially involved in ca-
talysis. Nonetheless, it was shown in this work that the O antigen 
of S. Typhimurium is transferred to acceptor proteins upon opti-
mization of recombinant PglB expression. This finding opens up 
the possibility of producing novel conjugate vaccines against Sal-
monella.
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Zusammenfassung
Infektionen mit Salmonellen können beim Menschen zu unter-
schiedlich schweren Krankheitsbildern führen die von einer un-
gefährlichen Gastroenteritis bis zu lebensbedrohendem Typhus 
reichen. Die Verbreitung von Antibiotika-resistenten Salmonellen 
Stämmen erschwert die Behandlung von Patienten massgeblich. 
Es existieren zwei Impfstoffe die gegen eine Infektion mit dem Ty-
phuserreger, Salmonella enterica Serovar Typhi, schützen. Diese 
Impfstoffe haben aber den Nachteil, dass sie bei Kleinkindern 
unwirksam sind und der Impfschutz alle paar Jahre erneuert 
werden muss. Demzufolge werden neue Impfstoffe gebraucht, 
die einen langzeitigen Schutz nicht nur gegen den Typhuserreger 
sondern auch andere gesundheitsgefährdende Salmonellen Se-
rovare vermitteln.
 Konjugierte Impfstoffe gehören zu den wirksamsten und si-
chersten vorbeugenden Massnahmen gegen bakterielle Erreger. 
Sie entstehen in einem aufwendigen chemischen Prozess, bei 
dem Antigene in Form von Polysacchariden, die vom Krankheit-
serreger isoliert werden, an Trägerproteine gekoppelt werden. 
Mehrere klinische Studien haben gezeigt, dass solche Glykopro-
teine vielversprechende Impfstoffe darstellen, die wirksam Sal-
monellen Infektionen vorbeugen können. Eine elegantere Her-
stellungsmethode beruht auf der bakteriellen Biosynthese von 
N-glykosidisch gebundenen Glykoproteinen, die zum ersten Mal 
in Campylobacter jejuni beschrieben wurde. Es wurde gezeigt, 
dass E. coli Zellen derart genetisch verändert werden können, 
dass sie massgefertigte N-glykosidisch gebundene Glykoproteine 
in vivo produzieren. In dieser Dissertation wurde diese neuartige 
Herstellungsmethode zur Entwicklung von konjugierten Impfst-
offen gegen Salmonellen angewandt. 
 Ein konjugiertes Vakzin, das durch die chemische Kopplung 
des kapsulären Polysaccharids des Typhuserregers (Vi Antigen) 
an ein Trägerprotein hergestellt wird, wurde bereits erfolgreich 
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in Kleinkindern getestet und vermittelt einen wirksamen Schutz 
gegen Typhus. Es ist jedoch fraglich, ob das Vi Antigen ein Sub-
strat der Oligosaccharyltransferase PglB, dem Schlüsselenzym 
der bakteriellen N-Glykosilierung darstellt. Verschiedene Aspek-
te der Vi Biosynthese sich noch immer unklar. Deshalb wurde 
eine molekulare Charakterisierung des viaB Lokus durchgeführt, 
welcher die biochemische Maschinerie zur Vi Kapsel Expression 
kodiert. Es wurden keine Anzeichen dafür gefunden, dass das 
Vi Antigen auf dem Trägerlipid Undecaprenyl-Pyrophosphat 
(Und-PP) aufgebaut wird. Des Weiteren wurden keine periplas-
matischen Zwischenprodukte beobachtet. Dies wären aber bei-
des Voraussetzungen an ein Substrat der bakteriellen Oligosac-
charyltransferase. In Bakterien existiert aber eine enorme Vielfalt 
unterschiedlichster Zuckerstrukturen. Einige ähneln in ihrer 
chemischen Struktur dem Vi Antigen und erfüllen auch die An-
forderungen eines Substrats von PglB. So wurde der O Antigen 
Lokus von Escherichia coli O121 genetisch modifiziert, dass die 
Zellen ein Polysaccharid exprimierten, das von Vi spezifischen 
Antiköpern erkannt wird. Mit Hilfe einer neuartigen Methode 
zur Strukturaufklärung von Und-PP gebundenen Oligosaccha-
riden wurde die Ähnlichkeit dieses veränderten O Antigens zum 
Vi Antigen nachgewiesen. Nachdem Glykoproteine mit Hilfe von 
genetisch Veränderten E. coli Zellen hergestellt wurden, wurde 
deren Immunogenität in Mäusen evaluiert.
 Die Expression des Vi Antigens ist aber beschränkt auf weni-
ge Salmonellen Serovare, darunter S. Typhi. Andere gesund-
heitsgefährdende Salmonellen Stämme exprimieren O Antigene, 
welche ebenfalls als Bestandteil von konjugierten Impfstoffen 
gegen S. Paratyphi A oder S. Typhimurium erfolgreich evaluiert 
wurden. Die Polysaccharidstrukturen dieser sehr ähnlichen O 
Antigene besitzen alle eine Galaktose am reduzierenden Ende. Es 
wurde berichtet, dass diese Zuckerstrukturen nicht durch PglB 
auf Akzeptorproteine übertragen werden können, da dem Zuck-
ermolekül des reduzierenden Endes eine N-Acetylgruppe am C-2 
fehlt, welche vermutlich essentiell im katalytischen Mechanismus 
involviert ist. In dieser Arbeit konnte gezeigt werden, dass diese 
11
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Polysaccharide dennoch durch PglB übertragen werden können. 
Dies eröffnet die Möglichkeit, neuartige konjugierte Impfstoffe 
gegen diverse krankheitsrelevante Salmonellen Serovare herzus-
tellen.
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Introduction
Nomenclature and taxonomy
of the genus Salmonella
Salmonella are enteric, Gram-negative, facultative anaerobic, rod-
shaped bacilli that are a major cause of infectious disease world-
wide. Salmonella is a genus of the large family of enterobacteriaceae 
that includes other well-known pathogens like Escherichia, Yersinia, 
Shigella and Klebsiella. The taxonomy within the genus Salmonella 
continues to evolve and is a source of considerable confusion.
 Salmonella is named after an American bacteriologist, D. E. 
Salmon, who identified the causative agent of swine fever in 1885 
(Salmonella choleraesuis). Originally, the species within the genus 
Salmonella were defined according to the disease they elicit (Sal-
monella typhimurium: typhoid fever in mice; Salmonella abortusovis: 
abort of sheep), or the geographical area where the organism was 
first isolated (Salmonella dublin, Salmonella kentucky). In 1966 F. 
Kauffman proposed that based on serologic classification deter-
mined using specific antibodies, each serovar should be considered 
as a separate species [1]. The most recent classification based on 
DNA relatedness and molecular analysis divides the genus Salmo-
nella into two species: Salmonella enterica and Salmonella bongori, 
which are further subdivided into subspecies (ssp.) designated 
with Roman numerals. Salmonella enterica (S. enterica) consists of 
six subspecies: I, S. enterica ssp. enterica; II, S. enterica ssp.salamae; 
IIIa, S. enterica ssp.arizonae, IIIb; S. enterica ssp. diarizonae; IV, S. 
enterica ssp. houtenae; and VI, S. enterica ssp. indica. Subspecies V 
represents the species Salmonella bongori. The subspecies are again 
further subdivided into serovars (serotypes) and strains (Figure 1). 
Subspecies I of Salmonella enterica comprises the medically im-
portant serovars and accounts for 99.5 % of isolated Salmonella 
strains. These serotypes are still referred to by their previous genus 
or species designation. For example, Salmonella enterica ssp. en-
14
Development of Novel Conjugate Vaccines Against Salmonella 
terica serovar Typhi continues to be referred as Salmonella typhi 
or Salmonella Typhi whereas serovars of other subspecies are des-
ignated by their antigenic formula. In this work the terminology 
Salmonella Typhi (S. Typhi) is used.
 The serovar classification system is based on the diversity of an- 
tigens present on the cell surface that can be analyzed in aggluti-
nation tests using specific antibodies. In Salmonella three differ-
ent cell surface antigens are examined: The H, O and Vi antigen 
(Figure 2).
 Almost all Salmonella serovars are motile, and express peri-
trichous flagella that bear flagellar (H) antigens. H is derived from 
the German word “Hauch” (breath) and refers to the colony mor-
Figure 1: Taxonomy of the genus Salmonella.
Salmonella is a genus of the family of enterobacteriaceae. The genus 
Salmonella is divided into two species: Salmonella enterica and Salmonella 
bongori. These species are further subdivided into subspecies, serovars (se-
rotypes) and finally strains. Subspecies I of Salmonella enterica comprises the 
medically important serovars, e.g. Salmonella enterica subspecies I serovar 
Typhi (S. Typhi).
15
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phology of motile bacteria on semisolid agar, which reminds one 
of the image that is generated by breathing on a glass surface. 
Most serotypes are biphasic, i.e. their genomes encode two differ-
ent forms of flagellar antigen whereof one is expressed on the cell 
surface, but with a low frequency the cell can switch to the expres-
sion of the other phase. In serovars capable of phase shifting both 
phases have to be determined in the classification process.
 O antigens are part of the lipopolysaccharide (LPS), found in 
the outer membrane of Gram-negative bacteria. This antigen was 
first discovered on non-motile bacteria. Therefore, the O refers 
to the German term “ohne Hauch” (without breath). The LPS 
consists of a conserved lipid part, the lipid A, the core oligosac-
charide and a highly variable repetitive glycan polymer, referred 
Figure 2. Bacterial cell surface antigens.
The serovar classification system in Salmonella is based on the examination of  
three different cell surface antigens: the H, O, and Vi antigen. The H anti- 
gen refers to the peritrichous flagella expressed by Salmonella. The O antigen 
is part of the lipopolysaccharide (LPS), found in the outer membrane of 
Gram-negative bacteria. Certain Salmonella serovars express a capsular 
polysaccharide known as the Vi antigen. The presence of the Vi capsule  
masks the subjacent O antigen and Vi positive Salmonella strains do not  
agglutinate with O specific antibodies.
16
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to as the O antigen or O specific polysaccharide (see page 45ff. 
about the biosynthesis of Salmonlla O antigens).
 The capsular polysaccharide expressed by a few Salmonella se-
rovars is known as the Vi antigen. The Vi was first associated with 
virulence because it is expressed by the important human patho-
gen S. Typhi, the causative agent of typhoid fever. The presence of 
the Vi capsule masks the subjacent O antigen and inhibits reaction 
with O specific antibodies.
 The antigenic formulae of Salmonella serovars are listed in a 
document called the White-Kauffmann-Le Minor scheme [2]. 
Today, more than 2500 different Salmonella serovars have been 
described. The vast variety of antigens found on the cell surface of 
the pathogen possibly indicates that diversification was driven by 
immune selection.
Evolution and host adaption 
of Salmonella serovars
Different bacterial isolates of the genus Salmonella not only show 
a great variability of cell surface antigens but also differ in terms 
of host adaption and virulence potential. During evolution Sal-
monella spp. have adapted to colonize many different niches and 
hosts. They can be found as commensals and pathogens in a wide 
range of cold and warm-blooded animals. Bäumler et al. wrote: 
“Studying the evolution of host adaption and understanding the 
strategies, which a pathogen develops to resist the host’s immune 
system, is also fundamental in understanding both the origin of 
infectious disease and the emergence of new pathogens” [3].
 It is estimated that the genus Salmonella has diverged from Es-
cherichia coli around 100 million years ago. During the evolution of 
virulence Salmonella spp. have acquired several large genomic in-
sertions by horizontal gene transfer. These insertions, also known 
as Salmonella pathogenicity islands (SPI), encode genes important 
for virulence and survival in the host. SPI possess a G+C content, 
which differs from that of the genomic backbone and they are of-
17
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ten integrated at tRNA gene sites. The acquirement of complex 
virulence modules by horizontal gene transfer dramatically accel-
erates the evolution of pathogenicity and it is referred to as evolu-
tion in quantum leaps [4]. It was postulated that the virulence in 
the genus Salmonella evolved in three phases [3]:
1  The first phase involved the acquisition of the Salmonella path-
ogenicity island 1 (SPI1) by horizontal gene transfer. SPI1 is 
found in all phylogenetic lineages of the genus Salmonella but 
is absent from the chromosome of Escherichia coli. SPI1 en-
codes a type-III secretion system (TTSS), which is a complex, 
needle-like molecular apparatus that is structurally related to 
the bacterial flagellum. By means of the TTSS, bacteria can 
directly inject a cocktail of virulence proteins (effectors) from 
the bacterial cell cytoplasm into the host cell. In the host cell 
cytoplasm the effectors interfere and modulate signaling path-
ways. The SPI1 encoded TTSS is used during the intestinal 
phase of infection and mediates invasion into non-phagocytic 
cells, triggering of proinflammatory cytokine production and 
induction of cell death of host phagocytes [5,6].
2  The second phase of evolution represents the formation of 
the two Salmonella species Salmonella enterica and Salmonella 
bongori. The divergence of the Salmonella lineages is character-
ized by the acquisition of the Salmonella pathogenicity island 
2 (SPI2), which is only found in the chromosome of Salmo-
nella enterica. The SPI2 encodes a second TTSS, which is used 
during the systemic phase of infection and the colonization 
of deeper tissues. Recently it has been shown, that the SPI2 
encoded TTSS is involved in pathogen traffic to the basolat-
eral side and exit into the lamina propria once the bacteria has 
invaded epithelial cells [7].
3  The differentiation of Salmonella enterica into the distinct phy-
logenetic subspecies reflects the third phase of virulence evo-
lution. This phase is characterized by a dramatic expansion in 
18
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host range. Whereas Salmonella bongori and Salmonella enterica 
subspecies II, IIIa, IIIb, IV, VI are mainly associated with cold-
blooded vertebrates, S. enterica ssp. I expanded its host range 
to warm-blooded vertebrates.
A new barrier encountered by S. enterica ssp. I serovars was the 
immune system of higher vertebrates, which is higher developed 
and comprises peripheral lymphoid filter organs, the lymph nodes. 
New strategies had to be developed by the pathogen to adapt to 
these systems of host defence. 
 Distinct serovars of S. enterica ssp. I are differently well adapt-
ed to a specific host. For example, S. Typhi is only isolated from 
humans, whereas S. Typhimurium is found to have a broad host 
range and is associated with infections not only in humans but 
many other warm-blooded vertebrates. In most cases, the human 
immune system can successfully limit bacterial expansion of S. 
Typhimurium to the intestine and the gut associated lymphoid 
system. In contrast, the human restricted serovar S. Typhi causes 
the systemic infection, known as typhoid fever. Furthermore, host 
specific serovars like S. Typhi have acquired the ability to infect 
full-grown animals, whereas broad host range serovars tend to be 
more frequently associated with disease in young animals, indicat-
ing that they are not fully adapted to the fully mature immune sys-
tem. Additionally, host specific serovars tend to be more virulent. 
For example, typhoid fever results in mortality rates of 10–20 % in 
the preantibiotic era, whereas human illness caused by the broad 
host range serovar S. Typhimurium or S. Enteritidis causes death 
in only 0.5 % of the cases [8]. It has been proposed that pathogens 
causing high mortality rates are not well adapted to their hosts, 
because they destroy their habitats and reduce their transmissi-
bility. Less virulent forms should therefore be preferably selected 
during evolution. However, the opposite has been observed for the 
evolution of S. Typhi and the question arose what selective forces 
were responsible for the increase of virulence that accompanied 
the adaption of S. Typhi to humans [3]. It has been noticed that 
patients recovering from typhoid fever more frequently become 
19
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chronic carriers as compared to patients with nontyphoidal Sal-
monellosis. A chronic, asymptomatic carrier has the potential to 
infect many other individuals, thereby increasing the transmissibil-
ity of the pathogen. Therefore, this mechanism seems to represent 
the evolutionary pressure on development towards a higher degree 
of virulence.
 The host restriction of S. Typhi might have evolved through 
loss of gene function. The S. Typhi genome possesses around 204 
pseudogenes, i. e. genes that have been inactivated by mutations 
[9], including several that play a role in virulence in S. Typhimu-
rium. In the broad host range pathogen S. Typhimurium only 39 
pseudogenes are found. The inactivation of genes responsible for 
host interaction might explain the host restriction of S. Typhi, 
which is not seen in other serovars.
Salmonella infections: 
pathogenesis and disease 
Salmonella infections are an important public health problem 
worldwide and it has been estimated that this pathogen is respon-
sible for 3 billion human infections each year. It is important to 
note that infection by different Salmonella serotypes can result 
in diverse clinical syndromes. The disease manifestation elicited 
upon interaction between the pathogen and the host is not only 
dependent on the serotype, but also on the host species, infect-
ing dose, immunologic competence and the gut flora. In humans, 
the disease pattern caused by Salmonella infections can be divided 
into typhoid fever (enteric fever) and non-typhoidal salmonello-
sis (NTS). Typhoid fever is a systemic infection, most commonly 
caused by the human restricted serovars S. Typhi and S. Paratyphi. 
On the other hand, non-typhoidal salmonellosis is a gut-associated, 
self-limiting gastroenteritis, which in developed countries is mostly 
caused by S. Typhimurium and S. Enteritidis [10]. Non-typhoidal 
Salmonella serovars have a broad host range and are frequently 
zoonotic. However, NTS serovars have emerged as a major cause 
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of invasive bacterial bloodstream infections in sub-Saharan Africa, 
amongst children with malaria and malnutrition, and amongst 
HIV-infected adults (reviewed in [11]). S. Typhi and S. Paratyphi 
colonize only in humans and infections are mostly acquired from 
water or food contaminated with human feces. In the following 
sections the pathogenesis of Salmonella infection and the resulting 
human diseases are described.
Pathogenesis
A general characteristic of Salmonella serovars is the ability to in-
vade and persist in host cells. They are well adapted to an intra-
cellular lifestyle and can even survive in macrophages and other 
immune cells. 
 Susceptible hosts typically ingest the pathogen orally in contam-
inated food and water. The dose of ingested bacilli greatly influenc-
es the onset of the disease. Volunteer studies with S. Typhi showed 
that subjects who ingested 103 organisms did not develop illness 
whereas doses of 105 and 109 caused typhoid fever in 28–55 % and 
98 % of the volunteers respectively [12]. The low pH environment 
of the stomach, which the ingested organisms encounter first, rep-
resents an initial barrier to infection. Conditions that increase the 
gastric pH, decrease the infectious dose [13]. However, Salmonella 
have an adaptive acid tolerance response, which enables the organ-
ism to withstand acidic conditions also found in the phagosomal 
vacuole encountered in a later step of pathogenesis [14].
 The epithelial barrier in the intestine forms the next barrier that 
is met by Salmonella during infection. The bacteria can breach the 
epithelial barrier by different mechanisms to arrive in the lamina 
propria. Salmonella are regarded as invasive bacteria and as men-
tioned on page 16ff. , Salmonella enterica subspecies possess two 
Type III secretion systems encoded in SPI-1 and SPI-2 (TTSS-1, 
TTSS-2). The TTSS is a complex, needle-like molecular appara-
tus, which enables the bacterium to inject a cocktail of virulence 
proteins (effectors) into the host cell [15]. In the host cell these ef-
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fector proteins interfere and modulate signalling pathways induc-
ing amongst other things profound cytoskeletal rearrangements. 
This cytoskeletal remodeling drives localized membrane ruffles, 
that reach out and enclose adherent bacteria, triggering their inter-
nalization into membrane bound vacuoles [16]. The SPI-1 encod-
ed TTSS and effector proteins are essential for invasion into non-
phagocytic cells. Besides triggering their internalization, Salmonella 
spp. can also be actively taken up by lamina propria phagocytes or 
by microfold cells (M cells). The former were shown to protrude 
thin, arm-like extensions across the epithelium into the intestinal 
lumen thereby establishing another route of entry. M cells are spe-
cialized epithelial cells that sample intestinal antigens and transport 
these antigens to lymphoid cells in the underlining Peyer’s patches. 
After entering M cells Salmonella can manipulate signalling path-
ways and induce for example apoptosis [17]. After the crossing 
of the epithelial M cells, Salmonella can access lymphoid cells. An 
additional invasion mechanism might involve paracellular traffic 
through the manipulation of tight junctions [18]. In a natural infec-
tion it is likely that Salmonella exploits a combination of different 
invasion strategies.
 It remains equivocal, which host cell functions are hijacked 
by the pathogen, resulting in transcellular migration and exit into 
the lamina propria. However, it has recently been shown in the 
mouse model for S. Typhimurium-induced enterocolitis, that the 
pathogen requires the type-III secretion system encoded on SPI-2 
(TTSS-2) for transepithelial traffic to the basolateral site of the cell 
where the pathogen is released by exocytosis [7].
 Once the pathogen has reached the lamina propria Salmonella 
encounter another obstacle of innate immunity, the submucosal 
phagocytes. In addition to the invasion of non-phagocytic cells, the 
ability to survive and replicate in host cells represents a further 
feature of Salmonella pathogenesis. The TTSS-2 and its effectors 
are fundamental to the intracellular lifestyle. In contrast to other 
facultative intracellular pathogens like Shigella spp. and Listeria 
monocytogenes, Salmonella spp. do not enter the cytoplasm but re-
main in the phagosomal vacuole. They can inhibit the maturation 
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of the phagosome, thereby forming a Salmonella containing vacu-
ole (SCV). By this mechanism the pathogen generates a protected 
niche where it can survive and replicate.
 In addition to invasion of the intestinal epithelial cell layer, 
non-typhoidal Salmonella serotypes induce a local inflammatory 
response, provoking recruitment and transmigration of polymor-
phonuclear leukocytes, including neutrophils, to the intestinal lu-
men and diarrhea. The pathogen exploits inflammation to compete 
with the intestinal microbiota and overcome colonization resistance 
[19]. However, infections with the human restricted serotypes S. 
Typhi or S. Paratyphi result in a systemic spread of the pathogen. 
Little is known about the mechanism that allows typhoidal Salmo-
nella serotypes to become systemic whereas NTS are mostly re-
stricted to the intestine in immunocompetent individuals. It seems 
that S. Typhi remains relatively undetected by the immune system 
during the invasion of the tissue, which is also characterized by the 
general lack of polymorphonuclear leukocyte influx. There is some 
evidence that the capsular polysaccharide expressed by S. Typhi, 
the Vi antigen, has anti-inflammatory properties by masking path-
ogen-associated molecular patterns (PAMPs) and by suppressing 
early inflammatory responses in intestinal epithelial cells [20,21]. 
The survival of S. Typhi in macrophages is essential for efficient 
systemic infection. Migration of infected phagocytes to other or-
gans of the reticuloendothelial system facilitates dissemination of 
bacteria in the host. S. Typhi resides within cells throughout the or-
gans of the reticuloendothelial system during an incubation period 
of 8–14 days. After that period the bacteria are released from this 
sequestered intracellular habitat and the onset of clinical typhoid 
fever is accompanied by a sustained bacteremia. In the bacteremic 
phase, the organism is widely disseminated.
 Another important characteristic of S. Typhi is the predilection 
of the pathogen to reach the gallbladder. Gallbladder infection be-
comes chronic in up to 6 % of infected individuals [22]. S. Typhi 
persists in these healthy carriers over long periods in the absence of 
clinical symptoms. These asymptomatic S. Typhi carriers are a key 
reservoir of typhoid infections.
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Typhoid fever
Causative agent and Epidemiology
Typhoid fever remains a serious public health problem of which 
there are 22–33 million cases occurring each year, including about 
216’000–500’000 deaths [23]. However, it is difficult to quantify 
the number of typhoid fever incidences, because the clinical symp-
toms can be confused with other febrile illnesses and detailed bac-
teriological and serological diagnosis are often not available in en-
demic areas. The causative agent of this human systemic infection 
is S. Typhi. S. Paratyphi, mainly S. Paratyphi A or B (infections 
with S. Paratyphi C are rare), cause paratyphoid fever, which is 
clinically indistinguishable from typhoid fever. Typhoid and para-
typhoid fevers are referred to as enteric fevers. Typhoid fever ac-
counts for > 75 % of the clinical cases in endemic regions whereas 
paratyphoid fever accounts for the rest. However, in certain re-
gions where typhoid vaccination programs are ongoing a decline 
in S. Typhi incidences was observed with a concomitant rise in S. 
Paratyphi infections.
 S. Typhi and S. Paratyphi express several cell surface anti-
gens. Besides the flagellar (H) antigen and the lipopolysaccha-
ride (LPS) O antigen S. Typhi and S. Paratyphi C also express 
a capsular polysaccharide known as the Vi antigen. The presence 
of the Vi antigen prevents binding of O specific antibodies to the 
O antigen.
 S. Typhi and S. Paratyphi are human restricted pathogens and 
therefore humans, i.e. short term and chronic carriers, are the 
sole reservoir. The infection is orally transmitted through water 
and food that has been contaminated with human fecal material. 
The occurrence of typhoid fever correlates to the availability of 
sewage treatment infrastructure and the quality of water supply. 
Hence incidences of typhoid fever drastically dropped in Europe 
and the United States in the 20th century with the introduction 
of water treatment. Today, typhoid fever remains endemic in less-
developed countries, where sanitary conditions remain poor. This 
includes many countries in Africa, Asia, and South America. 
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 In most endemic areas, the peak incidence of typhoid fever 
is typically observed in schoolchildren and young adults (5–19 
years). In children younger than 2 years of age, infections with S. 
Typhi are often unrecognized because of atypical clinical symp-
toms and difficulties of confirmation of the diagnosis due to the 
volume of blood that can be drawn for culture. However, in newer 
surveys using active surveillance methods a high incidence of ty-
phoid fever was observed in young children two to four years of 
age [24,25].
Clinical course of typhoid fever
The clinical course and severity of typhoid fever varies greatly 
between different patients. Important factors that determine the 
clinical manifestations of the disease are the age and the immuno-
logic competence of the patient. Additionally it seems important 
whether the patient has grown up in an industrialized country or 
in a country where typhoid fever is endemic. Travelers or military 
personnel from industrialized countries who visit endemic areas 
are especially at risk. These groups lack a certain background im-
munity, which the indigenous population acquired through con-
stant contact with the pathogen, often in doses that were not suf-
ficient for developing typhoid fever.
 The onset of the disease, which corresponds to the bacteremic 
phase, begins typically after an incubation time of 8–14 days. Clas-
sic cases begin with influenza-like symptoms with malaise, chills, 
anorexia, myalgia, abdominal discomfort, headache and fever that 
increases to reach 39–41 °C. A dry cough is also common in the 
early stages of illness. Adults often have constipation whereas di-
arrhea may occur in young children. Abdominal symptoms are 
usually rare in patients. Initially, the fever is low but rises in a step-
wise manner by daily increments of 0.5–1 °C. By the second week 
a sustained fever of 39–41 °C is present. Without any treatment 
the fever remains at this level for 10–14 days. During the period 
of high fever, 5–30 % of the patients manifest rose spots, which 
are skin lesions approximately 2–4 mm in diameter and localized 
on the abdomen and chest and more rarely on the back, legs and 
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arms. S. Typhi can be cultured from rose spots [26]. Occasion-
ally, cerebral dysfunction including delirium, coma and shock are 
observed in severe cases of typhoid fever. With convalescence, the 
fever decreases also in a stepwise fashion.
 Complications occur often in patients that have been ill for 
more than two weeks. The most feared complications are gastro-
intestinal bleeding, intestinal perforation and typhoid encepha-
lopathy. In up to 6 % of patients with typhoid fever the gallbladder 
infection becomes chronic. These individuals are asymptomatic 
carriers and therefore an important reservoir of the human re-
stricted pathogen.
 Immunity that follows clinical infection with pathogenic S. Ty-
phi is relative and can be overcome [27]. Volunteer studies have 
shown that prior infection with S. Typhi induced immunity that 
modestly protected against subsequent challenges with virulent 
bacteria. A study carried out by DuPont et al. [28] showed that the 
protective effect of a prior infection was only 33 %.
Treatment and emergence 
of antibiotic resistant strains
Before the discovery of antibiotics, typhoid fever had a case-fa-
tality rate of 10–20 % and hence was a much-feared disease. In 
1948 it was found that chloramphenicol can successfully be used 
to treat typhoid fever [29]. After the introduction of antibiotics 
the case fatality dropped to well below 1 %. However, in the early 
1970s antibiotic resistance emerged in S. Typhi and the treatment 
of typhoid fever with chloramphenicol became increasingly inef-
fective. Outbreaks with chloramphenicol resistant strains occurred 
in Mexico, India, Vietnam, Thailand, Korea, and Peru [30]. The 
resistance to chloramphenicol was often encoded in combination 
with resistance to streptomycin, sulfonamides, and tetracycline by 
a self-transferable plasmid of the H1 incompatibility group. At the 
beginning of the 1990s, S. Typhi strains emerged with resistance 
to all first line antimicrobials used at that time, like chlorampheni-
col, trimethoprim, sulfamethoxazole, and ampicillin. The resistant 
genes of these multi-drug resistant (MDR) strains were also en-
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coded on the IncH1 plasmid and MDR strains disseminated 
throughout Asia and northeast Africa.
 In 1962, the quinolone derivative, nalidixic acid was discovered. 
The subgroup of fluoroquinolones, containing a fluorine atom at-
tached to the quinolone framework, has a greater antimicrobial 
activity and represents the majority of quinolones used clinically. 
Quinolones and fluoroquinolones are a group of synthetic antibi-
otics that target the DNA gyrase and topoisomerase in bacteria 
and thereby inhibit the transcription and replication of the bacte-
rial DNA. Today, fluoroquinolones (e.g. ciprofloxacin, ofloxacin, 
fleroxacin, pefloxacin) are the most efficient drugs used for the 
treatment of typhoid fever [31,32]. But the emergence of nalidixic 
acid resistant S. Typhi isolates and strains with reduced suscepti-
bility to fluoroquinolones have become a major problem in Asia 
[32]. Resistance in S. Typhi is usually associated with single point 
mutations in the DNA gyrase gene gyrA, typically in the quinolone 
resistance-determining region.
 Full fluoroquinolone resistant S. Typhi strains are still rare and 
other antibiotics like azithromycin or the cephalosporins are the 
drugs of choice to cure typhoid fever caused by these multidrug 
resistant strains. A drawback of these antibiotics is that they are 
relatively expensive and not readily available in rural areas of less 
developed countries. In areas where quinolone resistant strains are 
uncommon, fluoroquinolones are the favored antibiotics and inex-
pensive antibiotics, like chloramphenicol, amoxicillin, and trimeth-
oprim-sulfamethoxazole are still used for the treatment of typhoid 
fever caused by S. Typhi strains fully susceptible to these antibiot-
ics [32]. Fluoroquinolones are also the favored antibiotic to cure 
chronic carriers, i.e. patients with chronic gallbladder infections. 
Before this class of antibiotics was available, the infected gallblad-
der was surgically removed (cholecystectomy) [27].
 The cost of the treatment is the critical factor in developing 
countries. The emergence of resistance in S. Typhi to widely used 
antibiotics and the necessity to use more expensive antimicrobials 
therefore poses a major problem in treatment of patients in many 
regions of the world.
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Typhoid vaccines
The development of vaccines against typhoid fever was temporar-
ily neglected because of the availability of inexpensive oral anti-
biotics. The emergence of S. Typhi strains with resistance to all 
oral antibiotics at the beginning of the 1990’s led to an increase 
in typhoid mortality and also to an increased need for efficacious 
vaccines that can be included in broad immunization programs. 
 Regarding the pathogenesis of a S. Typhi infection, a protec-
tive role is probably played by secretory immunoglobulin A (IgA) 
(preventing the invasion of the intestinal epithelium), circulating 
antibodies (preventing the spreading during the bacteremic phase) 
and cell-mediated immunity (eliminating intracellular bacteria). 
Oral and parenteral vaccines have been developed that show sig-
nificant protection by either eliciting a strong secretory intestinal 
IgA and cell-mediated immunity (oral route) or a predominant 
circulating antibody response (parenteral route). Until today there 
is no agreement on the critical antigens responsible for protection 
and variable cell surface structures might be exposed during the 
different phases of pathogenesis.
 Populations that are at particularly high risk of developing ty-
phoid fever would benefit from a vaccine. These include school-
age children from countries where typhoid fever is endemic, 
travelers and military personnel from industrialized countries who 
are visiting endemic areas, and microbiology technicians in clinical 
laboratories working with S. Typhi.
 Typhoid vaccines were already developed in 1896 in Germany 
and England [33,34]. These early vaccines consisted of killed and 
preserved S. Typhi bacilli that were usually injected subcutaneous-
ly (parenteral whole cell vaccines). Different methods of inacti-
vating S. Typhi without destroying important cell surface epitopes 
have been tested. A heat-inactivated, phenol preserved whole cell 
parenteral vaccine is currently still licensed and was produced 
by Wyeth up through the 1990’s for the U.S. Army. Because of 
frequent, severe adverse effects of this form of typhoid vaccine 
nearly all manufacturers stopped production. The other currently 
licensed, available and used vaccines are the purified Vi polysac-
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charide parenteral vaccine and the attenuated strain Ty21a, which 
is used as a live oral vaccine. These two vaccines are more closely 
described in the following sections. 
Purified Vi polysaccharide parenteral vaccine S. Typhi 
expresses a capsular polysaccharide known as Vi antigen (Vi). Vi 
is a linear, acidic homopolymer of Į-1,4-linked N-acetylgalactosa-
minuronate (D-GalNAcA), variably O-acetylated at C-3 (biosyn-
thesis of Vi is more closely described on page 43f.). The O-acetyl 
groups make up most of the surface and immunogenicity of Vi is 
closely related to the degree of O-acetylation [35,36]. In a mod-
ern purification procedure the polysaccharide is extracted from 
S. Typhi culture supernatant using hexadecyltrimethylammonium 
bromide, which preserves the important O- and N-acetyl groups. 
Earlier purification strategies resulted in partially de-acetylated 
and therefore less immunogenic Vi.
 The purified Vi vaccine is produced by Sanofi Pasteur MSD 
(Typhim Vi®), GlaxoSmithKline (Typherix®) and several other 
manufacturers. The Vi vaccine is not protected by patent rights. 
Hence, the production technology can be easily transferred to 
manufacturers in countries where typhoid fever is endemic. These 
locally produced Vi vaccines are available at lower prices as com-
pared to imported vaccines. An immunizing dose consists of 25 
µg or 30 µg of Vi polysaccharide in 0.5 ml of isotonic buffer. The 
vaccine is usually administered as a single subcutaneous or intra-
muscular injection.
 Besides the route of administration, number of doses required, 
vaccine stability is another important parameter. Especially for 
vaccines that are used in broad vaccination programs in the de-
veloping world, where the cold chain cannot be guaranteed. The 
purified Vi polysaccharide vaccine is highly stable and it retains its 
physicochemical characteristics even after 6 months’ storage at 37 
°C [27]. Nevertheless, manufacturers recommend that the vaccine 
is stored at 2–8 °C.
 Clinical studies in several endemic and nonendemic countries 
have shown that the purified Vi vaccine elicits serum IgG Vi anti-
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body responses in adults and children older than 2 years [37-42]. 
The usefulness of the Vi polysaccharide vaccine is limited by the 
fact that immune responses against polysaccharide antigens do not 
involve T-cells. Therefore, Vi is not a good immunogen in infants 
(< 2 years), immunological memory cannot be established, and 
revaccination does not elicit any booster effect [40,41].
 Large field trials conducted in Nepal, South Africa and China 
with a single dose of 25 µg (30 µg in China) of Vi polysaccharide 
demonstrated a vaccine efficacy of 64–72 % [37,38,43]. However, 
the duration of protective efficacy lasted only for 2–3 years [44], 
which implies that revaccination has to occur every 3 years.
 Proteins involved in Vi capsule formation are encoded within 
a DNA island, termed Salmonella pathogenicity island 7 (SPI-7) 
[45]. Precise excision of the SPI-7 in Vi-negative mutants has been 
demonstrated, indicating that Vi antigen expression is located on 
a unstable region in the S. Typhi genome [46]. The presence of 
the Vi capsule is not essential for infection, as Vi-negative S. Typhi 
have been reported to cause outbreaks of typhoid fever [12,47-49]. 
It is unlikely that a Vi vaccine protects against Vi-negative S. Typhi 
and concerns have been raised, that the widespread use of the pu-
rified Vi polysaccharide vaccine might select for such strains.
 The Vi vaccine is well tolerated and post-marketing surveillance 
from the Vaccine Adverse Event Reporting System (VAERS) of 
the USA reported an overall rate of 4.5 adverse events per 100’000 
doses [50].
Ty21a live oral vaccine Ty21a is an attenuated S. Typhi 
strain used as a live oral vaccine and is derived from the wild-type 
strain Ty2 by nitrosoguanidine-induced mutagenesis. This mutant 
strain does not express the Vi antigen, shows no activity of the en-
zyme uridine diphosphate (UDP)-galactose-4-epimerase (GalE), 
and possesses a reduced activity of the enzymes galactokinase 
(GalK) and the galactose-1-phosphate uridyl transferase (GalT) 
[51]. These mutations in the galactose operon lead to a defect in 
sugar metabolism. Ty21a cannot convert UDP-glucose to UDP-
galactose and vice versa due to the non-functional GalE. The nu-
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cleotide activated galactose is the donor substrate for galactose in-
corporation into the outer core and the O antigen (described on 
page 45ff.) of the S. Typhi lipopolysaccharide (LPS). Therefore, 
when grown in the absence of galactose, Ty21a does not express 
the O antigen because no UDP-galactose is synthesized. In the 
presence of exogenous galactose, the galactokinase (GalK) and the 
galactose-1-phosphate uridyl transferase (GalT) convert galactose 
to UDP-galactose and the O antigen is assembled. Besides being 
incorporated into the LPS, UDP-galactose cannot be further me-
tabolized because of the lack of the epimerase GalE. Therefore, 
Ty21a accumulates galactose-1-phosphate and UDP-galactose 
when grown in the presence of exogenous galactose, which again 
after reaching a critical concentration leads to cell instability and 
cell lysis [51,52]. In the production process of Ty21a, galactose is 
included in the medium to ensure that the O antigen is expressed 
which leads to a protective vaccine whereas the O antigen negative 
version is not [53].
 However, the mutations in the galactose operon and the Vi-
negative phenotype do not account for the attenuation of Ty21a. 
Construction of a Ty2 derivative containing defined deletions in the 
galE gene and the Vi biosynthetic gene cluster resulted in a strain 
that retained virulence in humans [47]. Two dozen additional mu-
tations were identified in Ty21a compared to its wild-type parent 
[54], that were also introduced by the nonspecific chemical mu-
tagenesis approach. Several of these mutations contribute signifi-
cantly to the safety of this live oral vaccine, like the mutation identi-
fied in rpoS [55]. rpoS encodes an RNA polymerase sigma factor 
(sigma s), which is a central regulator of the general stress response.
 The live oral vaccine Ty21a (Vivotif®) is manufactured by 
Berna Biotech (now Johnson & Johnson). The vaccine is produced 
as an enteric-coated capsule containing 2–6 x 109 colony forming 
units of Ty21a and 5–50 x 109 nonviable Ty21a in a lyophilized 
form. The capsules should be ingested on an empty stomach, fol-
lowing a three-dose or four-dose (recommended in Canada and the 
United States) immunization schedule with an interval of 2 days 
between doses. 
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 The Ty21a vaccine should be stored at 4 °C and is therefore 
dependent on the perpetuation of the cold chain. Storage at el-
evated temperatures results in a lower number of viable cells and 
therefore in a decreased potency of the vaccine.
 As previously mentioned, the Ty21a attenuated S. Typhi strain 
does not express the Vi antigen. Therefore no Vi specific immune 
response is raised. However, the vaccine elicits a serum IgG O 
antigen specific antibody response and it has been shown that se-
roconversion of O antibodies correlates with protective efficacy 
[56]. Furthermore vaccination with Ty21a results in mucosal IgA 
and systemic cell-mediated immune responses against H and O 
antigens.
 Several field trials in Santiago, Chile were conducted which in-
volved around 532’000 children between 6 and 19 years of age. 
The following findings resulted from these trials: (i) three doses 
of the enteric-coated vaccine formulation (every other day interval 
between doses) provided 67 % efficacy for 3 years and over 7 years 
of follow-up Ty21a conferred 62 % protection [57]; (ii) one or two 
doses of the enteric-coated Ty21a vaccine resulted in moderate, 
short lived protection [58]; (iii) four doses of the enteric-coated 
capsules resulted in a significant lower incidence of typhoid fever 
compared to the three-dose immunization schedule [59]. Based on 
this finding the four-dose immunization schedule is recommend-
ed in the United States and Canada. Furthermore, trials with the 
enteric-coated vaccine showed that young children are not as well 
protected as older children. It is recommended that the vaccine is 
administered to children older than 6 years of age and that revac-
cination should occur every 5 years.
 The Ty21a vaccine is well tolerated and adverse events are un-
common. Post-marketing surveillance from VAERS reported an 
overall rate of 9.7 adverse events per 100’000 doses of distributed 
Ty21a.
New generation vaccines In most endemic areas, the peak 
incidence of typhoid fever is typically observed in schoolchildren 
and young adults between 5 and 19 years of age. This would make 
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it possible to design school-based immunization programs in the 
developing world using the currently licensed vaccines to control 
typhoid fever. However, health authorities declined the initiation of 
such school-based vaccination programs because it would deduct 
scarce resources from the Expanded Program on Immunization 
(EPI). The EPI is a World Health Organization (WHO) program 
with the objective to vaccinate children throughout the world and 
which in developing world focuses mainly on infants less than 12 
months of age [27]. Unfortunately, Ty21a and the purified Vi vac-
cines are only moderately immunogenic in infants and young chil-
dren and the immunity elicited would not protect for the years 
later when the children reach the high-risk years of their lives. New 
typhoid vaccines that are well tolerated, highly immunogenic in 
infants, and confer a long term protection would be very benefi-
cial to include in the EPI. New typhoid vaccine candidates are de-
scribed in the following sections.
New attenuated strains of S. Typhi as live oral vaccines 
The licensed live oral vaccine Ty21a is only modestly immuno-
genic and requires three to four initial doses and boosters every 
5 years. Furthermore the mutations that attenuate Ty21a are not 
fully defined [47]. Several attempts have been undertaken to en-
gineer new candidate vaccine strains that are as well tolerated as 
Ty21a but much more immunogenic, so that a single dose will 
elicit long-term protective immunity. 
 The availability of the sequence of the complete genomes of 
wild-type S. Typhi strain Ty2 and CT18 has greatly facilitated the 
construction of defined genomic mutations using recombinant 
DNA technology. It became evident, that the choice of the par-
ent wild-type strain greatly influences the characteristics of the 
derived attenuated vaccine strain. The same mutation in distinct 
strain backgrounds can have different clinical outcome. To study 
the attenuating potential of various genomic mutations, S. Typh-
imurium strains have been constructed harbouring these muta-
tions and their virulence was tested in the mice model. However, 
the phenotype of attenuated S. Typhimurium strains in mice does 
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not exactly reflect the behaviour of the homologous S. Typhi strain 
in humans. The common strategy to engineer a candidate attenu-
ated vaccine is to inactivate genes encoding biochemical pathways, 
regulatory systems, stress proteins and virulence factors. Based on 
the results obtained in clinical trials, the most promising vaccine 
candidates are shortly described below.
 CVD908-htrA is a derivative from the parent strain CVD908 
which harbors precise deletion mutations of aroC and aroD in the 
Ty2 background [60,61]. AroC and aroD are genes encoding en-
zymes in the aromatic amino acid biosynthesis pathway. Therefore, 
the auxotrophic S. Typhi mutant is dependent on certain meta-
bolic intermediates that are only present in a very low concentra-
tion within the host cell. As the name implies, strain CVD908-htrA 
additionally harbors a deletion mutation of htrA, which is a stress 
protein required by many bacterial pathogens to successfully cause 
infection. HtrA deals with misfolded proteins in the periplasm and 
it has been shown that an htrA mutant of S. Typhimurium is great-
ly attenuated in mice [62]. In clinical trials CVD908-htrA was im-
munogenic and well tolerated, although some adverse effects like 
mild diarrhea were observed [63-65].
 CVD909 is a derivative of CVD908-htrA that constitutively 
expresses the Vi antigen. The licensed live attenuated strain Ty21a 
lacks the Vi capsular polysaccharide and other live attenuated vac-
cine candidates, although they express the Vi in vitro, did not elicit 
a Vi specific immune response. However, the purified Vi polysac-
charide and the Vi-rEPA conjugate vaccine (described on page 
34ff.) stimulate serum Vi antibodies that confer protection against 
typhoid fever. Therefore it was hypothesized that a live oral vac-
cine that is able to stimulate serum Vi antibodies could confer 
higher levels of protection. Expression of the Vi polysaccharide is 
highly regulated and it is linked to environmental signatures such 
as osmolarity [66]. CVD909 was constructed by replacing the 
promoter of the Vi biosynthetic operon, viaB, by a strong consti-
tutive promoter. This resulted in constitutive expression of the Vi 
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antigen [67]. A Phase I clinical study showed that CVD909 is well 
tolerated, but it did not consistently stimulate serum IgG anti-Vi 
antibodies However, higher dosages elicited mucosal IgA anti-Vi 
responses [68].
 Ty800 is a phoP and phoQ deletion mutant of Ty2 [69]. In a 
Phase II clinical trial the vaccine candidate was well tolerated and 
stimulated serum and mucosal anti-LPS antibody responses.
 M01ZH09 harbors deletion mutations in aroC and ssaV that 
were introduced into the wild-type strain Ty2 [70]. SsaV is a com-
ponent of the type III secretion system encoded on the Salmonella 
pathogenicity island 2 (SPI 2), which plays a role in systemic in-
fection and survival in macrophages. Mutations in ssaV result in 
the inability to translocate SPI 2 effector proteins. This vaccine 
candidate was tested in several dose-ranging trials to evaluate its 
immunogenicity and to optimize its formulation. The vaccine was 
well tolerated with only minor adverse effects. 14 of 15 volunteers 
who ingested a single dose of 109 CFU exhibited rises in antibody 
secreting cells making IgA anti-LPS antibodies. A ≥ 4-fold in-
crease in serum IgG anti-LPS antibodies was observed in 11 of 
15 recipients [71]. A phase II study was conducted in Vietnamese 
children 5 to 14 years of age and M01ZH09 proved to be safe and 
immunogenic in this study group.
Vi conjugate vaccine: Vi-rEPA Purified polysaccharide vac-
cines are T-cell independent antigens that do not induce a booster 
response upon revaccination, and are poor immunogens for young 
children and infants. Furthermore, T-independent antigens do not 
establish immunological memory and reinjections are recommended 
every 3–5 years. These disadvantages can be overcome by conjugat-
ing the polysaccharide to a protein carrier. When the polysaccharide 
is conjugated to a protein it behaves like a T-cell dependent antigen. 
This strategy has been successfully applied in the development of 
several licensed conjugate vaccine against Haemophilus influenza type 
B (Hib), pneumococcal, and meningococcal infections [72-76]. 
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 As with these other conjugate vaccines the deficiencies of the 
purified Vi polysaccharide vaccine were overcome by conjugating 
the capsular sugar of S. Typhi to carrier proteins. Szu and col-
leagues at the National Institute of Health developed a Vi conju-
gate vaccine candidate for clinical trials consisting of the purified 
Vi polysaccharide covalently linked to recombinant toxoid variant 
of exoprotein A (rEPA) of Pseudomonas aeruginosa, designated as 
Vi-rEPA [77]. Vi-rEPA was prepared by treating the carrier protein 
with adipic acid dihydrazide (ADH) and binding of Vi in the pres-
ence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). 
In animal models it was established that conjugates prepared with 
the native Vi polysaccharide elicited higher Vi antibody titers than 
conjugates containing lower molecular weight Vi [78] and that re-
vaccination clearly boost the serum Vi antibody titer. 
 A dose of the Vi-rEPA conjugate contained 25 µg of Vi poly-
saccharide and around the same amount of protein in 0.5 ml of 
isotonic buffer. This vaccine candidate was shown to be safe and 
immunogenic in U.S. adults before clinical trials were undertaken 
in highly endemic areas in the Mekong Delta, Vietnam. Phase I 
and phase II clinical trials demonstrated the safety and immuno-
genicity of Vi-rEPA in adults (18–35 years), school-age children 
(5–14 years) and pre-school children (2–4 years) [79]. In the 
group of adults the serum anti-Vi IgG response was followed for 
as long as 10 years after the injection. Although the antibody level 
declined slightly, serum Vi antibody remained more than sevenfold 
higher than the prevaccination baseline 10 years after vaccination. 
The group of pre-school children were injected once or twice (6 
weeks apart) with the conjugate. Children that were injected with 
the conjugate vaccine had a significant higher serum anti-Vi IgG 
titer as the control group that was injected with the purified poly-
saccharide vaccine and a booster response was observed after the 
second dose. Furthermore no adverse reactions were detected.
 In a double-blind randomized phase III trial, safety, immuno-
genicity and efficacy of the Vi-rEPA conjugate vaccine were evalu-
ated in children two to five years of age in Dong Thap province, 
Vietnam [80]. 11’091 children received two injections, six week 
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apart of either Vi-rEPA or a saline placebo. Cases of typhoid fever, 
diagnosed by the isolation of S. Typhi from blood cultures, were 
identified by active surveillance over a period of 27 months, and a 
passive surveillance during an additional 19 months. Less than 2 % 
of children had adverse reactions, and none of these were consid-
ered serious. After 27 months of follow-up, S. Typhi was isolated 
from 4 of the 5525 children who were vaccinated with the Vi-rEPA 
vaccine and from 47 of the 5566 children who received the pla-
cebo, resulting in an efficacy of 91.5 %. There was no correlation 
observed between level of efficacy and the children’s age nor was 
a decrease of efficacy observed over time. During the additional 
19 months of passive surveillance, typhoid fever was diagnosed in 
three children of the vaccine group versus 17 cases in the control 
group [81]. Over the full period of 46 months the overall vaccine 
efficacy was 89.0 %. Additionally, 771 children received only one 
injection. The efficacy of the vaccine in this group was 87.7 % after 
46 months of follow-up. A long-term follow-up study to determine 
the long-term protection and antibody persistence is underway, 
which should clarify the necessity of a booster dose.
 As with other conjugate vaccines a dosage-related immuno-
genicity was observed in a dosage study of the Vi-rEPA conjugate 
in children two to five years old in Pho Tho province, Vietnam 
[82]. Children received two injections, six weeks apart, containing 
25 µg, 12.5 µg, or 5 µg of Vi polysaccharide. After one year the 
serum anti-Vi IgG levels remained significantly higher than the 
preimmune levels and a correlation between the dosage and im-
mune response was observed. Based on this study a dosage of 25 
µg of polysaccharide is recommended.
 The Vi-rEPA vaccine was developed for administration to in-
fants as part of their routine immunization. Hence, the safety and 
immunogenicity of the Vi-rEPA conjugate vaccine was evaluated 
in a study comprising a total of 301 Vietnamese infants who re-
ceived Expanded Program of Immunization (EPI) vaccines alone 
or with Vi-rEPA or Haemophilus influenzae type b-tetanus toxoid 
conjugacte (Hib-TT) at 2, 4, and 6 months of age. A fourth dose 
of Vi-rEPA or Hib-TT was administered at 12 months. Infants 
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were visited regularly after each injection to monitor adverse ef-
fects and sera were assayed for anti-Vi IgG and antibodies specific 
for the other vaccine components at 7, 12, and 13 months. This 
study showed that the Vi-rEPA conjugate is safe in infants, induced 
protective anti-Vi levels, and was compatible with EPI vaccines 
[83].
Paratyphoid fever
Typhoid and paratyphoid fever are clinically similar acute febrile 
illnesses that are referred to as enteric fevers. In the case of para-
typhoid fever the causative agent is Salmonella enterica subspecies 
I serovar Paratyphi A, B and C (S. Paratyphi A, B and C). How-
ever, infections with S. Paratyphi C are rare. In the year 2000 it 
was estimated that paratyphoid fever caused 5.4 million illnesses 
worldwide [23]. The transmission and the epidemiology of this hu-
man restricted pathogen resemble that of S. Typhi. Furthermore, 
antimicrobial resistance is also a major public health problem in S. 
Paratyphi. 
 The complete genome sequence has been determined for S. 
Paratyphi A strains ATCC9150 and AKU_12601 [84,85]. Se-
quence analysis of S. Typhi and S. Paratyphi A suggests that they 
are much more closely related to each other than to other S. en-
terica serovars. The genomes of S. Paratyphi A and S. Typhi have 
independently accumulated many pseudogenes, which is a com-
mon feature found in many host restricted pathogenic bacteria. 
 Since only S. Paratyphi C expresses the Vi antigen, Vi-based 
vaccines are unlikely to protect against paratyphoid fever caused 
by S. Paratyphi A and B. There is some evidence that the typhoid 
live oral vaccine Ty21a might confer weak cross-protection against 
S. Paratyphi A and B [86,87]. However, there are currently no li-
censed vaccines against S. Paratyphi. The lack of effective vaccines 
is of great concern, because of the growing importance of S. Para-
typhi A as a cause of enteric fever. In a number of Asian countries 
S. Paratyphi A appears to be responsible for a growing proportion 
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of enteric fever whereas S. Typhi incidences decline. In Nepal, the 
proportion of S. Paratyphi A was 32.9 % and 62.5 % in 2007 and 
2008, respectively [88]. There has also been an increase in S. Para-
typhi A infections in the province of Guangxi, southeastern China 
after implementing Vi vaccination in 1999 [89]. This trend raises 
important concerns whether the introduction of a vaccine against 
S. Typhi, in the absence of a vaccine against S. Paratyphi, would 
have an impact at all on enteric fever [90,91].
 Konadu and colleagues at the National Institute of Health de-
veloped a conjugate vaccine against S. Paratyphi A that is currently 
evaluated in clinical trials [92]. This vaccine candidate consists of 
the O-specific polysaccharide (O-SP or O antigen) (described on 
page 45ff.) of S. Paratyphi A covalently linked to tetanus toxoid 
(TT) as carrier protein, designated as SPA-TT. The O-SP was 
purified from LPS, detoxified by acetic acid to remove the lipid 
A, and activated with 1-cyano-4-dimethylaminopyridinium tetra-
fluoroborate (CDAP). The activated O-SP was bound to tetanus 
toxoid with adipic acid dihydrazide (ADH) as a linker or directly. 
The safety and immunogenicity of those two conjugates was eval-
uated in Vietnamese adults, teenagers, and 2–4 year old children 
in phase I, and phase II clinical trials [93]. None of the volunteers 
experienced significant side effects. At 4 weeks after injection both 
conjugates elicited a greater than 4-fold rise in the serum IgG anti-
LPS levels in ≥ 80 % of the adult and teenage volunteers. The chil-
dren received one or two injections, administered 6 weeks apart. 
A significant rise in serum IgG anti-LPS titer was also observed 
in this study group after the first injection. However, a second in-
jection did not elicit a booster response. The antibodies raised by 
SPA-TT were bactericidal against S. Paratyphi A in vitro.
Nontyphoidal Salmonella disease
Nontyphoidal Salmonella (NTS) serovars cause a gut-associated 
self-limiting gastroenteritis in healthy individuals. It is estimated that 
each year in the United States around 1.5 million persons are in-
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fected with NTS, which results in 580 deaths (WHO, 2005). NTS 
serovars are frequently zoonotic and have broad host range specific-
ity. Therefore, foods of animal origin are the main source for NTS 
transmission. S. Enteritidis and S. Typhimurium are the most fre-
quent serovars causing Salmonella outbreaks worldwide [94].
 Antimicrobials are usually not required for treatment of gas-
troenteritis caused by NTS but may be required in severe cases 
that occur in more susceptible patients like young children, elderly 
and immunocompromised patients. However, the resistance of 
NTS strains against antibiotics has significantly increased in re-
cent years. Multidrug resistant NTS strains are commonly found 
in many food animals, like poultry, pigs, and sheep. Resistance is 
the result of inappropriate and uncontrolled usage of antibiotics in 
modern intensified farming and food production methods.
 NTS have emerged as an important cause of invasive blood-
stream infection in sub-Saharan Africa, amongst young children 
with malaria and malnutrition, and amongst adults with HIV [11]. 
NTS infection in these particular hosts, referred to as invasive 
nontyphoidal Salmonella (iNTS) disease, causes a nonspecific fe-
brile illness and the case fatality is 22–54 % [95]. In sub-Saharan 
Africa, the most common causes of iNTS disease are the Salmo-
nella enterica serovars Typhimurium and Enteritidis. The transmis-
sion of iNTS may be from human to human rather than zoonotic.
 There are currently no licensed vaccines for nontyphoidal Sal-
monella. Homologous to S. Paratyphi A it has been demonstrated 
that antibodies raised against the O-specific polysaccharide (O-
SP) of S. Typhimurium (described on page 45ff.) are protective in 
mice and rabbits [96]. Conjugate vaccines consisting of the O-SP 
of S. Typhimurium covalently linked to tetanus toxoid as protein 
carrier elicited antibodies in mice that were bactericidal and pro-
tected the immunized animals against intraperitoneal challenge 
with S. Typhimurium [97]. However, a study of humoral defence 
against S. Typhimurium in HIV-infected Malawian adults dem-
onstrated that high-titer antibodies directed against the LPS are 
associated with impaired serum killing of Salmonella [98]. Accord-
ingly, anti-LPS antibodies are not protective but rather inhibit the 
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binding of effective antibodies directed against Salmonella outer-
membrane proteins. These findings have important implications 
on the strategy of vaccine development against NTS, away from 
O antigen glycoconjugates, which could potentially cause harm, 
and towards cell surface protein targets. Identification of antigenic 
protein targets has recently been done using a Salmonella prot-
eomic array, containing over 2’700 proteins, probed with immune 
sera from Salmonella-infected mice and humans. Vaccination with 
SseB, the most prominent antigenic target identified with this 
method, significantly protected mice against Salmonella infection 
[99].
Scope of the thesis: 
A novel approach for conjugate 
vaccine production
Conjugate vaccines are among the most effective and safe vac-
cines against bacterial diseases and have been used in humans for 
over 30 years. As described in the previous sections, several clini-
cal trials have shown that glycoconjugates are promising vaccine 
candidates to prevent Salmonella infections. However, conjugate 
vaccines are currently produced by a complex manufacturing pro-
cess, illustrated in Figure 3A. Bacteria producing the polysaccharide 
antigen and the carrier protein are grown separately, the polysac-
charide and carrier protein are then each purified and the polysac-
charide is chemically linked to the carrier protein, before being fur-
ther purified. Chemical conjugation has a number of drawbacks: 
(i) Several purification steps are required, which might result in 
substantial loss of material throughout the process and thus lower 
yields; (ii) Chemical coupling is random and the glycoconjugate 
produced is not a uniform, customized structure, but a mixture 
of different glycoconjugates, each with potentially different effi-
cacy profile. Furthermore, chemical conjugation is never complete 
and free polysaccharide may interfere with immune responses to 
the glycoconjugates. Any small change in the mixture affects the 
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Figure 3: Production of conjugate vaccines.
A   Currently, conjugate vaccines are being produced by chemical conjugation 
of an antigenic polysaccharide and a protein carrier in vitro. Therefore, a 
bacterial strain expressing the carrier protein and the pathogen express-
ing the polysaccharide structure have to be grown in parallel. Both the 
protein carrier and the polysaccharide have to be purified separately. Toxic 
polysaccharides, like LPS, must additionally be detoxified prior to chemical 
conjugation. The final product has to be further purified from the reaction 
mixture to remove unconjugated components, which may interfere with 
immune responses to the glycoconjugates. 
B   A novel in vivo production process for glycoconjugates is based on the 
bacterial N-linked protein glycosylation system. A production strain is 
genetically modified so it expresses the antigenic polysaccharide structure, 
an engineered acceptor protein containing the consensus sequence for 
N-linked protein glycosylation, and the bacterial oligosaccharyltransferase 
PglB. After fermentation the final product is extracted form the cell’s 
periplasm and purified.
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characteristics of the vaccine, therefore the same mixture must be 
maintained throughout scale-up and production; (iii) chemical 
conjugation may affect the structure of both the polysaccharide 
and the carrier protein, which makes them less immunogenic or, 
in some cases, not immunogenic at all. Toxic polysaccharides, like 
LPS, must additionally be chemically detoxified, often leading to 
further loss of immunogenicity.
 A novel approach to produce conjugate vaccines is based on 
the bacterial N-linked protein glycosylation system. This bacte-
rial protein modification system was first described in the food-
borne pathogen Campylobacter jejuni [100,101]. The key enzyme 
of this system, C. jejuni oligosaccharyltransferase (PglB), transfers 
bacterially-synthesized oligosaccharides from a carrier lipid (un-
decaprenyl pyrophosphate; Und-PP) to periplasmic proteins with 
an asparagine-containing consensus sequence. This protein glyco-
sylation system was functionally transferred into Escherichia coli to 
produce glycoconjugates in vivo [101]. It has been shown that PglB 
exhibits relaxed substrate specificity towards the glycan moiety and 
various Und-PP linked polysaccharides can be transferred to pro-
teins [102,103]. Furthermore, it is possible to produce recombinant 
glycoproteins by inserting the consensus sequence for N-glyco-
sylation (D/E-Y-N-X-S/T, where Y and X can be any amino acid 
except proline) at multiple desired sites in proteins which are oth-
erwise not glycosylated, like rEPA [104,105]. Therefore, the type 
of glycoconjugate produced can be tailored by the introduction 
of genes driving synthesis of the antigenic polysaccharide and of 
the antigenic protein carrier. After fermentation of the production 
strain, the glycoconjugate is simply extracted from the periplasm 
and purified (Figure 3B). This cost-efficient in vivo production of 
glycoconjugates represents an alternative to the conventional man-
ufacturing process.
 In this work, the possibilities of using the in vivo glycosylation 
technology for the production of conjugate vaccines against certain 
Salmonella enterica serovars causing human illnesses were exploit-
ed. For the development of such vaccines it is crucial to identify an-
tigenic cell surface polysaccharide structures and learn more about 
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their chemical structure and biosynthetic pathways. The following 
sections provide an overview of the relevant cell surface polysac-
charide structures expressed by Salmonella enterica serovars caus-
ing human illnesses. Most of these structures have already been 
targeted for the development of conjugate vaccine candidates us-
ing the chemical coupling technology. Furthermore, challenges that 
might be encountered during development of glycoconjugates us-
ing the in vivo glycosylation technology are being discussed.
Vi antigen
The causative agent of typhoid fever, S. Typhi, expresses a cap-
sular polysaccharide (CPS), known as Vi antigen. Vi expression is 
largely restricted to S. Typhi but it is also found in some strains of 
S. enterica serotype Paratyphi C, S. enterica serotype Dublin, and 
in Citrobacter freundii.
 In the model organism Escherichia coli, CPS are divided into 
two major groups according to their mechanism of biosynthesis: 
Group 1 CPS are assembled by a Wzy-dependent pathway, group 
2 CPS by an ATP-binding cassette (ABC) transporter-dependent 
process [106]. The building blocks of group 1 CPS are preassem-
bled on Und-PP at the cytoplasmic leaflet of the inner membrane. 
These Und-PP-linked subunits are exported across the inner 
membrane by the putative flippase Wzx and subsequently polym-
erized at the periplasmic face of the inner membrane by the pu-
tative polymerase Wzy. Finally, the CPS is translocated from the 
periplasm to the cell surface. In contrast, group 2 CPS are com-
pletely assembled at the cytoplasmic face of the inner membrane, 
typically by a processive glycosyltransferase adding activated sugar 
molecules to the nonreducing end of the nascent chain. The as-
sembled polymer is exported across the inner membrane by an 
ABC transporter and subsequently translocated to the cell surface. 
The endogenous acceptor molecule for group 2 CPS biosynthe-
sis is equivocal and the details of initiation and termination of the 
chain growth have not yet been resolved.
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 The Vi is a linear, acidic homopolymer of Į-1,4-linked N-
acetylgalactosaminuronic acid (D-GalNAcA), nonstoichiometri-
cally esterified with acetyl groups at the C-3 (Figure 4). The O-acetyl 
groups make up most of the surface and immunogenicity of Vi is 
closely related to the degree of O acetylation [35,36]. Key proteins 
involved in Vi capsule formation are encoded within a cluster of 
genes, known historically as the viaB locus [107], a region located 
on a 134 kb DNA island, termed Salmonella pathogenicity island 7 
(SPI-7) within S. Typhi [45]. Precise excision of SPI-7 in Vi-neg-
ative mutants has been demonstrated, indicating that Vi antigen 
expression is located on an unstable region in the S. Typhi genome 
[46]. The S. Typhi viaB constitutes 10 genes involved in regulation 
of expression (tviA), biosynthesis (tviB to tviE), and cell surface 
localization of the Vi polysaccharide (vexA to vexE). Analysis of 
the bioinformatics signature of viaB, including the presence of a 
putative ABC transporter and the absence of a homologue of wzy/
wzx respectively, biosynthesis of Vi is thought to be similar to E. 
coli group 2 CPS [106].
 Since many important aspects of this group of CPS are equivo-
cal, a molecular characterization of the viaB locus encoding the 
biosynthetic machinery for Vi capsule formation was conducted 
(see page 53ff.). To date, there are no indications that the Vi poly-
saccharide is assembled on the lipid carrier Und-PP and no peri-
plasmic intermediates have been reported to exist. These are key 
criteria for being a substrate of the bacterial oligosaccharyltrans-
ferase PglB, the key enzyme of the in vivo glycoconjugate produc-
tion technology. However, Und-PP-linked polysaccharides exist in 
bacteria that resemble the Vi antigen. In the second part of the 
Results section, polysaccharides that mimic the Vi have been engi-
neered, conjugated, and their immunogenicity has been evaluated 
in mice for their potential use as a typhoid vaccine component (see 
page 87ff.). 
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O antigen
As described on page 15f. Salmonella spp. and other Gram nega-
tive bacteria express an O antigen (O-specific polysaccharide, 
O-SP), which is part of the lipopolysaccharide (LPS). Accord-
ing to the Kauffmann-White scheme, which is based on specific 
antisera used for cell surface antigen determination, O antigens of 
the genus Salmonella can be classified into groups. For example, 
S. Paratyphi A belongs to the O antigen group A, S. Paratyphi 
B and the nontyphoidal Salmonella enterica serovar Typhimurium 
belong to the O antigen group B, S. Enteritidis and S. Typhi are 
grouped into O antigen group D. The O antigen structures of se-
rogroups A, B, and D Salmonella share a common trisaccharide 
backbone illustrated in Figure 5A. This structure is recognized by 
O12 specific antisera, and is therefore associated with antigen fac-
tor 12 specificity of the Kauffmann-White scheme. The galactose 
of the backbone structure can be modified with Į-1,6-linked glu-
Figure 4: Structure of the Vi antigen.
The Vi is a linear, acidic homopolymer of Į-1,4-linked N-acetylgalactosaminu-
ronic acid (D-GalNAcA), variably O-acetylated at C-3.
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cose, which is associated with factor 1. Glucosylation of the back-
bone galactose at C-4 generates the 12-2 variant [108].
 The serogroups differ in the presence of a side-branch R, linked 
Į(1ĺ3) to the mannose of the backbone. Residue R is a 3,6-dide-
oxyhexose: paratose (3,6-dideoxyglucose) in group A (factor 2 
in the Kauffmann-White scheme), abequose (3,6-dideoxygalac-
tose) in group B (factor 4), and tyvelose (3,6-dideoxymannose) in 
group D (factor 9). 
 Furthermore, O-acetyl groups are present in some O antigen 
structures: The rhamnose of the backbone is partially O-acetylated 
at C-3 for S. Paratyphi A (there is no antigen factor assignment 
for this modification in the Kauffmann-White scheme), and the 
Figure 5: Structure and biosynthesis of the Salmonella 
serogroup A, B and D O antigens.
A   The O antigen repeating unit of serogroup A, B and D Salmonella are struc- 
turally related and share a common backbone trisaccharide structure  
that might be modified with branching glucoses and O-acetyls. The O anti- 
gen serogroups differ in the presence of an immunodominant side-branch 
R, linked Į(1ĺ3) to the mannose of the backbone. Residue R is a  
dideoxyhe-xose: paratose (3,6-dideoxyglucose) in group A (e.g. S. Paratyphi 
A), abequose (3,6-dideoxygalactose) in group B (e.g. S. Typhimurium),  
and tyvelose (3,6-dideoxymannose) in group D (e.g. S. Typhi). 
B   Enzymes involved in the assembly of the O antigen are encoded within a 
cluster of genes known historically as the rfb locus. Not only are the  
structures of the O-specific polysaccharides of group A, B and D Salmonella 
very similar, but also their respective rfb loci. The rfb gene cluster is typi- 
cally localized between the conserved genes galF and gnd in the chromo-
some. The functions of the individual enzymes are indicated by different 
coloration. Note that the individual rfb loci only differ in the organization 
of genes involved in CDP-3,6-dideoxyhexose biosynthesis. Group B rfb  
loci encode rfbJ, whereas this gene is replaced by rfbS and rfbE in group A 
and D strains. In group A strains rfbE is non functional due to a frame-
shift mutation.
C   RfbJ, RfbS and RfbE are involved in final steps of CDP-3,6-dideoxyhexose 
biosynthesis, giving rise to CDP-abequose, CDP-paratose and CDP-
tyvelose respectively.
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abequose residue of S. Typhimurium can be O-acetylated at C-2 
(factor 5). The O-acetyl groups play an essential role in immu-
nogenicity of the O antigen. For S. Paratyphi A, only conjugates 
with O-acetyls elicited serum IgG anti-LPS with bactericidal ac-
tivity [93]. Similarly, in S. Typhimurium both O-acetyl positive 
and negative strains can cause illness. However, O-acetylation has 
a dramatic effect on the structure of the molecule and its immuno-
genicity [109]. These immunodominant O-acetyl groups are sus-
ceptible to chemical treatment and could be lost during chemical 
conjugation, resulting in an ineffective vaccine.
 The enzymes involved in O antigen assembly are encoded 
within a cluster of genes, historically known as the rfb locus (Figure 
5B). O polysaccharides are generally assembled on the lipid carrier 
undecaprenyl pyrophosphate (Und-PP). The O polysaccharides of 
serogoups A, B, and D Salmonella are assembled according to the 
Wzy-dependent biosynthesis pathway (reviewed in [110]). The first 
step in this pathway involves the reversible transfer of galactose-1-P 
from UDP-galactose to undecaprenyl phosphate (Und-P) result-
ing in the formation of Und-PP-linked galactose. This reaction is 
catalyzed by the enzyme WbaP (formerly RfbP). Subsequently, rfb 
locus encoded glycosyltransferases assemble the O repeating unit 
at the inner face of the cytoplasmic membrane. Following their as-
sembly, the Und-PP-linked O units are transported across the cyto-
plasmic membrane to the periplasmic side by the flippase Wzx (for-
merly RfbX). At the periplasmic face of the cytoplasmic membrane 
Und-PP-linked O units are polymerized by the O polysaccharide 
polymerase Wzy. Surprisingly, Wzy is not encoded in the rfb locus 
of Salmonella. The reaction of polymerization involves the transfer 
of nascent polymer from its Und-PP carrier to the nonreducing 
end of a new Und-PP-linked O repeating unit. The chain length of 
Wzy-dependent O antigens is regulated. The Wzz protein gener-
ates a modal distribution of O polysaccharide chain lengths. Several 
S. enterica serovars have two wzz genes, resulting in a bimodal dis-
tribution of chain lengths. Finally, the assembled O polysaccharide 
is transferred from Und-PP and ligated to the lipid A-core by the O 
antigen ligase WaaL.
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 Enzymes responsible for O-acetylation of the Salmonella O 
polysaccharide backbone structure, illustrated in Figure 5A, are en-
coded outside the rfb locus [111]. Similarly, enzymes involved in 
glucosylation are not encoded within the rfb locus. The branch-
ing glucose residues are typically added in the periplasm after po-
lymerization of the O repeat units by a prophage encoded system, 
which is found in many other species like Shigella flexneri (re-
viewed in [112]). Three genes are typically involved in glucosyla-
tion of the O antigen repeat: gtrA, B, and gtr(type). The products of 
the first two genes are highly conserved between the different glu-
cosylation systems, whereas the third appears to be unique. GtrB 
contains motifs that are also found in Alg5 of Saccharomyces cerevi-
siae, a well characterized dolichyl phosphate glucosyltransferase. 
It is proposed that GtrB catalyzes the transfer of glucose from 
UDP-glucose to undecaprenyl phosphate (Und-P) at the cytosolic 
side of the inner membrane, resulting in the formation of Und-P-
glucose [113,114]. This lipid linked glucose is then flipped across 
the cytosolic membrane by the putative flippase GtrA, before the 
glucosyl residue is transferred to the growing O antigen chain by 
the glucosyltransferase Gtr(type). This system resembles the bio-
synthesis of the eukaryotic N-glycan oligosaccharide in the lumen 
of the endoplasmatic reticulum, where mannosyl and glucosyl resi-
dues are transferred from dolichyl phosphate (Dol-P)-mannose 
and Dol-P-glucose precursors. The prophage encoded system in-
volved in glucosylation of the S. Typhimurium O antigen galactose 
(C-4 position) has been identified [108]. The glucosyltransferase 
involved in C-6 modification of the O antigen galactose has not yet 
been described. However, BLAST search identifies two GtrB ho-
mologous in the S. Typhimurium LT2 genome: STM0558 [108] 
and STM4205. The latter genomic region might be responsible 
for C-6 glucosylation.
 Not only are the O antigen structures of serogroups A, B, and D 
Salmonella very similar, but also their respective rfb gene clusters, 
which differ only in genes for the biosynthetic pathways of the im-
munodominant 3,6-dideoxyhexoses. The gene rfbJ found in group 
B strains encodes abequose synthase, which catalyzes the conver-
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sion of CDP-4-keto-3,6-dideoxy-D-glucose to CDP-abequose. 
In group A and D strains rfbJ is replaced by rfbS and rfbE. RfbS 
catalyzes the conversion of CDP-4-keto-3,6-dideoxy-D-glucose 
to CDP-paratose and RfbE is a C-2 epimerase, catalyzing the fi-
nal step of CDP-tyvelose formation (Figure 5C) [115]. However, S. 
Paratyphi A contains a frameshift mutation in rfbE, resulting in 
pseudogene formation and the inability to convert CDP-paratose 
to CDP-tyvelose.
 As described in previous sections conjugate vaccine candidates 
have been developed against S. Paratyphi A and S. Typhimurium, 
both consisting of the O-specific polysaccharide covalently linked 
to a protein carrier. The presence of chemical instable O-acetyl 
groups in these O-SPs would favor the in vivo glycoconjugate 
production technology. However, a commonality of the vaccine 
relevant Salmonella O-SPs is a reducing end galactose. The PglB-
mediated transfer of such polysaccharide structures has not yet 
been observed, and it was proposed that only glycans containing 
an acetamido group at the C-2 position of the reducing end sac-
charide serve as substrates to the bacterial OST [103]. In the third 
part of the results section, the substrate specificity of the bacterial 
oligosaccharyltransferase PglB was explored and the transfer of 
a Salmonella O-SP to an acceptor protein was investigated (see 
page 117ff.). In this work, the S. Typhimurium O-SP was used as 
a model. However, if it would be possible to produce such a gly-
coconjugate it would quickly be adaptable to other important Sal-
monella enterica serovars causing human illnesses due to the close 
relatedness of their O-SP structures.
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Abstract
The Vi capsular polysaccharide (CPS) of Salmonella enterica sero-
var Typhi, the cause of human typhoid, is important for infectivity 
and virulence. The Vi biosynthetic machinery is encoded within the 
viaB locus composed of 10 genes involved in regulation of expres-
sion (tviA), polymer synthesis (tviB-tviE), and cell surface locali-
zation of the CPS (vexA-vexE). We cloned the viaB locus from S. 
Typhi and transposon insertion mutants of individual viaB genes 
were characterized in Escherichia coli DH5Į. Phenotype analysis of 
viaB mutants revealed that tviB, tviC, tviD and tviE are involved 
in Vi polymer synthesis. Furthermore, expression of tviB-tviE in E. 
coli DH5Įdirected the synthesis of cytoplasmic Vi antigen. Mu-
tants of the ABC transporter genes vexBC and the polysaccharide 
copolymerase gene vexD accumulated the Vi polymer within the 
cytoplasm and productivity in these mutants was greatly reduced. 
In contrast, de novo synthesis of Vi polymer in the export deficient 
vexA mutant was comparable to wild-type cells, with drastic ef-
fects on cell stability. VexE mutant cells exported the Vi, but the 
CPS was not retained at the cell surface. The secreted polymer of 
a vexE mutant had different physical characteristics compared to 
the wild-type Vi. 
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Introduction
The causative agent of the human systemic infection typhoid fe-
ver, Salmonella enterica subspecies I serotype Typhi (S. Typhi), ex-
presses a capsular polysaccharide (CPS) known as Vi antigen (Vi). 
The Vi capsule provides S. Typhi with mechanisms to avoid host 
defenses [116,117] and it is important in enhancing infectivity and 
virulence [12,47,49]. Besides being an important virulence factor, 
the Vi is also a protective antigen and a vaccine based on purified 
Vi polysaccharide has been developed and licensed for use as a 
parenteral vaccine against typhoid fever [118].
 Vi is a linear, acidic homopolymer of Į-1,4-linked N-acetylga-
lactosaminuronate (D-GalNAcA), variably O-acetylated at C-3. 
The O-acetyl groups make up most of the surface and the im-
munogenicity of Vi is closely related to the degree of O acetyla-
tion [35,36]. Key proteins involved in Vi capsule formation are 
encoded within a cluster of genes, known historically as the viaB 
locus [107], a region located on a 134 kb DNA island, termed Sal-
monella pathogenicity island 7 (SPI-7) within S. Typhi [45]. The S. 
Typhi viaB constitutes 10 genes involved in regulation of expres-
sion (tviA), biosynthesis (tviB to tviE), and cell surface localization 
of the Vi polysaccharide (vexA to vexE) (Figure 1A). Analysis of the 
bioinformatics signature of viaB highlighted the presence of a pu-
tative ATP-binding cassette (ABC) transporter and the absence of 
a homologue of wzy/wzx respectively. Therefore, biosynthesis of Vi 
is thought to be similar to E. coli group 2 CPS [106].
 Vi expression in S. Typhi is under control of the RcsB-RcsC 
and OmpR-EnvZ two-component regulator systems [119-121] 
and when the complete viaB operon is expressed in Escherichia 
coli K12 a similar pattern of regulation can also be observed [122]. 
RcsB-RcsC and OmpR-EnvZ likely interact with TviA and re-
gions upstream of the tviA promoter thereby linking Vi expression 
to environmental signatures such as osmolarity [66]. TviA is an 
activator of the viaB operon and deletion of the tviA gene strongly 
decreases expression of the Vi capsule [123].
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Figure 1: Overview of the viaB operon and Vi capsular polysaccha-
ride biosynthetic pathway.
A  Schematic diagram of the S. Typhi viaB operon. 
B   The Vi antigen is a linear polymer of Į-1,4-linked N-acetylgalatosaminuro-
nate, nonstoichiometrically esterified with acetyl groups at the C-3. A TviB- 
catalyzed oxidation of UDP-N-acetylglucosamine (UDP-GlcNAc) followed 
by the TviC-catalyzed epimerization at the C-4 of UDP-N-acetylglucosami-
nuronate (UDP-GlcNAcA) results in the formation of UDP-N-acetyl-
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 Biosynthesis of the Vi polysaccharide takes place in the cyto-
plasm and requires functional TviB, TviC, TviD and TviE proteins 
[123] (Figure 1B). TviB and TviC are involved in catalyzing the con-
version of UDP-N-acetylglucosamine (UDP-GlcNAc) to UDP-
N-acetylgalactosaminuronate (UDP-GalNAcA), which serves as 
the building block for the assembly of the Vi polymer [124]. As-
sembly of the Vi polymer is dependent on functional expression of 
tviD and tviE [123]. The enzyme responsible for O-acetylation of 
the Vi polysaccharide has not yet been identified.
 Cell surface localization of the Vi polymer is dependent on 
functional expression of vexA, vexB, vexC, vexD and vexE (Figure 
1B). The predicted lipoprotein VexA belongs to group B of the out-
er membrane polysaccharide export (OPX) proteins [125]. OPX 
proteins for which a high-resolution structures have been solved 
include Wza [126], a protein essential for group 1 CPS expres-
sion on the surface of E. coli and the E. coli group 4 capsule pro-
tein GfcC [127]. The Wza protein forms an octameric structure 
that spans the outer membrane and protrudes into the periplasm, 
thereby forming a water-filled channel. One of the most exten-
sively studied bacterial group 2 capsules is the K1 serotype of E. 
coli. The E. coli K1 capsular gene cluster encodes KpsD, which 
is the functional homologue of VexA. VexBC belong to the large 
family of ABC transporters whose members have been implicated 
in the transport of substrates across membranes. The E. coli K1 
ABC transporter KpsMT is a close homologue of VexBC [128]. 
KpsM is a hydrophobic, integral inner membrane protein with six 
galactosaminuronate (UDP-GalNAcA), the building block for Vi polymer 
formation. The Vi polymer is synthesized in the cytoplasm and assembly  
is dependent on TviD and TviE. The enzyme catalyzing the O-acetylation of 
the capsular polysaccharide has not yet been identified. Subsequent trans-
location of the polysaccharide to the cell surface follows an ATP-binding cas-
sette (ABC) transporter-dependent process. The transporter consists of  
VexA, VexB, VexC and VexD. The precise function of VexE is equivocal although 
it might be involved in anchoring the Vi to the cell surface.
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transmembrane domains whereas KpsT is a hydrophilic, periph-
eral inner membrane protein containing an ATP-binding domain. 
The functional transporter is proposed to consist of two subunits 
each of KpsM and KpsT. VexD and its homologous protein KpsE 
of E. coli K1 belong to a family called the polysaccharide copoly-
merases subfamily 3 (PCP-3) [125]. There is no structural infor-
mation yet available about this subfamily but all PCP proteins have 
a characteristic membrane topology in which a large periplasmic 
loop is flanked by two transmembrane regions localized in the in-
ner membrane. PCP-3 proteins might provide a periplasmic scaf-
fold for linking the ABC transporter in the inner membrane with 
the OPX protein in the outer membrane therefore assembling the 
complete polysaccharide translocation machinery. VexE seems to 
be responsible for anchoring the Vi to the cell surface [123].
 To investigate the function of individual proteins involved in 
biosynthesis and cell surface expression of the Vi CPS in greater 
detail, the viaB cluster was cloned from S. Typhi and transposon 
insertion mutants of individual viaB genes were characterized in E. 
coli DH5Į. A detailed and comprehensive phenotype characteriza-
tion of viaB single gene mutants and their effect on biosynthesis 
and cell surface expression of the Vi CPS is reported here.
Results
Expression of the Vi capsule in E. coli DH5Ơ 
The low copy plasmid pGVXN158 was constructed using a 14.9 kb 
DNA fragment of S. Typhi BRD948 that harbors the 10 open 
reading frames of the viaB operon with around 900 bp upstream 
of the first gene tviA. Therefore the viaB operon contains the natu-
ral regulatory sequences and expression is not controlled by ele-
ments encoded on the plasmid backbone. E. coli DH5Į was trans-
formed with pGVXN158 whereupon the transformants changed 
colony morphology towards a smooth colony appearance, indicat-
ing the expression of a capsule. These cells could be agglutinated 
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using a Vi specific antibody. Furthermore, these encapsulated cells 
were tested for susceptibility to infection by well characterized Vi 
phages that are part of the classical typing set [129-133]. All 7 Vi 
phage types were able to infect E. coli DH5Į(pGVXN158) but not 
the plasmid free controls. Thus, using these simple methodologies 
the Vi produced by E. coli was indistinguishable from Vi expressed 
by the parenteral S. Typhi. Therefore, this Vi expression system 
harbored in E. coli DH5Į was used for further analysis of the bio-
synthetic machinery assembling the Vi capsule.
Quantification and localization of the 
Vi in E. coli DH5Ơ(pGVXN158) 
harboring single gene transposon 
insertions within viaB genes
Next the role of the individual genes of the viaB operon in Vi 
capsule expression was analyzed. For this purpose single genes 
within the viaB operon encoded on pGVXN158 were inacti-
vated by Tn5-mediated transposon insertional mutagenesis. To 
this end, viaB single gene insertion mutants in all of the genes 
except the regulator tviA were selected and the insertion site 
was mapped (Table I). Washed cell pellets and the corresponding 
supernatants of overnight cultures from individual transposon 
insertion mutants were spotted onto nitrocellulose membranes 
and the presence of the Vi CPS was detected by immunoblot-
ting using a monoclonal Vi specific antibody. To exclude polar 
effects on downstream genes, tviB::Tn5, tviC::Tn5, tviD::Tn5, 
tviE::Tn5, vexB::Tn5, vexC::Tn5 transposon insertion mutants 
were complemented with the corresponding gene cloned and Vi 
expression was restored (data not shown). Detection of Vi poly-
saccharide in the individual E. coli DH5Į(pGVXN158) transpo-
son mutant derivatives revealed three distinguishable phenotypes 
(Figure 2A): i) a strong signal was detected with cell cultures from 
E. coli DH5Į(pGVXN158) and E. coli DH5Į(pGVXN158) har-
boring vexA::Tn5 (pGVXN158vexA::Tn5) ii) an intermediate 
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staining was associated with vexB::Tn5 (pGVXN158vexB::Tn5), 
vexC::Tn5 (pGVXN158vexC::Tn5), and vexD::Tn5 (pGVXN-
158vexD::Tn5), whereas iii) no Vi was detected in cell cultures of 
E. coli DH5Į carrying the empty plasmid control pGVXN157 or 
E. coli DH5Į(pGVXN158) harboring tviB::Tn5 (pGVXN158- 
tviB::Tn5), tviC::Tn5 (pGVXN158tviC::Tn5), tviD::Tn5 (pGV- 
XN158tviD::Tn5), tviE::Tn5 (pGVXN158tviE::Tn5) or vexE::T-
n5 (pGVXN158vexE::Tn5). To determine if the detection of Vi 
observed in the vexA::Tn5, vexB::Tn5, vexC::Tn5 or vexD::Tn5 
transposon insertion mutants was associated with surface expres-
sion of capsular Vi, slide agglutination and Vi phage infections were 
performed (Table I). None of the cells harboring these transposon 
insertion mutants could be agglutinated with a Vi specific antibody 
and none of the tested mutants could be infected with either one 
of the seven Vi phages. Taken together these results indicate that Vi 
Plasmid Tn5 insertion site* Immunoblotting Agglutination Phage infection**
pGVXN157 – – – –
pGVXN158 – +++ + +
pGVXN158tviB::Tn5 679/ 1278 – – nd
pGVXN158tviC::Tn5 268/ 1047 – – nd
pGVXN158tviD::Tn5 1909/ 2496 – – nd
pGVXN158tviE::Tn5 388/ 1737 – – nd
pGVXN158vexA::Tn5 350/ 1068 ++ – -
pGVXN158vexB::Tn5 679/ 795 + – nd
pGVXN158vexC::Tn5 515/ 696 + – –
pGVXN158vexD::Tn5 820/ 1305 + – nd
pGVXN158vexE::Tn5 1247/ 1971 – – –
Table I
Overview of transposon insertion mutants analyzed in this study.
* bp of insertion site from 3’ end of the gene/ total length of gene
** nd: not determined 
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Figure 2: Localization and quantification of the Vi polysaccharide in 
different viaB transposon insertion mutants. 
A   Washed cell pellets (wc) and the corresponding supernatants (sn) of DH5Į 
overnight cultures harboring the indicated plasmids were spotted onto  
nitrocellulose and blotted with anti-Vi antiserum. 
B   Vi content was measured in cell culture supernatants (extracellular Vi), in 
a suspension of washed and fixed cells (cell associated Vi), and in cell lysates 
using a quantitative sandwich ELISA. Intracellular Vi was defined using  
the difference in Vi measured in cell lysates and fixed cells. The amount of 
Vi was normalized to the protein content measured in the cell pellets.
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polysaccharide is still produced in cells expressing the viaB locus 
with a transposon insertion in vexA, vexB, vexC and vexD but this 
is not cell surface associated.
 To generate a more detailed view about the quantities and the 
localization of the Vi polysaccharide produced in the different viaB 
insertion mutants, a sandwich ELISA was developed. With this 
method Vi polysaccharide contents were measured in the cell cul-
ture supernatant (extracellular Vi), in a suspension of washed cells 
that were fixed with paraformaldehyde (cell associated Vi), and in 
cell lysates. Intracellular Vi was defined using the difference in Vi 
measured in cell lysates and fixed cells (Figure 2B). 
 E. coli DH5Į(pGVXN158) cells expressed 6–7 times more 
Vi than S. Typhi BRD948, although the cellular distribution of 
Vi was similar. Vi was mainly detected on the cell surface, and 
in the cell culture supernatant. No Vi was detected in DH5Į
(pGVXN158tviB::Tn5), DH5Į(pGVXN158tviC::Tn5), DH5Į
(pGVXN158tviD::Tn5), DH5Į(pGVXN158tviE::Tn5) or DH5Į
(pGVXN157). These data confirm the results by Virlogeux et 
al. [123] that TviB, TviC, TviD and TviE are involved in the bio- 
synthesis of the Vi polysaccharide. Vi distribution looked similar 
in DH5Į(pGVXN158vexB::Tn5), DH5Į(pGVXN158vexC::Tn5) or 
DH5Į(pGVXN158vexD::Tn5) whereas these insertion mutants 
produced 15–35 times less Vi in total as compared to DH5Į
(pGVXN158). Vi in these mutants was mainly detected predomi- 
nantly inside the cells and in the culture supernatants. In contrast, 
DH5Į(pGVXN158vexA::Tn5) and DH5Į(pGVXN158vexE::Tn5) 
produced large amounts of Vi the former in the same magnitude 
range as DH5Į(pGVXN158) whereas the vexE::Tn5 mutant 
produced approximately half the amount of the total Vi meas-
ured in DH5Į cells expressing the wild type viaB locus. Howev-
er, cellular distribution of the Vi in these two insertion mutants 
was different. In DH5Į(pGVXN158vexA::Tn5) cultures, slightly 
lower amounts of Vi were detected in the cell culture supernatant, 
whereas comparable amounts of intracellular and cell associated 
Vi was measured. The detection of surface exposed Vi in this viaB 
insertion mutant is potentially in conflict with the observed re-
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sistance of this strain to Vi phage infection and the fact that it is 
not agglutinable with a Vi antigen specific antibody. The Vi pro-
duced by cells harboring a vexE transposon insertion plasmid 
was mainly localized in the cell culture supernatant with similar 
amounts comparable to DH5Į(pGVXN158). However, in con-
trast to DH5Į(pGVXN158), only low levels of intracellular and 
cell surface associated Vi was detectable. This result indicates that 
the vexE mutant expresses a functional Vi translocation machinery, 
but once the polymer is exported, the Vi is not efficiently retained 
on the cell surface. 
Characterization of vex transposon 
insertion mutants by trans- 
mission electron microscopy and 
immunogold labeling of the Vi
In addition to the Vi quantification and localization studies by 
ELISA, several selected vex transposon insertion mutants were 
analyzed by transmission electron microscopy (TEM) and immu-
nogold labeling of the Vi polysaccharide using the monoclonal an-
ti-Vi antibody P2B1G2/A9 [134]. The specificity of the antibody 
was tested by immunogold labeling of DH5Į cells carrying the 
empty plasmid pGVXN157 (Figure 3E). These cells do not express 
the Vi polysaccharide and practically no staining was observed. 
Figure 3A shows the normal cellular distribution of the Vi antigen 
in DH5Į(pGVXN158). The images show encapsulated bacteria 
where the polysaccharide is mainly localized at the cell surface, but 
Vi antigen is also detectable in the periplasmic space and inside 
inclusion-like bodies within the cytoplasm. 
 As expected, the Vi polysaccharide was differently distrib-
uted within the cells carrying viaB transposon insertion mutant 
plasmids. In cells harboring vexA::Tn5 encoding a nonfunctional 
outer membrane polysaccharide export (OPX) protein, the Vi was 
mainly stained within large inclusion-like bodies and sometimes 
clustered at the inside of the inner membrane (Figure 3B). Vi accu-
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mulation at the cytoplasmic membrane might indicate the site of 
Vi translocation over the inner membrane or an accumulation due 
at a blocked pore complex. Very occasional labeling of filamentous 
Vi erupting externally from the cell surface was observed.
 In cells expressing a nonfuctional ABC transporter ATP-bind-
ing protein VexC, DH5Į(pGVXN158vexC::Tn5), the Vi was labeled 
in large inclusion-like bodies inside the cells (Figure 3C). Disruption 
of the transport motor in this mutant appears to completely block 
Vi translocation through the pore complex.
 Cells harboring the vexE::Tn5 plasmid display a similar phenotype 
as seen in the vexC::Tn5 insertion mutant (Figure 3D). Vi was mainly 
stained within inclusion-like bodies inside the cells. The extracellular 
Vi detected by ELISA was not visualized in the extracellular spaces.
Figure 3: Transmission electron micrographs of ultrathin sections 
from E. coli DH5α expressing the Vi polysaccharide.
The Vi has been labeled with the immunogold technique by using an  
anti-Vi antibody. 
A   E. coli DH5Į cells expressing the wild-type viaB operon (pGVXN158)  
are shown. The Vi is mainly localized on the cell surface (CS) but  
is also stained in the periplasmic space (PP) and inside inclusion-like  
bodies within the cytoplasm (IB). 
B   E. coli DH5Į cells containing the viaB operon with a transposon insertion 
in vexA (pGVXN158vexA::Tn5), the outer membrane polysaccharide export 
(OPX) protein, are shown. Vi was mainly stained within large inclusion-like 
bodies (IB) and sometimes clustered at the inside of the inner membrane 
(CM). Very occasionally, filamentous Vi erupting from the cell surface was 
labeled. 
C   E. coli DH5Į cells containing the viaB operon with a transposon insertion 
in vexC (pGVXN158vexC::Tn5), the ATP-binding protein of the ABC trans- 
porter, are shown. The Vi polysaccharide was labeled in large inclusion 
bodies in the cytoplasm. 
D   E. coli DH5Į cells containing the viaB operon with a transposon insertion  
in vexE (pGVXN158vexE::Tn5) are shown. The Vi polysaccharide was labeled 
in large inclusion bodies in the cytoplasm. 
E   As a control E. coli DH5Į cells containing the empty plasmid pGVXN157 
are shown. 
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Defect of the outer membrane 
polysaccharide export (OPX) 
protein VexA results in cell instability
It was unexpected to detect large amounts of Vi in the cell cul-
ture supernatant and on the cell surface of E. coli harboring the 
vexA::Tn5 mutant derivative. In TEM only very occasionally cell 
surface associated Vi could be detected (Figure 3B) whereas using 
ELISA and immunoblotting (Figure 2) nearly wild-type levels of 
surface exposed capsular sugar were detected. One hypothesis to 
explain these observations would be, that cells have a functional 
transporter in the inner membrane but lack the outer membrane 
pore might show potential leakiness, therefore releasing the Vi 
from these instable cells. To test this hypothesis we analyzed the 
presence of a cytosolic protein, GroEL, in the cell culture super-
natant of individual vex mutants. Therefore, cells of an overnight 
culture equivalent to an A600 of 1 were collected and proteins 
were precipitated from the supernatant with trichloroacetic acid. 
Samples that were hereby normalized to the optical density of the 
overnight culture were separated by SDS-PAGE and GroEL was 
detected by western blot using an anti-GroEL antibody (Figure 4). 
As expected, GroEL was mainly detected in the cell pellet and 
not in the cell culture supernatant of E. coli DH5Į(pGVXN158). 
There were only traces of GroEL detectable in the supernatants 
of DH5Į(pGVXN158tviB::Tn5), DH5Į(pGVXN158vexB::Tn5), 
DH5Į(pGVXN158vexC::Tn5), DH5Į(pGVXN158vexD::Tn5) and 
DH5Į(pGVXN158vexE::Tn5). In contrast, large amounts of 
GroEL were detected in the supernatant of DH5Į(pGVXN-
158vexA::Tn5) cultures. These data indicate that in this mutant de-
rivative a propensity for cell instability does exist. Therefore, the 
Vi detectable in the ELISA gives an impression of surface asso-
ciated polysaccharide, when in fact the Vi originated from lysed 
cells. This explanation is also in agreement with the inability to ag-
glutinate DH5Į(pGVXN158vexA::Tn5) cells, or infect these cells 
with a Vi phage.
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Size exclusion chromatography of 
exported Vi produced by E.  
coli DH5Ơ(pGVXN158) and a vexE::Tn5 
 transposon insertion mutant
The observed inability of Vi expressed by DH5Į(pGVXN158-
vexE::Tn5) cells to bind to nitrocellulose membranes or form a capsule 
once transported to the cell surface lead to the hypothesis, that this 
polymer might have different physical properties compared to the 
wild-type polysaccharide. To further characterize these different Vi 
polymer species we radiolabeled the Vi and separated the purified 
Figure 4: Detection of the cytosolic protein GroEL in cell culture 
supernatants of individual vex mutants.
Either whole cells (wc) or supernatants (sn) of DH5Į cell cultures carrying the  
indicated plasmids were separated by SDS-PAGE and after transfer to a  
nitrocellulose membrane, GroEL was detected by western blot using an anti-
GroEL antibody. Supernatant samples were normalized by TCA precipitation 
to the optical density of the cell culture. In DH5Į cells expressing the wild- 
type viaB operon (pGVXN158), GroEL is mainly detected in the cell pellet. In  
contrast, the supernatant of a vexA transposon insertion mutant (pGVXN- 
158vexA::Tn5) contains substantial amounts of the cytosolic marker protein, 
indicating cell instability.
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polymers by size exclusion chromatography. DH5Į(pGVXN157), 
DH5Į(pGVXN158) or DH5Į(pGVXN158vexE::Tn5) cells were 
metabolically labeled with [3H]GlcNAc and Vi polysaccharide 
was purified from the cell culture supernatants. There was around 
600–700 times more incorporation of radioisotopes into samples 
purified from cell cultures expressing Vi than from cells carrying 
the empty plasmid, indicating that the Vi polysaccharide has been 
labeled specifically (Table II). Subsequently, [3H]Vi was analyzed by 
size exclusion chromatography using a Sephacryl S-1000 column. 
The elution profile revealed that the Vi produced by the vexE::Tn5 
mutant derivative is clearly distinguishable from the one produced 
by E. coli DH5Į(pGVXN158) (Figure 5). The wild-type Vi appears 
to have a uniform size distribution and the molecular size of the 
Vi polysaccharide was estimated to be 2 x 103 kDa against dex-
tran standards. The Vi polymer secreted by the vexE::Tn5 mu-
tant derivative displayed a tailing of the peak in the earlier elution 
fractions indicating the presence of either longer polysaccharide 
chains or the presence of a polymer with a different Stokes radius.
O-acetyl content of the 
Vi polysaccharide
The ability of a Vi phage to infect a cell is dependent on the 
expression of a Vi capsule that is partially O-acetylated at the 
C-3 position of the N-acetylgalactosaminuronic acid polymer 
[135]. The bacterial enzyme responsible for this Vi polysaccha-
ride modification has not yet been identified. PFAM analysis 
and other bioinformatics interrogations of the proteins encoded 
in the viaB locus did not identify a potential acetyltransferase 
gene. This suggests that any acetylase is located outside the 
viaB operon. The observation that a Vi phage is able to infect 
DH5Į(pGVXN158) cells implies, that it is well O-acetylated. 
Furthermore, we speculated that the different elution profiles 
observed in the size exclusion chromatographic analysis of 
Vi produced by E. coli DH5Į(pGVXN158) and a vexE::Tn5 
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Strain cpm mg-1 protein
DH5Į(pGVXN157) 459.1
DH5Į(pGVXN158) 325’984.4
DH5Į(pGVXN158vexE::Tn5) 281’563.9
Table II
Incorporation of [3H] into purified samples 
(counts/total mg protein).
Figure 5: Size exclusion chromatography of exported Vi 
produced by wild type and vexE transposon insertion mutant.
DH5Į(pGVXN158) and DH5Į(pGVXN158vexE::Tn5) cells were metabolically 
labeled with  [3H]GlcNAc and the Vi polysaccharide was purified from the  
cell culture supernatants. Purified [3H]Vi polysaccharide was analyzed by size 
exclusion chromatography using a Sephacryl S-1000 column. The elution 
profiles of the [3H]Vi preparations are shown. The void volume (vo) and the 
inclusion volume (vi) of the column are indicated. 
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transposon insertion mutant derivative could be due to a dif-
ferent degree of O-acetylation. We therefore determined O-
acetyl contents of Vi produced by S. Typhi BRD948, E. coli 
DH5Į(pGVXN158), DH5Į(pGVXN158vexC::Tn5) or DH5Į
(pGVXN158vexE::Tn5). Vi polysaccharide of these derivatives 
was purified either from the cell culture supernatant (in S. Typhi 
BRD948, DH5Į(pGVXN158) and DH5Į(pGVXN158vexE::- 
Tn5)) or from cell lysates (in DH5Į(pGVXN158vexC::Tn5)). The 
O-acetyl content of the purified Vi preparations was then meas-
ured by the alkaline hydroxylamine method of Hestrin [136]. 
The average values of the O-acetyl content from three separate 
preparations are presented in Table III. The O-acetyl content was 
comparable in all different derivatives, being around 2.5 mmol 
per gram of dried Vi polysaccharide, which corresponds to a level 
of O-acetylation of around 60 %. These data show that the Vi pro-
duced in E. coli has a similar O-acetyl content as the Vi expressed 
by S. Typhi. The undistinguishable levels of O-acetylation of Vi 
purified from the cell lysate of DH5Į(pGVXN158vexC::Tn5) in-
dicates that the O-acetylation reaction takes place in the cytosol 
and that the reaction is independent of polymer translocation. 
Furthermore, the inability of DH5Į(pGVXN158vexE::Tn5) to 
form a capsule does not correlate with different levels of O-acet-
ylation of the Vi polymer.
Table III
O-acetyl content of Vi.
Strain O-acetyl content (mmol g-1)
S. Typhi BRD948 2.4 ± 0.2
DH5Į(pGVXN158) 2.7 ± 0.2
DH5Į(pGVXN158vexC::Tn5) 2.5 ± 0.3
DH5Į(pGVXN158vexE::Tn5) 2.4 ± 0.2
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Discussion
Typhoid fever remains a serious public health problem in many 
developing countries, with, according to conservative WHO es-
timates, 16 million cases occurring each year, including about 
600,000 deaths. The Vi capsule plays an important role in S. Ty-
phi virulence by increasing the infectivity of the pathogen and the 
severity of the disease. Parenteral vaccines based on purified Vi 
CPS have been licensed and are widely used. Yet, many aspects of 
the biosynthesis, export and capsule formation of this important 
polysaccharide remain unclear. Here, a detailed molecular charac-
terization of the viaB operon, encoding the biosynthetic machin-
ery for Vi capsule formation is reported.
O-acetylation of the Vi
The Vi CPS is a linear, acidic homopolymer of Į-1,4-linked N-
acetylgalactosaminuronate (D-GalNAcA), 60–90 % O-acetylated 
at the C-3. The bulky nonpolar O-acetyl groups make up most of 
the surface of the Vi and complete O-deacetylation eliminates the 
immunogenicity of this CPS [35]. The bacterial enzyme capable of 
introducing this modification in the Vi has not yet been described. 
PFAM analysis of the proteins encoded in the viaB operon did not 
identify an O-acetyltransferase domain, indicating that the gene is 
located outside the viaB cluster in the S. Typhi genome. This situa-
tion has been demonstrated for the phase-variable O-acetylation of 
the group 2 capsule of E. coli K1. In this bacteria the modification 
is catalyzed by a prophage encoded O-acetyltransferase that is not 
linked to the capsular cluster [137].
 Clearly the viaB operon can be functionally expressed in E. coli 
[122,138]. However, the Vi expressed in E. coli has not yet been 
thoroughly characterized and the presence of O-acetyl modifica-
tions was equivocal. We found that the Vi produced in E. coli is rec-
ognized by Vi phage types I–VII, thereby converting E. coli into a 
Vi phage susceptible bacteria. Recognition of Vi polymer by a Vi 
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phage is dependent on the presence of O-acetyl groups at the C-3 
position of the N-acetylgalactosaminuronate (GalNAcA) build-
ing blocks and it has been shown that phage particles have dea-
cetylating properties [135]. A conserved protein domain carrying 
an acetyl esterase was found to be associated with at least one tail 
fiber gene for all Vi phages [139]. This implies that in contrast to 
the tip enzymes of K1 or K5 phages, that degrade the polysaccha-
ride backbone, the Vi phages specifically target the acetyl modifica-
tion on the sugar polymer. Besides the observed susceptibility to 
Vi phage infection, we could show through chemical analysis that 
the Vi produced in E. coli is substantially O-acetylated. In addition, 
a similar degree of O-acetylation could be measured in an intra-
cellular Vi preparation produced by a transporter deficient mutant 
(DH5Į(pGVXN158vexC::Tn5)), indicating that O-acetylation is tak-
ing place in the cytoplasm and that it is a translocation independent 
process.
Vi productivity in E. coli 
DH5Ơ(pGVXN158) is higher compared 
to S. Typhi BRD948
It was observed that E. coli cells expressing the wild-type viaB op-
eron produce around 6–7 times more Vi than S. Typhi BRD948. 
This observation could be explained by the presence of the viaB 
cluster in different copy numbers in the particular expression sys-
tems. The pLAFR1 plasmid derivative that contains the viaB clus-
ter is reported to be present in 5–7 copies per cell [140], whereas 
S. Typhi BRD948 holds a single viaB operon. Furthermore, spon-
taneous loss of SPI-7 in Vi-negative S. Typhi has been reported 
in stored isolates [141]. The robust plasmid borne expression of 
the Vi might additionally account for the difference seen in CPS 
productivity. The observed high efficiency of wild-type Vi poly-
saccharide production in E. coli makes this strain a good model 
system to characterize Vi capsule formation and an interesting Vi 
production system.
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tviBCDE is the minimal set of  
genes required for Vi 
polysaccharide synthesis
Our data confirm the results obtained by Virlogeux et al., 1995, 
that TviB, TviC, TviD and TviE are required for Vi polymer as-
sembly. Firstly, no Vi could be detected in these individual trans-
poson insertion mutants. Secondly, intracellular Vi was identified 
in E. coli cells carrying a plasmid encoding tviBCDE (results not 
shown). The latter result indicates that the Vi polymer is assem-
bled in the cytoplasm and that assembly is independent of the 
translocation machinery. Similar results have been obtained with 
the well-characterized group 2 capsule of E. coli K1. It has been 
shown that cells harboring a plasmid encoding the biosynthetic 
region-2 genes alone can synthesize intracellular polysialic acid 
[142]. Additionally, synthesis of full-length polymer has been 
shown to occur in vitro and in a variety of transport-deficient 
backgrounds in vivo [143,144].
Synthesis and export of the 
Vi polysaccharide seem  
to be coupled processes
It appears to be common to group 2-like capsules that biosyn-
thesis of intracellular polymer is independent of the sugar export 
machinery. However, Vi quantification in the different vex::Tn5 
transposon insertion mutants that encode the CPS transporter 
(vexABCD) by ELISA demonstrated different productivity in 
the individual mutants. Whereas DH5Į(pGVXN158vexA::Tn5) 
expressed almost wild-type levels of Vi, the CPS productivity in 
DH5Į(pGVXN158vexB::Tn5), DH5Į(pGVXN158vexC::Tn5) and 
DH5Į(pGVXN158vexD::Tn5) was greatly reduced. This result in-
dicates that synthesis and export of the Vi are coupled processes. 
A reduction in endogenous glycosyltransferase activity has also 
been shown for E. coli K1 cells harboring export defects [128,143]. 
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Moreover, the formation of a hetero-oligomeric complex consist-
ing of both biosynthetic and export machinery has been demon-
strated in E. coli K5 [145] and E. coli K1 [146]. It is possible that 
the predicted inner membrane associated components of the Vi 
transporter (VexB, VexC and VexD) interact with the cytoplasmic 
based biosynthetic machinery and that disruption of the transport-
er indirectly decreases biosynthesis of the Vi polymer by unknown 
mechanisms. It seems that this observed negative feedback mecha-
nism between a non-functional exporter and the biosynthesis of 
Vi polymer does not exist when the outer membrane polysaccha-
ride export protein VexA is nonfunctional. These mutant cells pro-
duce almost wild-type amounts of CPS. Furthermore, the Vi could 
sometimes be detected clustered against the inner membrane by 
transmission electron microscopy in DH5Į(pGVXN158vexA::Tn5) 
cells, which might indicate the formation of a functional complex 
between inner membrane export and biosynthesis components. 
Nevertheless, periplasmic accumulations of Vi could not be detect-
ed in these mutant cells as it has been described for E. coli K1 and 
K5 mutations in the homologous gene kpsD [147,148].
 DH5Į(pGVXN158vexC::Tn5) cells accumulated the Vi polysac-
charide in large intracellular, inclusion-like bodies as seen by trans-
mission electron microscopy. This phenotype has also been de-
scribed in E. coli K1 [144,149]. However, inactivation of the E. coli 
K1 ABC transporter protein KpsT, resulted in a slightly different 
localization of the K1 polymer within the cell, where it accumulated 
at discrete sites around the periphery of the cells, located against 
the cytosolic membrane.
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High Vi expression and non-
functional export machinery results 
in cell instability
Our data clearly demonstrate that the high levels of Vi produced 
in DH5Į(pGVXN158vexA::Tn5) cells is not cell surface exposed. 
These cells can neither be agglutinated using Vi specific antisera 
nor be infected by a Vi phage. In addition, transmission electron 
microscopy pictures of these mutant cells do not show a capsule but 
intracellular accumulations of the Vi polymer. Substantial amounts 
of the cytosolic protein GroEL could be detected in the cell culture 
supernatant, indicating that large amounts of Vi produced by this 
export deficient mutant destabilize the cell. The Vi detected in the 
cell culture supernatant and in fixed cells by ELISA and immuno-
blot represents therefore not translocated but rather released poly-
saccharide from lysed cells. In transporter deficient mutants show-
ing reduced Vi assembly activity (DH5Į(pGVXN158vexB::Tn5), 
DH5Į(pGVXN158vexC::Tn5) and DH5Į(pGVXN158vexD::Tn5)) 
less GroEL was detected in the cell culture supernatant compared 
to the vexA::Tn5 transposon insertion mutant. It seems that the 
level of Vi biosynthesis in transporter deficient mutants correlates 
with cell instability. The observed destabilizing effect of intracellu-
lar CPS accumulations on cell integrity also underlines the neces-
sity that assembly and export have to be coupled and coordinated 
processes. However, the observed phenotype of a vexA mutant 
might be less pronounced in a S. Typhi where the Vi polysaccha-
ride is not overexpressed.
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Retention of the Vi polysaccharide 
on the cell surface is dependent 
on VexE
VexE shows no homologies to other proteins encoded in group 
2-like capsular gene clusters and it is exclusively found in the viaB 
operon. PFAM analysis of VexE identified a C-terminal acyltrans-
ferase domain also found in HtrB (LpxL), an enzyme involved 
in Kdo2-Lipid A biosynthesis. Vi quantification by ELISA dem-
onstrated, that Vi production in DH5Į(pGVXN158vexE::Tn5) cells 
was only slightly decreased compared to E. coli cells expressing 
the wild-type viaB operon. The Vi polysaccharide produced by a 
vexE::Tn5 mutant is mainly found in the cell culture supernatant 
as determined by ELISA. There was no Vi visualized in the extra-
cellular spaces by TEM and immunogold labeling, but this could 
be lost during sample preparation. Together, these results indicate 
that the Vi in a vexE::Tn5 mutant is efficiently transported to the 
cell surface, but once translocated, the polysaccharide is not re-
tained on the cell surface but is rather secreted. Therefore these 
mutant cells can neither be agglutinated using Vi specific antisera 
nor be infected by a Vi phage. Besides the observed inability of 
this Vi species to form a capsule, the polysaccharide also does not 
bind to nitrocellulose membranes, indicating that this species has 
different physical characteristics compared to the wild type Vi. We 
can rule out that the observed properties are due to a different 
degree in O-acetylation because in both Vi preparations a simi-
lar O-acetyl content was determined. However, these observations 
might be explained by a lipid modification that is introduced by the 
acyltransferase-like enzyme VexE. In addition, the polysaccharide 
produced by a vexE::Tn5 mutant displays a broader size distribu-
tion compared to the wild-type Vi on a Sephacryl S-1000 column. 
This lipid modification might lead to a different stoke radius, ex-
plaining the different behavior in size exclusion chromatography. 
It is equivocal if the observed phenotype of a vexE mutant plays 
a biological role. It might be possible that S. Typhi can switch be-
tween a capsule producing and a Vi secreting state during differ-
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ent stages of pathogenesis by regulating VexE activity. The precise 
function of VexE in Vi capsule formation should be addressed in 
future research. 
Conclusions
In summary, we conclude that the Vi capsule biosynthesis shows 
many characteristics that are typical for group 2-like capsules. The 
Vi is completely assembled in the cytoplasm by the gene products 
of tviBCDE, and is subsequently transported to the cell surface by 
an ABC transporter encoded by vexABCD, that closely resembles 
the transporters of the Haemophilus influenzae type b and Neisse-
ria meningitides group B CPSs. However, several genes indicative 
for E. coli group 2 capsular gene clusters, like kpsFU and kpsSC, 
that are believed to be involved in CMP-Kdo synthesis and the 
speculative addition of a diacylglycerophosphate-Kdo to the CPS 
[106], are absent in the viaB operon. In contrast, the viaB operon 
contains a gene, vexE, uniquely found in this cluster and possibly 
involved in lipidation of the Vi polysaccharide. Despite sharing the 
basic mechanism of group 2-like capsule formation, biosynthesis 
of the Vi capsule displays features uniquely found in this cell sur-
face structure.
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Materials and Methods
Strains, plasmids, 
and culture conditions
All bacterial strains and plasmids used in this study are listed in 
Table IV. Construction of the plasmids is described below. E. coli 
DH5Į and EC100 were grown in LB medium (10 g tryptone, 5 g 
yeast extract, and 5 g NaCl per liter) or on LB agar (LB medium 
with the addition of 15 g agar per liter) at 37 °C. S. Typhi BRD948 
[60] was grown in LB medium supplemented with 1 % v/v Aro-
mix (40 mg L-phenylalanine, 40 mg L-tryptophan, 10 mg 4-ami-
nobenzoic acid, and 10 mg 2,3-dihydroxybenzoic acid in 10 ml of 
ddH2O) and 1 % v/v Tyr-mix (40 mg L-tyrosine disodium salt in 
10 ml ddH2O) at 37 °C. If appropriate, the media contained tet-
racycline (20 µg ml-1), trimethoprim (100 µg ml-1), or kanamycin 
(50 µg ml-1). Cells containing pEXT22 derivatives were grown 
in the presence of 1 mM isopropyl ȕ-D-1-thiogalactopyranoside 
(IPTG).
DNA manipulations
Plasmid DNA was isolated using the NucleoSpin Plasmid or 
NucleoBond Xtra Maxi Plus kit (Macherey-Nagel). Total chro-
mosomal DNA was isolated using NucleoSpin Tissue kit (Mach-
erey-Nagel). Restriction enzymes (Fermentas), shrimp alkaline 
phosphatase (Fermentas), T4 DNA ligase (Fermentas), and Phu-
sion High-Fidelity DNA polymerase (Finnzyme) were used ac-
cording to the manufacturer’s instructions. PCR and restriction 
fragments were purified for cloning using the NucleoSpin Extract 
II kit (Macherey-Nagel). All DNA sequencing was completed by 
Synergene Biotech GmbH (Switzerland) and synthetic oligonu-
cleotides were ordered at Microsynth AG (Switzerland).
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Strain Genotype or relevant description Reference
S. Typhi BRD948 S. Typhi Ty2 ǻaroC ǻaroD [60]
E. coli DH5Į K-12 ĳ80dlacZǻM15 endA1 recA1 hsdR17(rK−mK) 
supE44 thi-1 gyrA96 relA1 ǻ(lacZYA-argF)U169 F−
Clonetech
E. coli EC100 F– mcrA ǻ(mrr-hsdRMS-mcrBC) ĭ80dlacZǻM15 
ǻlacX74 recA1 endA1 araD139 ǻ(ara, leu)7697 galU 
galK Ȝ– rpsL nupG
Epicentre
Plasmid Genotype or relevant description Reference
pLAFR1 low copy-number broad host-range cosmid cloning 
vector; TetR 
[140]
pGVXN157 pLAFR1 derivative with multiple cloning site inserted  
in EcoRI site
This study
pGVXN158 pGVXN157 derivative carrying viaB operon  
of S. Typhi BRD948 on an AscI/SpeI fragment; TetR
This study
pGVXN209 pGVXN158 with tviB::Tn5 insertion  
(pGVXN158tviB::Tn5); TetR, TmpR
This study
pGVXN224 pGVXN158 with tviC::Tn5 insertion  
(pGVXN158tviC::Tn5); TetR, TmpR
This study
pGVXN198 pGVXN158 with tviD::Tn5 insertion  
(pGVXN158tviD::Tn5); TetR, TmpR
This study
pGVXN200 pGVXN158 with tviE::Tn5 insertion  
(pGVXN158tviE::Tn5); TetR, TmpR
This study
pGVXN225 pGVXN158 with vexA::Tn5 insertion 
(pGVXN158vexA::Tn5); TetR, TmpR
This study
pGVXN227 pGVXN158 with vexB::Tn5 insertion 
(pGVXN158vexB::Tn5); TetR, TmpR
This study
pGVXN201 pGVXN158 with vexC::Tn5 insertion 
(pGVXN158vexC::Tn5); TetR, TmpR
This study
pGVXN202 pGVXN158 with vexD::Tn5 insertion 
(pGVXN158vexD::Tn5); TetR, TmpR
This study
pGVXN204 pGVXN158 with vexE::Tn5 insertion 
(pGVXN158vexE::Tn5); TetR, TmpR
This study
Table IV
Strains and plasmids used in this study.
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Plasmid constructions
pGVXN158 contains the viaB cluster cloned into the pLAFR1 [140] 
derivative pGVXN157. pGVXN157 contains a synthetic oligo- 
nucleotide cassette formed from annealing of 5’- AATTGGCG-
CGCCCGGGACTAGTCTTGGG and 5’- AATTCCCAAGA- 
CTAGTCCCGGGCGCGCC ligated into the EcoRI-digested 
pLAFR1 therefore introducing unique AscI and SpeI single restric-
tion sites. The viaB gene cluster was amplified from genomic DNA 
prepared from S. Typhi BRD948 using the primers 5’- AAAG-
GCGCGCCGGAGTATCAGTGTGGGGCATAATC and 5’- 
AAAACTAGTGGCCATGAGTCTGAAGCCAGGAG- 
GAATT. The viaB cluster containing PCR fragment was insert-
ed into the AscI/SpeI digested pGVXN157 therefore producing 
pGVXN158. 
Transposon insertion 
mutagenesis and screening of 
viaB insertion mutants
In vitro transposon insertion mutagenesis was done with pGV-
XN158 containing the viaB cluster using the EZ-Tn5 <DHFR-
1> insertion kit (Epicentre Biotechnologies, Madison WI 53713, 
U.S.A.) according to manufacturer’s instructions. The in vitro 
transposon insertion reaction was transformed into TransforMax 
EC100 electrocompetent E. coli (Epicentre) and insertion mutants 
were selected for the marker encoded by the EZ-Tn5 transposon 
(dihydrofolate reductase gene (dhfr-1)) on trimethoprim contain-
ing plates. To identify transposon insertions into single genes of 
the viaB cluster the library was screened for Vi negative colonies. 
Therefore a colony blot was performed. Transformants were trans-
ferred to a nitrocellulose membrane. After washing the membrane 
3 x with PBST (PBS, 0.1 % Tween 20) for 10 min the membranes 
were blocked by incubating with 10 % milk in PBST for 1 h on 
a shaker at room temperature (RT). Membranes were incubated 
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with a monoclonal anti Vi antibody (P2B1G2/A9, [134]) diluted 
1:100 in 1 % milk in PBST for 1 h. After washing the membranes 
3 x with PBST the membranes were incubated with a horseradish 
peroxidase labeled goat anti-mouse IgG (Sigma, A9824) diluted 
1:2000 in 1 % milk in PBST. Membranes were developed using 
3,3ƍ,5,5ƍ-tetramethylbenzidine (TMB) liquid substrate system for 
membranes (Sigma). Plasmid DNA of Vi negative colonies or 
colonies that appeared to have a reduced expression of the Vi cap-
sule was isolated and the transposon insertion site was mapped 
by sequencing out of the EZ-Tn5 <DHFR-1> transposon using 
primers DHFR-1 RP-1 and DHFR-1 FP-1 provided with the 
EZ-Tn5 transposon insertion kit. Single gene insertion mutants 
of every gene of the viaB cluster except tviA were selected. In all 
the selected mutants the coding strand of the transposon encoded 
dhfr-1 gene was identical to the coding strand of the genes in the 
viaB cluster.
Antibody detection of Vi 
antigen on washed cells and in cell 
culture supernatants
Overnight cultures were centrifuged and the supernatant was sep-
arated from the cell pellet. The cells were washed 3 x with PBS 
and finally resuspended in an equal volume of PBS. 100 µl of cell 
culture supernatant and washed cells were pipetted onto nitrocel-
lulose, and the membranes were blocked for 1 h at room tempera-
ture in 10 % milk in PBST (PBS, 0.1 % Tween 20). The presence of 
Vi was detected by using a monoclonal anti Vi antibody (P2B1G2/
A9, [134]) as the primary antiserum, followed by horseradish per-
oxidase labeled goat anti-mouse IgG (Sigma, A9824). Membranes 
were developed using 3,3ƍ,5,5ƍ-tetramethylbenzidine (TMB) liq-
uid substrate system for membranes (Sigma).
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Sample preparation for measuring
Vi content by ELISA
1 ml of an overnight culture was centrifuged 5 min at 20’000 g us-
ing an eppendorf microcentrifuge. The supernatant was separated 
from the cell pellet and used to measure Vi content. The pellet was 
washed 3 x with PBS and divided into two eppendorf tubes. One 
half of the cells was fixed by resuspending the pellet in 4 % para-
formaldehyde in PBS and incubation for 30 min at RT. Afterwards 
the fixed cells were washed 3 x with PBS and cell associated Vi 
was measured. The other half of the washed cells was lysed using 
B-PER protein extraction reagents (Pierce) according to manu-
facturer’s instructions. Protein and Vi contents were measured in 
the cell lysate by the bicinchoninic acid assay (BCA, Pierce) and 
ELISA. The amount of intracellular Vi was defined using the dif-
ference in Vi measured in cell lysates and in fixed cells. The Vi con-
tent of different samples was normalized to the protein amount 
measured in the cell pellets.
Vi quantification by ELISA
Vi polysaccharide content of samples was measured using a sand-
wich ELISA. Two monoclonal Vi specific mouse antibodies P2B1G2/
A9 (IgG1, coating antibody) and P5B2D8/A9 (IgM, primary anti-
body) were used in the ELISA and are described elsewhere [134]. 
In order to saturate the binding of the Vi to the ELISA plate, the 
coating antibody P2B1G2/A9 was partially purified from the hybri-
doma supernatant using a 5 ml HiTrap Protein A HP column (GE 
Healthcare). Briefly, 50 ml of P2B1G2/A9 hybridoma supernatant 
were diluted 1:10 with binding buffer (20 mM sodium phosphate, 
pH 7.5) and loaded on the Protein A column using a peristaltic 
pump at a flow rate of 20 ml min-1. The column was eluted with 100 
mM citric acid pH 3.25 and 1 ml fractions were collected. The tubes 
destined to collect the antibody fractions contained 100 µl 1 M Tris-
HCl, pH 9.0 to instantly neutralize the sample.
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 Flat bottom 96 well micro-titer plates (Nunc immuno Max-
iSorb) were coated with 50 µl of the partially purified antibody 
P2B1G2/A9, diluted 1:100 in PBS, at 4 °C overnight. The coating 
solution was poured away and the plate was submerged and vig-
orously agitated in 4000 ml of wash buffer (1 x PBS with 0.05 % 
Triton X 100). This washing step was performed at least 4 times 
to completely wash out unbound antibody. Subsequently, the plate 
was dried by spinning upside down in a micro plate rotor. This 
washing procedure was always applied in further washing steps. 
Each well was completely filled with 300 µl of blocking buffer (1 x 
PBS with 2.5 % BSA (globulin free BSA, Sigma, A7030)) and in-
cubated 2 h at RT on a plate shaker. After washing and drying the 
plate the sample was applied in an appropriate dilution in dilution 
buffer (1 x PBS with 0.5 % BSA). As a standard, Vi polysaccharide 
(Typhim Vi, Sanofi Pasteur MSD) was used in several dilutions in 
the range from 0–4 ng ml-1. 100 µl of sample and standard were ap-
plied in doublicates to the corresponding wells and incubated 1 h 
at RT on a plate shaker. After washing and drying the plate, 100 µl 
of the primary antibody (hybridoma supernatant of P5B2D8/A9) 
diluted 1:100 in dilution buffer was added to the wells and incubat-
ed 1 h at RT on a plate shaker. After another washing and drying 
step the wells were incubated with 100 µl of secondary antibody 
(goat anti-mouse IgM peroxidase conjugated, Sigma A8786) di-
luted 1:2000 in dilution buffer for 1 h at RT on a plate shaker. Fol-
lowing washing and drying the reaction was developed with 100 µl 
of Ultra TMB substrate (3,3’,5,5’-tetramethybenzidine liquid sub-
strate, Pierce) for 15 min and stopped with the addition 100 µl of 2 
M sulphuric acid. The bottom surface of the plate was wiped with 
70 % 2-propanol and the absorption at 450 nm was measured.
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Vi polysaccharide purification
Vi polysaccharide was purified by a modified procedure as descri- 
bed elsewhere [150]. The Vi was either purified from the cell cul-
ture supernatant (in strains S. Typhi BRD948, DH5Į(pGVXN158) 
and DH5Į(pGVXN158vexE::Tn5)) or from sonicated cells that 
were treated with proteinase K and nucleases (in strain DH5Į
(pGVXN158vexC::Tn5)). Vi was precipitated from the supernatant 
or enzyme treated cell lysate with 0.1 % hexadecyltrimethylammo-
nium bromide (CTAB, Sigma, H6269). 20 g l-1 celite 545 (Sigma, 
20199-U) was added and the mixture was stirred for 1 h at RT in 
order to allow the formation of a polysaccharide-CTAB complex, 
which adsorbs onto the celite. The celite was poured into a reser-
voir of appropriate size (Extract-clean EV SPE Reservoir, Socochim 
S.A.) equipped with a frit (Socochim S.A.). The column was washed 
successively by gravity flow with 10 column volumes (CV) of 0.05 % 
CTAB, 10 CV of 20 % ethanol, 50 mM sodium phosphate buffer pH 
6.0, and 15 CV of 45 % ethanol to eliminate adsorbed impurities. The 
Vi polysaccharide was finally eluted with 1.5 CV of 50 % ethanol, 0.4 
M NaCl. Following elution, the polysaccharide was precipitated by 
addition of ethanol to a final concentration of 80 % and incubation 
for 20 min at RT. The precipitate was washed twice with 80 % etha-
nol prior to lyophilization. The protein and nucleic acid content of 
the purified Vi polysaccharide was determined by the bicinchoninic 
acid assay (BCA, Pierce) and UV spectroscopy respectively.
Determination of O-acetyl content 
in the Vi polysaccharide
The method was used as described elsewhere [136]. Briefly, the O-
acetyl groups were released by mild base treatment of the Vi poly-
saccharide solution. The O-acetyl groups reacted with the added 
hydroxylamine in alkali to form hydroxamic acid. The formed hy-
droxamic acid was measured by the formation of a purple-brown 
complex with Fe3+. Acetylcholine was used as a standard.
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Radiolabeling of Vi polysaccharide
Cells were cultured in LB medium supplemented with antibiot-
ics at 37 °C in the shaker incubator (180 rpm). Cultures were 
inoculated from an overnight culture to an A600 of 0.01. After 4 
cell doublings, 1 µCi ml-1 [3H]GlcNAc (American Radiolabeled 
Chemicals, Inc., ART 0142) was added and the culture was in-
cubated 2 h at 37 °C in the shaker incubator. After incubation the 
cells were centrifuged and the cell culture supernatant was used to 
purify the labeled Vi polysaccharide as described above. After dry-
ing of the purified Vi, the polysaccharide was resuspended in 50 
mM NaCl. Incorporation of radioactivity in the purified samples 
was measured and normalized to the protein content measured in 
the cell pellets.
Size exclusion chromatography
Sephacryl S-1000 (GE Lifescience) gel filtration medium was 
used in a column with the proportions of 23 cm x 1.7 cm (height 
x diameter). Chromatography was done by gravity flow using 50 
mM NaCl as the mobile phase and 1 ml fractions were collected.
Transmission Electron Microscopy (TEM)
TEM was done as described elsewhere [151].
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Abstract
State-of-the-art production technologies for conjugate vaccines 
are complex, multi-step processes. An alternative approach to pro-
duce glycoconjugates is based on the bacterial N-linked protein 
glycosylation system first described in Campylobacter jejuni. The 
C. jejuni N-glycosylation system has been successfully transferred 
into Escherichia coli, enabling in vivo production of customized re-
combinant glycoproteins. However, some antigenic bacterial cell 
surface polysaccharides, like the Vi antigen of Salmonella enterica 
serovar Typhi, have not been reported to be accessible to the bac-
terial oligosaccharyltransferase PglB, hence hamper development 
of novel conjugate vaccines against typhoid fever. In this report, 
Vi-like polysaccharide structures that can be transferred by PglB 
were evaluated as typhoid vaccine components. A polysaccharide 
fulfilling these requirements was found in Escherichia coli serovar 
O121. Inactivation of the E. coli O121 O antigen cluster encoded 
gene wbqG resulted in expression of O polysaccharides reactive 
with antibodies raised against the Vi antigen. The structure of the 
recombinantly expressed mutant O polysaccharide was elucidated 
using a novel HPLC and mass spectrometry based method for 
purified undecaprenyl pyrophosphate (Und-PP)-linked glycans, 
and the presence of epitopes also found in the Vi antigen was con-
firmed. The mutant O antigen structure was transferred to accep-
tor proteins using the bacterial N-glycosylation system, and im-
munogenicity of the resulting conjugates was evaluated in mice. 
The conjugate-induced antibodies reacted in an enzyme-linked 
immunosorbent assay with E. coli O121 LPS. One animal devel-
oped a significant rise in serum immunoglobulin anti-Vi titer upon 
immunization.
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Introduction
Typhoid fever remains a serious public health problem of which 
there are 22–33 million cases occurring each year, including 
about 216’000–500’000 deaths [23]. The causative agent of this 
human systemic infection, Salmonella enterica subspecies I sero-
var Typhi (S. Typhi), is feco-orally transmitted through contami-
nated water and food. Hence, typhoid fever is endemic in less 
developed areas where sanitary conditions remain poor. This in-
cludes many countries of Asia, Africa and South America, where 
schoolchildren and young adults are most frequently affected 
[152]. Antimicrobial treatment of typhoid fever has become in-
creasingly complicated through the emergence of multidrug re-
sistant strains of S. Typhi [30].
 Vaccination of high-risk populations is considered the most 
promising strategy for the control and prevention of typhoid fe-
ver. Currently, there are two licensed typhoid vaccines: the orally 
administered, live attenuated whole cell vaccine Ty21a and the 
purified Vi polysaccharide parenteral vaccine. The Ty21a vaccine 
has several disadvantages: (i) The mutations contributing to the 
attenuated phenotype of this S. Typhi strain are not fully defined 
[47], (ii) attenuated strains could theoretically revert to virulence 
and (iii) Ty21a is only modestly immunogenic and requires three 
to four initial doses and boosters every 5 years [57,58,153-155]. 
The usefulness of the Vi polysaccharide vaccine is limited by its 
age-related immunogenicity and the fact that immune responses 
against polysaccharides are T cell independent. Therefore, immu-
nological memory cannot be established and revaccination does 
not elicit any booster response [156,157]. Due to these drawbacks, 
the replacement of current typhoid vaccines with well defined, well 
tolerated and highly immunogenic vaccines is desirable.
 The disadvantages of a polysaccharide vaccine can be over-
come by conjugating the carbohydrate to a protein carrier (con-
jugate vaccine). Upon conjugation, the polysaccharide behaves 
like a T cell dependent antigen. It has been shown that purified Vi 
polysaccharide covalently linked to recombinant Pseudomonas aer-
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uginosa exotoxin A (EPA) induces a protective immune response 
against S. Typhi in young children [41,80].
 However, production of conjugate vaccines is a complex, mul-
ti-step process. First, separate bacterial strains producing the re-
combinant protein carrier and the polysaccharide antigen have to 
be cultivated. The polysaccharide and the protein carrier have to 
be purified by different procedures, before the two components 
are chemically coupled. The last step involves additional purifica-
tion steps for obtaining the final product. This laborious produc-
tion process has disadvantages: (i) several purification steps are 
required, where considerable losses might occur and (ii) due to the 
random nature of chemical coupling the product is not a uniform 
structure but a mixture of different glycoconjugates, with poten-
tially different efficacy profile.
 A novel approach to produce conjugate vaccines is based on the 
bacterial N-linked glycosylation system first described in Campy-
lobacter jejuni [100,101]. This protein glycosylation system can be 
functionally transferred into Escherichia coli to produce specified 
glycoproteins in vivo [101]. It has been shown that various bacte-
rial polysaccharide structures assembled on the lipid carrier unde-
caprenyl pyrophosphate (Und-PP) can be transferred to selected 
periplasmic proteins by the oligosaccharyltransferase PglB of C. 
jejuni [102,103]. Furthermore, it is possible to produce recom-
binant glycoproteins by grafting the consensus sequence for N-
glycosylation (D/E-Y-N-X-S/T, where Y and X can be any amino 
acid except proline) into proteins which are otherwise not glyco-
sylated [104]. This cost-efficient in vivo production of glycoconju-
gates represents an alternative to the conventional manufacturing 
process.
 Vi is a linear, acidic homopolymer of Į-1,4-linked N-acetylga-
lactosaminuronic acid (D-GalNAcA) residues, 60-90 % O-acety-
lated at C-3 (Figure 1). Immunogenicity of the Vi is closely related 
to its degree of O-acetylation [35,36]. Analysis of the bioinformat-
ics signature of the Vi biosynthetic gene cluster (viaB) highlighted 
the presence of a putative ABC transporter and the absence of 
a wzy polymerase. Therefore, biosynthesis of Vi is thought to be 
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similar to group 2 capsular polysaccharides (CPS). This class of 
CPSs is most likely not assembled on Und-PP and no periplasmic 
intermediates exist [106], which are both prerequisites for being a 
substrate of PglB. However, Und-PP-linked polysaccharides ex-
ist in bacteria that resemble the Vi antigen. The O antigen of E. 
coli O121 (identical to Shigella dysenteriae type 7) contains an N-
acetylgalactosaminuronamide (D-GalNAcAN) residue, partially 
O-acetylated at the C-3, which is Į-1,4-linked to a D-GalNAcA 
(Figure 1) [158]. The O antigen cluster of E. coli O121 contains the 
gene wbqG, encoding a glutamine-dependent amidotransferase in-
volved in the biosynthesis of UDP-D-GalNAcAN [159]. It has 
Figure 1: Structure of the Salmonella Typhi Vi polysaccharide  
and the repeating unit of the Escherichia coli O121 O antigen.
Mutation of the O121 O antigen cluster encoded gene wbqG results in 
expression of a modified O polysaccharide structure. GalNAcA: 2-acetamido-
2-deoxy-D-galacturonic acid; GalNAcAN: 2-acetamido-2-deoxy-D-galacturon-
amide; Qui4N: 4-amino-4,6-dideoxy-D-glucose.
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been shown that the O antigen of an E. coli O121 wbqG mutant 
contains D-GalNAcA (30-40 % O-acetylated at C-3) instead of 
D-GalNAcAN [159]. Hence, this mutant O polysaccharide con-
tains structural similarities to the Vi (Figure 1). 
 In this study the possibilities of producing a typhoid conjugate 
vaccine using the bacterial N-glycosylation system were exploited. 
The cross-reactivity of the E. coli O121 wbqG mutant O antigen 
with antibodies raised against the Vi is reported. Furthermore, gly-
coconjugates were produced and their immunogenicity was ana-
lyzed in mice.
Results
Analysis of the E. coli O121 wbqG 
mutant O polysaccharide.
First we examined whether the O polysaccharide produced by 
an E. coli O121 wbqG mutant would be recognized by antibod-
ies specific for the Salmonella Typhi Vi capsular polysaccharide. 
Therefore, the E. coli O121 O antigen gene cluster was cloned, 
and the open reading frame of wbqG was interrupted by insertion 
of a STOP codon containing oligocassette. The cloned plasmids 
were transformed into the E. coli K-12 strain W3110 and the li-
popolysaccharide (LPS) was analyzed by SDS-PAGE and staining 
with silver, or after transferring to a nitrocellulose membrane by 
Western blot (Figure 2A). As previously reported, mutation of the 
wbqG gene did not abolish O antigen expression [159]. However, 
the LPS profile of the wbqG mutant visualized in the silver-stained 
polyacrylamide gel differed from the wild type in several points: (i) 
the staining of polymerized O antigen containing bands is fainter 
relative to wild type LPS, (ii) the band consisting of one O anti-
gen repeating unit attached to the lipid A-core (core+1RU) stained 
more intensely and (iii) the O antigen containing bands migrated 
faster than the equivalent bands of the wild type LPS. It was esti-
mated that both LPS profiles contained an average of 12 O antigen 
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repeat units attached to the lipid A-core by analyzing an overex-
posed silver-stained SDS-PAGE gel. Western blot analysis of the 
LPS revealed that anti-O121 sera reacted with the wbqG mutant 
O antigen. Interestingly, the wbqG mutant O polysaccharide was 
recognized by anti-Vi serum.
 In order to confirm the structure of the expressed O antigen 
repeat unit and to determine the degree of O-acetylation, glycolip-
ids were extracted from E. coli SCM6 strains expressing either the 
O121 wild type or the wbqG mutant O antigen. The lipid-linked 
oligosaccharides were purified using a C18 SepPak column and 
treatment with mild acid specifically released Und-PP-linked gly-
cans. After an additional purification step using again a C18 SepPak 
column, the glycans were labeled with 2-aminobenzamide (2AB) 
and subsequently resolved by normal phase HPLC using a Gly-
coSep N column. Figure 2B shows a section of the chromatogram 
where single repeat units and short polymerized O antigens are ex-
pected to elute. Fractions containing putative 2AB-labeled glycan 
species were analyzed by mass spectrometry (MS) (Figure 3), and 
the glycan structures identified by MS are illustrated in Figure 2B.
 The chromatogram of the 2AB-labeled glycans prepared from 
SCM6 cells expressing the O121 wild type O antigen, featured a 
peak eluting at 58.8 min. In this peak fraction a molecule with a 
mass-to-charge ratio (m/z) of 1083 was identified. The peak frac-
tion with the retention time of 65.1 min contained mainly a species 
with m/z of 1041. This detected m/z corresponded to the single-
charged sodium adduct of a 2AB-labeled, non-acetylated O121 
wild type subunit. The difference between the two detected masses 
corresponded to 42 Da, which is the mass difference between an 
O-acetyl and a hydroxyl group. These two species were subjected 
to collisionally induced dissociation (CID) MS-MS. The series of 
single-charged fragment ions obtained from the precursor with m/z 
of 1083 (Figure 3A) was consistent with glycosidic cleavage products 
from the 2AB-labeled O121 wild type O antigen repeat unit, con-
taining an O-acetyl group at residue c. Whereas the CID MS-MS 
spectra of the molecular species with m/z of 1041 corresponded to 
the non-acetylated 2AB-labeled O121 subunit (Figure 3B).
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 The chromatogram of the 2AB-labeled glycans prepared 
from SCM6 cells expressing the wbqG mutant polysaccharide re-
vealed two prominent peaks. In the peak fraction with the reten-
tion time of 67.2 min a molecule with m/z of 1084 was detected. 
This measured mass differed by 1 Da from the mass measured 
in the corresponding peak of the O121 wild type trace eluting at 
58.8 min. Likewise an m/z of 1042 was measured for the 2AB-
labeled molecule with a retention time of 73.5 min. CID MS-MS 
of these precursor ions (Figure 3C and 3D) resulted in a fragmenta-
tion pattern that resembled the spectra obtained from the O121 
wild type 2AB-labeled glycans. The measured mass difference of 
1 Da was assigned to residue c of the glycan structure. The mass 
difference of 1 Da corresponded to the calculated mass differ-
ence between an acid and an amide group, in agreement with the 
published structure of the wbqG mutant O antigen [159].
 Furthermore polymerized 2AB-labeled O antigen subunits 
were identified in the O121 wild type trace. Two subunits variably 
O-acetylated were identified in the peak fractions with the reten-
tion times 83.1 min. 86.9 min and 90.6 min respectively. The dou-
Figure 2: O polysaccharide analysis of E. coli O121 
and its wbqG mutant derivative. 
A   LPS from E. coli W3110 cells expressing the O121 wild type O antigen 
gene cluster or its wbqG mutant derivative was separated by SDS-PAGE 
and stained with silver or after transfer to a nitrocellulose membrane 
detected with anti-O121 and anti-Vi antibodies. Mutation of wbqG results 
in the assembly of a modified O antigen reactive with anti-Vi sera.
B   Und-PP-linked glycans were extracted from E. coli SCM6 cells expressing 
the O121 wild type O antigen gene cluster or its wbqG mutant deri- 
vative followed by 2AB labeling and separation by normal phase HPLC 
using a GlycoSep N column. Individual peak fractions were analyzed  
by mass spectrometry and the identified glycan structures are indicated. 
(black square): N-acetylhexosamine; (black right-pointing triangle): 
dideoxyhexosamine; (white diamond): hexuronic acid; (white diamond)N: 
hexuronamide; Ac: acetyl; NAc: N-acetyl.
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Figure 3: CID MS-MS spectra of glycan species separated 
by normal phase HPLC.
The CID MS-MS spectra correspond to the glycan species identified in the 
individual peak fractions seen in Figure 2B with the retention times: 
A 58.8 min.   B 65.1 min.   C 67.2 min.   D 73.5 min.
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ble acetylated species eluted first followed by the single acetylated 
and non-acetylated form. Due to the separation of the acetylated 
and non-acetylated forms, the degree of O-acetylation could be 
determined. In both strains approximately 50 % of the single re-
peating units were O-acetylated.
 Precursors of the peptidoglycan monomer were also identified 
in some peaks of the O121 wild type trace (Figure 2B). Peptidog-
lycan precursors are also assembled on undecaprenyl pyrophos-
phate and are expected to be purified and labeled with the method 
used for O antigen subunits.
Production of glycoconjugates
The structure of the O121 wbqG mutant was confirmed, and it 
was shown to be cross-reactive with antibodies raised against the Vi 
antigen. Next, we examined whether the wbqG mutant O polysac-
charide can elicit antibodies that bind to the Vi. Therefore, glyco-
conjugates were prepared for immunization studies. Glycoproteins 
were produced by expressing the bacterial oligosaccharyltransferase 
PglB, the engineered periplasmic carrier protein EPA (toxoid re-
combinant Pseudomonas aeruginosa exotoxin A), and either the E. 
coli O121 wild type or the wbqG mutant antigen in the E. coli K12 
derivative CLM24 [102]. Strain CLM24 lacks the O antigen li-
gase (WaaL). Therefore, the transfer of O antigen to lipid A-core is 
blocked and the Und-PP-linked O antigen substrate accumulates at 
the periplasmic face of the inner membrane providing the O antigen 
donor for the PglB-catalyzed transfer to specific asparagine residues 
within the protein acceptor. Additionally, E. coli K12 derivatives lack 
a functional endogenous O antigen gene cluster [160,161]. A plas-
mid encoded O antigen gene cluster can therefore be expressed 
without producing mixed O antigen populations.
 As described elsewhere EPA was used as protein acceptor with 
a N-terminal signal sequence for Sec-dependent secretion to the 
periplasm, and a C-terminal hexahistidine tag for purification by af-
finity chromatography [105]. Furthermore, EPA contained two en-
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gineered N-glycosylation sites. The low copy plasmid pGVXN114 
was used for the expression of PglB under the control of the IPTG 
inducible tac promoter.
 After induction of PglB and EPA, the newly synthesized gly-
coprotein was purified from periplasmic extracts by nickel affinity 
chromatography. Due to the presence of negatively charged poly-
saccharides in the glycoconjugate, anion exchange chromatography 
was used to separate the glycosylated from the non-glycosylated 
forms. Based on the separation of the two species it was found that 
in cultures expressing the O121 wild type O polysaccharide gene 
cluster approximately 70 % of the total EPA was glycosylated. The 
glycosylation efficiency was lower in cultures expressing the wbqG 
mutant O antigen whereas 35 % of the total carrier protein con-
tained the glycan modification.
 The purified glycoconjugates were separated by SDS-PAGE and 
visualized by Coomassie blue staining or by western blot after trans-
fer to a nitrocellulose mambrane using anti-EPA, anti-O121, and 
anti-Vi antibodies (Figure 4). By Coomassie blue staining a band of 
the same mass as that of unglycosylated EPA (70 kDa) could be de-
tected in the purified O121 polysaccharide-EPA conjugate (O121-
EPA), that is also recognized by the anti-EPA but not the anti-O121 
sera. Therefore, unglycosylated EPA was largely removed in the 
glycoconjugate preparations. Mainly, a ladder of bands clustered 
between 100 and 130 kDa was detected by Coomassie blue stain-
ing. These bands reacted with anti-EPA serum, indicating modified 
forms of EPA. These larger polypeptides, but not EPA modified 
with the Shigella dysenteriae O1 antigen (O1-EPA) (described in 
[105]), were also detected with anti-O121 specific antibodies indi-
cating the modification of the carrier with the co-expressed polysac-
charide. EPA glycosylated with the wbqG mutant O polysaccharide 
(O121wbqG-EPA) was additionally stained with anti-Vi antibodies.
 As determined by SDS-PAGE analysis, mainly mono-glyco-
sylated EPA was purified, i.e. EPA modified on one of the two engi-
neered glycosylation sites with the corresponding O-polysaccharide. 
Traces of di-glycosylated EPA could be detected by western blot in 
the purified O121wbqG-EPA sample (Figure 4). The di-glycosylated 
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Figure 4: Production of glycoconjugates using the bacterial 
N-glycosylation system.
Glycoconjugates were produced in E. coli CLM24 by co-expressing the bacte-
rial oligosaccharyltransferase PglB, the engineered carrier protein EPA, and 
genes driving the synthesis of an antigenic polysaccharide (E. coli O121, E. 
coli O121 wbqG mutant, Shigella dysenteriae O1). Purified glycoconjugates 
were analyzed by SDS-PAGE, followed by Coomassie blue staining or by 
western blot after transfer to nitrocellulose membranes using anti-EPA, anti-
O121, and anti-Vi antibodies.
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form of EPA runs as a second fainter ladder of bands slightly bigger 
than 130 kDa. As seen in Figure 2A, the expressed O-antigens display 
a modal chain length distribution with an average of 12 repeating 
units. Assuming the purified glycoconjugates consisted of mono-
glycosylated EPA, containing a single polysaccharide chain of an 
average length of 12 repeating units, the sugar-to-protein weight 
ratio was estimated to be 0.15:1.
Immunogenicity of the glycoconjugates 
in mice and evaluation of the polysaccharide 
specific antibody response.
Next we analyzed the immune response elicited in mice upon im-
munization with the conjugate vaccines. Pilot experiments were 
conducted in small groups of CB6F1 mice to determine the dose 
range and adjuvantation of the purified glycoconjugates. These 
established that 20 µg of protein (approximately 3 µg of polysac-
charide), in combination with Alum, were reproducibly immuno-
genic (data not shown). Subsequently, groups of CB6F1 mice (7 
per group) were immunized subcutaneously on days 1, 22 and 57 
with O121-EPA, O121wbqG-EPA, or with 5 µg of purified Vi poly-
saccharide (Typhim Vi, Sanofi Pasteur MSD). Mice were sample 
bled on days 32 and 67 and the sera were tested for the presence of 
anti-O121 LPS and anti-Vi total immunoglobulin (Ig). By day 67, 
a significant rise in serum Ig anti-O121 LPS titer was observed in 
13 of 14 animals immunized with either conjugate (Figure 5A). One 
animal in the group of mice that were immunized with O121wbqG-
EPA did not show seroconvertion. Interestingly, the same animal 
developed a significant rise in serum Ig anti-Vi titer (Figure 5B). As 
expected, the control group that was immunized with purified Vi 
polysaccharide did not show a detectable anti-O121 LPS response 
but a significant rise in serum Ig anti-Vi titer.
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Figure 5: Immunization studies with glycoconjugates.
Groups of mice were immunized with purified glycoconjugates adjuvanted 
with Alum. The control group was immunized with purified Vi polysaccharide. 
A  Anti-O121 total immunoglobulin titers of sera collected on day 67. 
B   Anti-Vi antibody titers of sera collected on day 67. Data is represented as 
individual (black circle) and mean (-) titers. One animal immunized with the 
O121wbqG-EPA conjugate did not develop an O121-LPS specific antibody 
response, but the same animal showed a significant rise in anti-Vi antibody 
titer.
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Discussion
In this study a novel method for the analysis of undecaprenyl py-
rophosphate (Und-PP)-linked glycans is presented. The procedure 
described here is based on the method used to analyze dolichyl py-
rophosphate (Dol-PP)-linked oligosaccharides of eukaryotic cells. 
Main modifications include an optimized extraction procedure for 
bacterial glycolipids and a purification step prior to glycan release 
by mild acid hydrolysis. The purification strategy of bacterial Und-
PP-linked glycans is further complicated by the vast variety of dif-
ferent sugar structures assembled on this lipid carrier. The choice 
of an appropriate expression strain used to analyze a specific sub-
class of Und-PP-linked glycans is crucial. In this report, Und-PP-
linked O polysaccharides were analyzed. Since Und-PP-linked O 
antigens represent an intermediate species of LPS biosynthesis, an 
E. coli strain was used lacking the O antigen ligase(∆waaL). There-
fore, Und-PP-linked O polysaccharides are not transferred to lipid 
A-core, resulting in accumulations of this lipid intermediate. If O 
antigens were expressed in a waaL positive strain no 2AB-labeled 
O glycans could be identified, most likely due to the rapid turnover 
of this glycolipid species. Furthermore, O antigens are polymer-
ized structures with high molecular weights, making it increasingly 
difficult for analysis by mass spectrometry. We therefore chose a 
strain background containing a mutation in the O antigen chain 
length regulator (wzz) gene involved in efficient polymerization of 
O antigen subunits. This resulted in the production of mainly single 
repeat units and short polymerized O antigens, hence simplifying 
MS analysis. As mentioned previously, several other polysaccha-
ride structures are also assembled on Und-PP, like peptidoglycan 
precursors, capsular polysaccharides and the enterobacterial com-
mon antigen (ECA), which might complicate the identification 
and characterization of O glycan species. We therefore used E. coli 
strain SCM6 for O antigen expression, which contains deletions in 
all major polysaccharide gene clusters.
 With this modified method the O121 wbqG mutant O polysac-
charides was analyzed. This study confirms the published struc-
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ture by King et al. [159]. Furthermore, we could show that the 
recombinant expressed wbqG mutant O antigen structure con-
tained O-acetylated N-acetylgalactosaminuronic acid, most likely 
modified at C-3. Therefore this mutant O polysaccharide contains 
structural motifs also present in the Vi. O-acetyl groups of the Vi 
polysaccharide form an immunodominant epitope and immu-
nogenicity of Vi is closely related to the degree of O-acetylation 
[35,36].
 For the first time it is reported that the wbqG mutant O poly-
saccharide is cross-reactive with antibodies raised against the Vi 
antigen. The strategy of using cross-reactive polysaccharide struc-
tures as vaccine components has been evaluated in several pub-
lished studies. For example the cell wall polysaccharide (CWP) 
of the nonpathogenic bacterium Bacillus pumilus strain Sh18 was 
shown to be cross-reactive with the capsular polysaccharide (CPS) 
of Haemophilus influenzae type b. Conjugates containing the Sh18 
CWP induced antibodies that reacted in an enzyme-linked immu-
nosorbent assay (ELISA) with the CPS of H. influenzae type b 
strains [162]. Another study reported that Shewanella spp. CPSs 
share structural features with glycoproteins found in the Bacillus 
anthracis spore. A conjugate containing the Shewanella CPS in-
duced antibodies that bound to B. anthracis spores and it will be 
further evaluated as a component of an anthrax vaccine [163].
 Similarly, glycoconjugates composed of the E. coli O121 wild 
type or the wbqG mutant O polysaccharide and the P. aeruginosa 
exotoxin A (O121-EPA/ O121wbqG-EPA) were prepared in this 
study. EPA has already been successfully used as immunogenic 
carrier in a typhoid conjugate vaccine [41]. Both groups of mice 
immunized with glycoconjugates developed glycan specific anti-
body responses. 6 of 7 mice immunized with the O121wbqG-EPA 
conjugate showed a significant rise in serum immunoglobulin (Ig) 
anti-O121 LPS titer, indicating that other antigenic determinants 
than the uronamide groups are important for inducing an anti-
O121 LPS specific immune response. Interestingly, antibodies of 
one animal immunized with the O121wbqG-EPA conjugate were 
not reactive with the E. coli O121 LPS but rather with the Vi poly-
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saccharide. This implies that this animal developed an antibody re-
sponse against the epitope constituted by residues b and c’ (Figure 
1), which resembles the Vi structure. However, the other animals of 
this group raised antibodies against an O121-LPS specific epitope, 
most likely residue d, containing a prominent surface exposed side 
group. Further optimizations of the O121 glycan structure might 
improve a Vi specific immune response upon immunization and 
experiments are planned to investigate if immunization with the 
O121wbqG-EPA conjugate primes a Vi-specific immune response 
that could be boosted with purified Vi polysaccharide. 
Experimental Procedures
Bacterial strains, plasmids, 
and culture conditions
All bacterial strains and plasmids used in this study are listed in 
Table I. Construction of the plasmids is described below. E. coli 
strains were grown in LB medium (10 g tryptone, 5 g yeast extract, 
and 5 g NaCl per liter) or LB agar (LB medium with the addition 
of 15 g agar per liter) at 37 °C. S. Typhi BRD948 was grown in 
LB medium supplemented with 1 % v/v Aro-mix (40 mg L-phe-
nylalanine, 40 mg L-tryptophan, 10 mg 4-aminobenzoic acid, and 
10 mg 2,3-dihydroxybenzoic acid in 10 ml of ddH2O) and 1 % v/v 
Tyr-mix (40 mg L-tyrosine disodium salt in 10 ml ddH2O) at 37 
°C. If appropriate, the media contained tetracycline (20 µg ml-1), 
spectinomycin (80 µg ml-1), or ampicilin (100 µg ml-1).
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Strain Genotype or relevant description Reference
S. Typhi BRD948 S. Typhi Ty2 ǻaroC ǻaroD [60]
E. coli DH5Į K-12 ĳ80dlacZǻM15 endA1 recA1 hsdR17(rK−mK) 
supE44 thi-1 gyrA96 relA1 ǻ(lacZYA-argF)U169 F−
Clonetech
E. coli O121 Escherichia coli serotype O121 CCUG 11422*
SCM6 Sĭ874, ǻwec ǻwaaL C. Marolda and 
M. Valvano,  
unpublished
W3110 rph-1 IN(rrnD-rrnE)1 Ȝ− CGSC 4474**
Clm24 W3110, ǻwaaL [102]
Plasmid Genotype or relevant description Reference
pLAFR1 low copy-number broad host-range cosmid cloning 
vector; TetR
[140]
pEXT21 tac promoter expression vector; SpR [172]
pGVXN157 pLAFR1 derivative with multiple cloning site inserted 
in EcoRI site; TetR
This study
pGVXN331 pGVXN157 derivative carrying O121 O antigen 
gene cluster of E. coli CCUG11422 on an AscI/SpeI 
fragment; TetR
This study
pGVXN333 pGVXN331 derivative containing inactivated wbqG This study
pGVXN121 pEXT21 derivative carrying wecA, IPTG inducible, SpR This study
pGVXN150 Soluble periplasmic His6-tagged toxoid variant 
(L552V, ǻE553) of P. aeruginosa exotoxin A (EPA) 
containing two engineered N-glycosylation sites 
cloned in pEC415, arabinose inducible, AmpR
[105]
pGVXN114 HA-tagged pglB cloned in pEXT21, IPTG inducible, SpR [105]
Table I
Strains and plasmids used in this study.
* Culture Collection University of Göteborg, Curator: Prof. E. R. B. Moore,   
 Göteborg, Sweden
** The Coli Genetic Stock Center, Yale University, New Haven, CT, USA
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DNA manipulations
Plasmid DNA was isolated using the NucleoSpin Plasmid or 
NucleoBond Xtra Maxi Plus kit (Macherey-Nagel). Total chro-
mosomal DNA was isolated using NucleoSpin Tissue kit (Mach-
erey-Nagel). Restriction enzymes (Fermentas), shrimp alkaline 
phosphatase (Fermentas), T4 DNA ligase (Fermentas), and Phu-
sion High-Fidelity DNA polymerase (Finnzyme) were used ac-
cording to the manufacturer’s instructions. PCR and restriction 
fragments were purified for cloning using the NucleoSpin Extract 
II kit (Macherey-Nagel). All DNA sequencing was completed by 
Synergene Biotech GmbH (Switzerland) and synthetic oligonu-
cleotides were ordered at Microsynth AG (Switzerland).
Plasmid constructions
pGVXN157 contains a synthetic oligonucleotide cassette formed 
from annealing of 5’- AATTGGCGCGCCCGGGACTAGTCT- 
TGGG and 5’- AATTCCCAAGACTAGTCCCGGGCGCGCC 
ligated into the EcoRI-digested pLAFR1 [140], thereby intro-
ducing unique AscI and SpeI single restriction sites. The E. coli 
O121 O antigen cluster was amplified from genomic DNA pre- 
pared from E. coli O121 (CCUG 11422) using the primers 5’- AAA-
GGCGCGCCGCGAAGGTAAAGTCAGCCG and 5’- AAAA- 
CTAGTCAGGAGTGAATTAAGTCATTG. The digested PCR 
fragment was ligated into the AscI/SpeI digested pGVXN157 re-
sulting in pGVXN331. pGVXN333 was constructed by inserting 
a synthetic oligonucleotide cassette formed from annealing of 5’- 
TGAATGAATGAACTAGTTCAATCACTCA and 5’- TGAGT- 
GATTGAACTAGTTCATTCATTCA into the single restriction 
site PmlI, interrupting the open reading frame of wbqG.
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LPS analysis
Cells of an overnight culture equivalent to an A600 of 1 were col-
lected, resuspended in 100 µl of 1x sample buffer according to 
Laemmli [164] and boiled at 95 °C for 10 min. Proteinase K (Fer-
mentas) was added to a final concentration of 200 µg ml-1 and the 
sample was incubated at 60 °C for 1 h. The LPS molecular species 
from the proteinase K-digested whole cell lysates were separated 
by SDS-PAGE using a 12 % BisTris NuPAGE gel from Invitrogen 
and MES running buffer according to manufacturer’s instructions. 
LPS was visualized by staining with silver [165]. Immunologi-
cal properties of O antigens were analyzed by Western blot using 
standard methods. The structure of the E. coli O121 O antigen is 
identical to the Shigella dysenteriae type 7 O antigen. Therefore, an 
anti-S. dysenteriae type 7 sera was purchased from Reagensia AB 
(Sweden) and used in a 1:100 dilution. Anti-Vi polyclonal anti-
body was purchased from Murex Biotech Ltd (England) and used 
in a 1:100 dilution.
Analysis of undecaprenyl 
pyrophosphate (Und-PP)-linked 
O specific polysaccharides
The O antigen glycans were analyzed in E. coli strain SCM6 (C. 
Marolda and M. Valvano, unpublished), which contains chromo-
somal deletions in several polysaccharide gene clusters. The O 
polysaccharide was expressed by transforming SCM6 cells with 
a plasmid encoding the O antigen cluster and the wecA expres-
sion plasmid pGVXN121. SCM6 transformed with empty plas-
mids was used as a negative control to identify O antigen spe-
cific signals. The strains were grown over night in a shake flask. 
Cells equivalent to an A600 of 400 were harvested, washed once 
with 0.9 % NaCl, and lyophilized. Lipids were extracted from the 
dried cells with 95 % methanol (MeOH) by repeated rounds of 
vortexing and incubation on ice for 10 min. The suspension was 
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converted into 85 % MeOH by the addition of ddH2O and fur-
ther incubated for 10 min on ice while regularly vortexing. After 
centrifugation, the supernatant was collected and the extract was 
dried under N2. The dried lipids were dissolved in 1:1 methanol/
water (M/W) containing 10 mM tetrabutylammonium phosphate 
(TBAP) and subjected to a C18 SepPak cartridge (Waters Corp., 
Milford, MA). The cartridge was conditioned with 10 ml MeOH, 
followed by equilibration with 10 ml 10 mM TBAP in 1:1 M/W. 
After loading of the sample, the cartridge was washed with 10 ml 
10 mM TBAP in 1:1 M/W and eluted with 5 ml MeOH followed 
by 5 ml 10:10:3 chloroform/methanol/water (C/M/W). The com-
bined elution fractions were dried under N2.
 The lipid sample were hydrolyzed according to Glover et al. 
[166] by dissolving the dried samples in 2 ml 1 M trifluoroacetic 
acid (TFA) in 50 % n-propanol and heating to 50 °C for 15 min. 
The hydrolyzed sample was dried under N2, dissolved in 4 ml 
3:48:47 C/M/W and subjected to a C18 SepPak cartridge (Waters 
Corp., Milford, MA) to separate the lipids from the hydrolyzed 
glycans. The cartridge was conditioned with 10 ml MeOH, fol-
lowed by equilibration with 10 ml 3:48:47 C/M/W. The sample was 
applied to the cartridge and the flow-through was collected. The 
cartridge was washed with 4 ml 3:48:47 C/M/W and the combined 
flow-through fractions were dried using a SpeedVac.
 The dried samples were labeled with 2-aminobenzamide 
(2AB) according to Bigge et al. [167]. The glycan clean-up was 
performed using the paper disk method as described in Merry et 
al. [168]. The separation of 2AB-labeled glycans was performed 
by HPLC using a GlycoSep N normal phase column according to 
Royle et al. [169], but modified to a three solvent system. Solvent 
A: 10 mM ammonium formate pH 4.4 in 80 % acetonitrile. Sol-
vent B: 30 mM ammonium formate pH 4.4 in 40 % acetonitrile. 
Solvent C: 0.5 % formic acid. The column temperature was 30 °C 
and 2AB-labeled glycans were detected by fluorescence (Ȝex= 
330 nm, Ȝem= 420 nm). Gradient conditions: A linear gradient 
of 100 % A to 100 % B over 160 min at a flow rate of 0.4 ml min-1, 
followed by 2 min 100 % B to 100 % C, returning to 100 % A over 
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2 min and running for 15 min at 100 % A at a flow rate of 1 ml min-
1, then returning the flow rate to 0.4 ml min-1 for 5 min. samples 
were injected in ddH2O.
 To identify O antigen specific glycans, the 2AB glycan profile 
from cells carrying an empty plasmid control was subtracted from 
the trace obtained from cells harbouring an O antigen cluster. The 
O antigen specific peaks were collected and 2AB glycans were ana-
lyzed on a MALDI SYNAPT HDMS Q-TOF system (Waters 
Corp., Milford, MA). Samples were dissolved in 5:95 acetonitrile/
water and spotted 1:1 with 20 mg ml-1 2,5-dihydroxybenzoic acid 
(DHB) in 80:20 methanol/water. Calibration was done with PEG 
(Ready mixed solution, Waters Corp., Milford, MA), spotted 1:3 
with 5 mg ml-1 Į-cyano-4-hydroxycinnamic acid (CHCA, Sigma-
Aldrich, Switzerland) in 60:40:0.1 acetonitrile/water/trifluoroacet-
ic acid. The instrument was equipped with 200 Hz solid state UV 
laser. Mass spectra were recorded in positive ion mode. For MS-
MS: laser energy was fixed at 240 at a firing rate of 200 Hz, collision 
gas was argon. A collision energy profile was used to ramp collision 
energy depending on the m/z. Combined, background subtracted, 
and smoothened (Savitzsky Golay) spectra were centered using 
MassLynx v4.0 software (Waters Corp., Milford, MA).
Production and purification 
of glycoconjugates
The production of glycoconjugates was achieved by expressing the 
oligosaccharyltransferase PglB, the engineered acceptor protein 
EPA (exotoxin A of Pseudomonas aeruginosa), and a gene cluster 
producing undecaprenyl-pyrophosphate (Und-PP)-linked glycans 
in E. coli. pGVXN114 (expressing PglB), pGVXN150 (express-
ing C-terminal His6-tagged EPA) and pGVXN331 (O121 antigen 
cluster) or pGVXN333 (O121 wbqG mutant antigen) were co-
transformed into E. coli strain Clm24 [102]. Cells were cultured in 
LB medium supplemented with antibiotics at 37 °C in the shaker 
incubator (180 rpm). Shake flask expression cultures were inocu-
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lated from an uninduced overnight culture to an A600 of 0.05. Ex-
pression of PglB and the carrier protein EPA was induced at an 
A600 of 0.4–0.6 by IPTG (1 mM) and L-arabinose (0.02 % w/v). 
Four hours after the first induction a second pulse of L-arabinose 
(0.02 % w/v) was added. Cells were harvested after overnight in-
cubation (total induction time of 19–22 h). Pellets were washed 
with 0.9 % NaCl and suspended in resuspension buffer (25 % su-
crose, 10 mM EDTA, 200 mM Tris HCl pH 8.0) at a concentra-
tion equivalent to an A600 of 50. The cell suspension was incubated 
on a shaker for 20 min at 4 °C. After centrifugation the cell pellet 
was resuspended in the same volume of osmotic shock buffer (10 
mM Tris HCl pH 8.0). The suspension was incubated on a shaker 
for 30 min at 4 °C and centrifuged at 10’000 g for 20 min to remove 
the spheroblasts. The supernatant containing periplasmic proteins 
was collected and the recombinant EPA containing a C-terminal 
hexahistidine tag was purified using a HisTrap crude FF 1 ml col-
umn (GE Healthcare, Switzerland). The extract was diluted with 
5x HT binding buffer (2.5 M NaCl, 150 mM Tris HCl pH 8.0, 50 
mM imidazole) to optimize the binding conditions and MgCl2 was 
added to a final concentration of 50 mM. The extract was filtered 
and applied to the HisTrap crude FF column equilibrated with 
1x HT binding buffer. After loading the column was washed with 
the same buffer containing 20 mM imidazole to remove unbound 
proteins. Proteins were eluted from the column with HT elution 
buffer (HT binding buffer containing 0.5 M imidazole).
 Subsequently, the glycoprotein was separated from the ung-
lycosylated EPA using a Resource Q 1 ml column (GE Health-
care, Switzerland). The HisTrap elution fractions containing EPA 
were pooled and diluted 10x with RQ binding buffer (20 mM 
L-histidine, pH 6.0). The diluted EPA sample was applied to the 
anion exchange column equilibrated with RQ binding buffer. The 
column was eluted with a linear gradient from 0 % to 32.5 % of 
RQ elution buffer (RQ binding buffer containing 1 M NaCl) in 
25 column volumes and 0.5 ml fractions were collected using an 
Äkta FPLC (Amersham Biosciences). The fractions were analyzed 
by SDS-PAGE and proteins were stained with Coomassie blue. 
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Fractions containing glycoprotein were pooled and buffer was ex-
changed to PBS using an Amicon Ultra-4 centrifugal filter unit 
with a 30 kDa membrane (Millipore) by performing several con-
centration and dilution steps according to manufacturer’s instruc-
tions. The concentration of the final purified protein sample was 
adjusted to 1 mg ml-1.
Purification of E. coli O121 LPS
LPS of an E. coli O121 (CCGU 11422) culture was purified by 
phenol extraction as described elsewhere [170].
Purification of Vi 
polysaccharide and modi-
fication with tyramine
Vi polysaccharide was purified from S. Typhi BRD948 by a modi-
fied procedure as previously described [150]. Briefly, S. Typhi 
BRD948 was grown in LB medium supplemented with Aro- and 
Tyr-mix. After overnight incubation at 37 °C in the shaker incuba-
tor (180 rpm) the culture was heated to 60 °C for 1 h and centri-
fuged. Vi was precipitated from the supernatant with 0.1 % hexa-
decyltrimethylammonium bromide (CTAB, Sigma, H6269). 20 g 
l-1 celite 545 (Sigma, 20199-U) was added and the mixture was 
stirred for 1 h at room temperature (RT) in order to allow the for-
mation of a polysaccharide-CTAB complex, which adsorbs onto 
the celite. The celite was poured into a reservoir of appropriate size 
(Extract-clean EV SPE Reservoir, Socochim S.A.) equipped with 
a frit (Socochim S.A.). The column was washed successively by 
gravity flow with 10 column volumes (CV) of 0.05 % CTAB, 10 
CV of 20 % ethanol, 50 mM sodium phosphate buffer pH 6.0, and 
14 CV of 45 % ethanol to eliminate adsorbed impurities. The Vi 
polysaccharide was finally eluted with 1.5 CV of 50 % ethanol, 0.4 
M NaCl. Following elution, the polysaccharide was precipitated by 
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the addition of ethanol to a final concentration of 80 % and incuba-
tion for 20 min at RT. Finally, the precipitated polysaccharide was 
collected by centrifugation for 20 min at 15000 g, washed twice 
with 80 % ethanol, and lyophilized.
 The protein and nucleic acid content of the purified Vi poly-
saccharide was determined by the bicinchoninic acid assay (BCA) 
and UV spectroscopy respectively. O-acetyl content was measured 
with acetylcholine as standard [136].
 To increase the binding efficiency of the Vi to microtiter plates, 
the polysaccharide was tyraminated (Vi-Tyr). Tyramine hydro-
chloride (30 mg ml-1, Sigma) was added to 10 mg of purified Vi. 
100 µl of 0.5 M N-(3-dimethylaminopropyl)-N’-ethylcarbodiim-
ide HCl (Sigma) was added and the mixture was incubated at pH 
4.9–5.1 for 3 h. The reaction mixture was dialyzed against ddH2O.
Immunization studies
Groups of 7 CB6F1 female mice, 6–8 weeks old, were used in im-
munization experiments. Mice were immunized, subcutaneously, 
with 20 µg of glycoconjugate with Alum (Rehydragel LV- Alumin-
ium Hydroxide, General Chemical) as adjuvant or 5 µg of Vi poly-
saccharide (Typhim Vi, Sanofi Pasteur MSD). Adjuvantation of 
the glycoconjugate was done just before immunization. Briefly, the 
purified glycoconjugates were diluted with PBS to a final concen-
tration of 200 µg ml-1, Alum (final amount of Al3+ corresponded to 
0.6 mg ml-1) was added, and the solution was gently mixed for 1 h 
at room temperature. Immunizations were performed on days 1, 
22 and 57. Groups of mice normally received 100 µl doses of vac-
cines, corresponding to 20 µg of conjugate (protein). Blood sam-
ples were collected 10 days after the second and 10 days after the 
last immunization.
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Enzyme-linked immunosorbent 
assay (ELISA) for murine antibodies
Flat bottom 96 well micro-titer plates (Nunc immuno PolySorb) 
were coated with 50 µl of 5 µg ml-1 E. coli O121 LPS or 5 µg ml-1 
of tyraminated Vi (Vi-Tyr), diluted in PBS, at 4 °C overnight. The 
coating solution was poured away and the plate was submerged and 
vigorously agitated in 4000 ml of wash buffer (1x PBS with 0.05 % 
Triton X 100). This washing step was performed at least 4 times. 
Subsequently, the plate was dried by placing and spinning upside 
down in a micro plate rotor. This washing procedure was always 
applied in further washing steps. Each well was completely filled 
with 300 µl of blocking buffer (1x PBS with 2.5 % BSA (globulin 
free BSA, Sigma, A7030)) and incubated 2 h at room temperature 
(RT) on a plate shaker. After washing and drying the plate, dilu-
tions of mouse serum in dilution buffer (1x PBS with 0.5 % BSA) 
were added to the plate (100 µl) and incubated 1 h at RT on a plate 
shaker. To detect total immunoglobulin (Ig), 100 µl of horserad-
ish peroxidase (HRP) labeled goat anti-mouse Ig (Sigma) diluted 
1:2000 in dilution buffer was added to each well and the plate was 
incubated for 1 h at RT on a plate shaker. Following washing and 
drying the plate, the reaction was developed with 100 µl of Ultra 
TMB substrate (3,3’,5,5’-tetramethybenzidine liquid substrate, 
Pierce) for 15 min and stopped with the addition of 100 µl of 2 M 
sulphuric acid. Optical density (OD) was measured at 450 nm.
 To determine the endpoint titer a 95 % confidence level was de-
fined according to [171]. As negative sample a pool of preimmune 
sera was used.
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Abstract
The substrate specificity of the bacterial oligosaccharyltransferase 
(OST) PglB from Campylobacter jejuni towards the glycan moi-
ety of the LLO substrate was extensively studied, including the 
structural requirements of the reducing end saccharide, which is 
directly involved in recognition and catalysis. These studies were 
conducted in vivo by recombinantly expressing PglB, an acceptor 
protein and making use of diverse bacterial glycan structures that 
are assembled on the lipid carrier undecaprenyl pyrophosphate 
(Und-PP), therefore serving as potential donor substrates in the 
glycosylation reaction. As a result of those studies it has been pos-
tulated that Und-PP linked glycans containing an N-acetyl group 
at the C-2 of the reducing end saccharide solely serve as substrates 
for the bacterial OST. However, the recombinantly expressed N-
linked protein glycosylation system reconstituted in Escherichia 
coli did not reach the efficiency of glycosylation observed in the 
natural host. Therefore, previous work describing the substrate 
specificities of PglB using this in vivo glycosylation system might 
be inaccurate. In this study, the in vivo efficiency of glycosyla-
tion was improved by optimizing the conditions for recombinant 
PglB expression. With this improved system we re-examined the 
PglB-mediated transfer of an Und-PP-linked O-antigen from Sal-
monella enterica serovar Typhimurium containing a reducing end 
galactose. We have shown that: (i) PglB mediates the transfer of 
the S. Typhimurium O-antigen and (ii) that both species of the 
S. Typhimurium Und-PP-linked O-antigen substrate, i.e. the long 
form consisting of 16–35 repeating units and the very long form 
(VL) assembled of >100 subunits, serve as substrates for the gly-
cosylation reaction.
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Introduction
The post-translational modification of asparagine side chains with 
oligosaccharides (N-linked glycosylation) is a vital process in eu-
karyotes and involved in a multitude of cellular functions [173-175]. 
N-linked glycosylation occurs at the luminal side of the endoplas-
matic reticulum (ER) membrane and is catalyzed by the oligosac-
charyltransferase (OST), a hetero-oligomeric membrane protein 
complex [176]. OST catalyzes the formation of an N-glycosidic 
linkage by transferring the C1 carbon of the reducing end of the 
saccharide moiety of a preassembled lipid-bound Glc3Man9Glc-
NAc2 oligosaccharide from the polyisoprenyl carrier lipid dolichyl 
pyrophosphate to the amide nitrogen atom of the acceptor aspara-
gine residue in the glycosylation consensus sequon Asn-X-Ser/Thr 
(where X is any amino acid except proline) of polypeptide chains. 
In yeast (Sacchoromyces cerevisiae) OST consists of nine subunits 
of which Stt3p is the catalytically active component [177,178].
 In recent years it has been shown that N-linked glycosylation 
is not restricted to eukaryotes, but is found in all domains of life. 
A homologous process in bacteria was first described in the food-
borne pathogen Campylobacter jejuni [100,101]. Examination of 
genome sequence data demonstrated that N-glycosylation systems 
are widely spread in the į and İ subdivisions of proteobacteria 
[179]. Compared to the eukaryotic pathway, biosynthesis of glyco-
proteins in prokaryotes is less complex. The bacterial OST, PglB, 
consists of a single subunit, which is homologous to the eukaryotic 
STT3 subunits. The N-linked glycosylation machinery of C. jejuni 
is encoded in a single gene cluster termed pgl (protein glycosyla-
tion) [180], which can be functionally transferred into Escherichia 
coli for recombinant glycoprotein expression [101]. Pgl-encoded 
enzymes assemble a heptasaccharide (Figure 1) attached to the pol-
yisoprenyl carrier lipid undecaprenyl pyrophosphate (Und-PP), 
on the cytosolic face of the inner membrane [166,181-183]. The 
lipid-linked oligosaccharide (LLO) diffuses transversely to the 
periplasmic side by the ATP-binding cassette (ABC) transporter 
PglK [184], where the glycan is subsequently transferred to select-
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ed asparagine residues of periplasmic acceptor proteins by PglB. 
The optimal bacterial consensus sequence for N-glycosylation is 
Asp/Glu-Y-Asn-X-Ser/Thr (where Y and X are unspecified amino 
acid residues excluding proline) [104]. However, the presence of 
the sequon within a polypeptide chain is not sufficient for glyco-
sylation. Acceptor sites that are located in rigid regions of the pro-
Figure 1: Structure of the Campylobacter jejuni N-glycan and the 
repeating units of the Salmonella Typhimurium, Shigella dysenteriae 
O1, and Shigella flexneri 2a O-antigen.
Acetylation of the Salmonella Typhimurium O-antigen on the abequose  
moiety determines the O5 epitope. Bac: bacillosamine (2,4-diacetamido-
2,4,6-trideoxy-D-glucose); Abe: abequose (3,6-dideoxy-D-galactose).
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tein are suboptimal substrates for the bacterial OST. Grafting the 
sequon into flexible loops of the folded protein greatly enhances 
glycosylation efficiencies [185] and enables the production of re-
combinant glycoproteins with specified engineered glycosites. The 
recently published X-ray structure of the PglB orthologue from 
Campylobacter lari in complex with an acceptor peptide provided 
insights into glycosylation sequon recognition and amide nitrogen 
activation [186].
 Besides recognition of the acceptor sequon, the OST has to 
bind the LLO substrate to complete catalysis. The structural re-
quirements of the polyisoprenyl glycosyl carrier lipid and the oli-
gosaccharide moiety were extensively studied in diverse in vitro 
and in vivo assay systems. Kinetic studies with a truncated C. je-
juni N-glycan linked to polyisoprenyl carrier lipids that differed in 
polyisoprene chain length, degree of saturation, and double bond 
stereochemistry revealed that PglB exhibits distinct preferences, 
whereby cis-double bond geometry and Į-unsaturation are impor-
tant features of the polyisoprenyl carrier [187].
 The vast variety of oligosaccharide structures that are assem-
bled on Und-PP was used to study the structural requirements 
of the glycan moiety. It has been recognized that some of these 
polysaccharide biosynthetic pathways are highly homologous to 
the generation of the LLO substrate for bacterial N-glycosylation. 
The polymerase-dependent pathway for synthesis of O-antigens 
involves the assembly of oligosaccharides on Und-PP at the cy-
tosolic side of the inner membrane. These LLOs are flipped to 
the periplasmic side by a flippase, Wzx, where the subunits are 
polymerized by Wzy polymerase. After polymerization the O-an-
tigen polysaccharide is transferred to the lipid A-core by the ligase 
WaaL. It has been shown that PglB expressed in a waaL deficient 
mutant strain can accept a variety of different Und-PP linked O 
polysaccharides [102,103]. All of the PglB substrates identified 
so far contain either 2,4-diacetamido-2,4,6-trideoxyglucose (ba-
cillosamine, Bac), D-GlcNAc, D-GalNAc or D-FucNAc at the 
reducing end [103]. A commonality of these sugars is the aceta-
mido group at the C-2 position, which is also found in the glycan 
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substrate of eukaryotic OST complexes. Furthermore, the PglB-
mediated transfer of Und-PP linked polysaccharides containing 
a galactose at the reducing end, like the O-antigen of Salmonella 
enterica subspecies I serovar Typhimurium (S. Typhimurium, Fig-
ure 1) was not observed [103]. Therefore, it was proposed that the 
acetamido group at the C-2 position plays a crucial role during 
catalysis either by interacting with the OST catalytic site through 
critical H-bonding or by stabilizing the oxonium intermediate after 
release of the undecaprenyl pyrophosphate leaving group [103]. 
Modeling of the LLO substrate into the PglB structure such that 
the 2,4-diacetamido-2,4,6-trideoxyglucose (Bac) moiety is prop-
erly aligned for a nucleophilic attack by the activated amide nitro-
gen, places the C-2 N-acetyl group of the first saccharide in the vi-
cinity of a conserved tyrosine residue [186]. Therefore, additional 
H-bonding would favor a C-2 N-acetylated glycan substrate. 
 In this study the efficiency of glycosylation was improved by 
optimizing the recombinant expression of the bacterial OST. In 
this optimized system the substrate specificity of PglB was re-ex-
amined by transferring lipid-linked polysaccharides containing a 
hexose at the reducing end, i.e. the O-antigen of S. Typhimurium.
Results
Improving the efficiency of 
N-glycosylation in E. coli by optimizing 
recombinant expression of PglB.
 
Wacker et al. [101] complemented a C. jejuni pglB mutant strain by 
introducing the 16 kb protein glycosylation locus (pgl) on a plas-
mid. Analysis of the membrane protein extract revealed that the 
mutant phenotype was only partially complemented. The mem-
brane bound periplasmic protein AcrA, containing two glycosites, 
is 100 % glycosylated in the wild type C. jejuni strain, whereas in 
the complemented pglB mutant strain unglycosylated and mono-
glycosylated forms of AcrA were detected. Feldman et al. [102] 
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reconstituted the C. jejuni N-glycosylation machinery in E. coli by 
coexpressing the pgl locus and a soluble, periplasmic form of AcrA. 
However, the degree of protein glycosylation in the E. coli system 
did not reach wild type levels; periplamic protein extracts showed 
di-, mono-, and unglycosylated forms of AcrA. Furthermore, Feld-
man et al. [102] constructed a plasmid containing an HA-tagged 
PglB under the control of an arabinose inducible promoter in pM-
LBAD (pMAF10). The activity of the arabinose inducible pglB 
construct was tested by coexpressing the pgl gene cluster express-
ing the non-functional W458A, D459A PglB mutant (pglmut) and 
acrA. Also in this three-plasmid system wild type efficiency of gly-
cosylation was not achieved.
 We speculated that the availability of high levels of active PglB 
enzyme within the cell is crucial for efficient glycan transfer to ac-
ceptor proteins. For PglB expression optimization, the HA-tagged 
version from pMAF10 was subcloned into a variety of expression 
plasmids with different inducible promoters and copy numbers. 
Pre-experiments showed that subcloning of the OST into the low-
copy plasmid pEXT21, thereby producing pGVXN114, was su-
perior to all other constructs in terms of expression levels (results 
not shown). PglB expression in pGVXN114 is under control of 
the IPTG inducible tac promoter. Glycosylation efficiency of this 
expression system was compared to the pMAF10 construct by co-
expression with the pglmut gene cluster and the soluble form of 
AcrA in E. coli (Figure 2A). Periplasmic proteins were extracted and 
AcrA was analyzed by SDS-PAGE and visualized by immunode-
tection. Mainly di-glycosylated AcrA was detected in presence of 
pGVXN114 whereas expression of the arabinose inducible PglB 
(pMAF10) resulted in incomplete modification of the periplas-
mic protein with the C. jejuni N-glycan. Furthermore, glycosyla-
tion efficiency was tested using a different Und-PP linked glycan 
structure, the Shigella dysenteriae O1 (O1S.d.) O-antigen (Figure 
2B). The O1S.d. O-antigen contains a D-GlcNAc at the reducing 
end instead of the bacillosamine found in the C. jejuni N-glycan 
(Figure 1). After induction of PglB, the C-terminally His6-tagged 
AcrA was purified from periplasmic extracts by affinity chroma-
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Figure 2: Improvement of glycosylation efficiency by optimizing the 
recombinant PglB expression in E. coli cells.
A   Periplasmic proteins were extracted from E. coli CLM24 co-expressing acrA, 
the mutant pgl cluster of C. jejuni that encodes an inactive PglB (pglmut), 
and the HA-tagged wild-type PglB either encoded in pMLBAD (pMAF10) or 
pEXT21 (pGVXN114). Samples were analyzed by SDS-PAGE, transferred  
to nitrocellulose membranes and detected with antibodies directed against 
AcrA. Only partially modified AcrA was detected in cells containing 
pMAF10. Besides the di-glycosylated form also mono- and unglycosylated 
AcrA were detected. Cells harbouring pGVXN114 efficiently glycosylated 
AcrA and mainly the di-glycosylated form was observed. 
B   AcrA was purified from E. coli CLM24 transformed with either pMAF10 or 
pGVXN114 and expressing the S. dysenteriae O1 (O1S.d.) O-antigen.  
Samples were analyzed by SDS-PAGE, followed by transfer to a nitrocellu-
lose membrane and immunodetection using an anti-AcrA antibody. 
C   Whole-cell extracts of the expression cultures described in (A) and (B) were 
analyzed by SDS-PAGE and the HA-tagged PglB was detected by Western 
blot using an anti-HA antibody. The expression level of PglB encoded in the 
pGVXN114 was higher compared to the pMAF10 construct.
125
PglB mediated transfer of S. Typhimurium O antigen
tography. Purified AcrA was analyzed by SDS-PAGE and after 
transferring to a nitrocellulose membrane visualized with an anti-
AcrA antibody. A band of the same mass as that of unglycosylated 
AcrA (34 kDa) and a ladder of bands of higher molecular weight 
clustered around 55 kDa were stained by immunodetection. These 
larger polypeptides, but not the unmodified form of AcrA, were 
also detected by the anti- O1S.d. antiserum, indicating the covalent 
modification with the O1S.d. O-antigen (results not shown). 
 These results illustrated, that the efficiency of glycosylation was 
dramatically improved in both cases by using the IPTG inducible 
PglB expression system. Expression of the HA-tagged PglB was 
analyzed in all cultures by Western blot using an anti-HA antibody 
(Figure 2C). In both cases, the expression level of PglB was signifi-
cantly higher in cells carrying the pGVXN114 plasmid. However, 
we observed that cells carrying the IPTG inducible PglB construct 
displayed a reduced growth rate after induction compared to cells 
harboring the arabinose inducible plasmid pMAF10.
The S. Typhimurium O-antigen 
is a substrate for PglB.
Wacker et al. [103] reported that the S. Typhimurium O-antigen 
(Figure 1) and the E. coli K30 capsular polysaccharide were not 
transferred to AcrA. Both glycan structures contain a galactose at 
the reducing end. The optimized, recombinant PglB expression 
system was used to re-examine the substrate specificity of the bac-
terial OST. S. Typhimurium strain SL3749 was used to test the 
transfer of its O-antigen by coexpressing an acceptor protein and 
PglB. Strain SL3749 contains a non-functional WaaL O-antigen 
ligase thereby accumulating Und-PP linked glycan substrate as 
transfer to lipid A-core is inhibited. 
 First, the O-antigen structure expressed by S. Typhimurium 
SL3749 was analyzed. Western blot analysis of a proteinase K di-
gested whole cell sample revealed that an anti-S. Typhimurium 
O5 (O5S.T.) sera reacted with the glycan structure, indicating the 
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expression of an O-acetylated variant of the O-antigen (Figure 3A). 
The numbers of repeating units in the O-antigen polymer are clus-
tered around a modal value determined by the chain length regu-
lator Wzz. Each wzz specifies the synthesis of an O-antigen of a 
characteristic length. The S. Typhimurium chromosome encodes 
two wzz genes, giving rise to a bimodal chain length distribution 
of polymerized O-antigen: The long (L) form containing 16–35 
repeating units and the very long (VL) form consisting of >100 
subunits [188]. No O-antigen was detected in StGVXN1794 con-
taining a wbaP knockout. WbaP is the enzyme catalyzing the re-
versible transfer of Gal-1-P to undecaprenyl phosphate, thereby 
initiating O-antigen assembly [189]. In order to confirm the struc-
ture of the expressed O-antigen repeating unit, purified, 2AB-la-
beled O-antigen glycans were analyzed using a high-performance 
liquid chromatography (HPLC) and mass spectrometry (MS) 
based method. Und-PP-linked oligosaccharides were extracted 
from StGVXN2556 containing a knockout of the O-antigen 
polymerase wzy. Deletion of wzy results in the accumulation of 
single O-antigen repeats, thereby facilitating MS analysis. As a 
control Und-PP-linked oligosaccharides of the wbaP knockout 
StGVXN1794 were extracted. The lipid-linked oligosaccharides 
were purified using a C18 SepPak column and treatment with mild 
acid specifically released Und-PP linked glycans. After an addi-
tional purification step using a C18 SepPak column, the glycans 
were labeled with 2-aminobenzamide (2AB) and subsequently 
separated by normal phase HPLC using a GlycoSep N column. 
Figure 3B shows the chromatogram of the area where subunits of 
O-antigens are expected to elute. Specific peaks were collected, 
and the 2AB-labeled glycans were analyzed by mass spectrometry 
(Figure 3C and 3D). The glycan structures identified by mass spec-
trometry are indicated in Figure 3B.
 The chromatogram of the 2AB-labeled glycans prepared from 
StGVXN2556, displayed a specific peak eluting at 24.1 min. In 
this peak fraction a molecule with a mass-to-charge ratio (m/z) 
of 781.30 was identified. The fraction with the retention time of 
36.2 min contained a species with m/z of 739.30. The latter m/z 
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corresponded to the single charged, 2AB-labeled S. Typhimurium 
subunit. The difference between these two masses corresponded 
42 Da, which is the mass difference between an O-acetyl and a 
hydroxyl group. These two species were subjected to collisionally 
induced dissociation (CID) MS-MS. The corresponding series of 
single charged fragment ions was consistent with glycosidic cleav-
age products from the 2AB-labeled S. Typhimurium subunit (Fig-
ure 3C and 3D). Furthermore, the series of single charged fragment 
ions beginning at m/z 781.3 and ending at m/z 301.13 seen in Fig-
ure 3C indicated the presence of an O-acetylated dideoxyhexose. 
The m/z 301.13 corresponded to a 2AB-labeled hexose, hence 
confirming its presence at the reducing end.
 Next, we co-expressed PglB (encoded in pGVXN114) and 
the engineered, His6-tagged acceptor protein EPA (toxoid vari-
ant of the Pseudomonas aeruginosa exotoxin A) in S. Typhimurium 
SL3749. As a negative control, we used cells harboring a pEXT21 
plasmid encoding the HA-tagged non-functional mutant version 
of PglB (PglBmut). After induction of PglB and the acceptor pro-
tein, EPA was purified from periplasmic extracts using affinity 
chromatography. Purified EPA was analyzed by SDS-PAGE and 
visualized by immunodetection (Figure 4A). A band corresponding 
to unglycosylated EPA (70 kDa) and a ladder of bands of higher 
molecular weight clustered between 100 and 170 kDa were detect-
ed. These bands reacted with anti-EPA antibodies, indicating the 
presence of modified forms of EPA. These larger polypeptides, but 
not the unmodified form of EPA, were also detected by the anti-
O5S.T. antiserum. The high molecular weight bands were absent in 
the sample purified from cells expressing PglBmut, suggesting the 
modification of EPA with the S. Typhimurium O-antigen (O5S.T.-
EPA).
 For further analysis, the glycoprotein was enriched and separated 
from the unmodified EPA using anion exchange chromatography. 
The protein samples were analyzed by SDS-PAGE and visualized 
by Coomassie blue staining or immunodetection (Figure 4B). Pres-
ence of a band that was recognized by anti-EPA, but not by an-
ti-O5S.T. antibodies confirmed that unglycosylated EPA was not 
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completely removed. However, most of the unmodified form was 
removed and based on the separation of the two species it was 
found that around 2 % of the total EPA was glycosylated. In ad-
dition to a ladder of bands clustered between 100 and 170 kDa, 
glycosylated forms of EPA were detected with a molecular weight 
clearly higher than 170 kDa as seen by Commassie blue staining 
and detection with an anti-O5S.T. antibody.
Analysis of EPA glycosylated 
with the S. Typhimurium O-antigen.
The purified glycoprotein and the unmodified EPA seen in Figure 
4B were subjected to high-mass MALDI ToF MS analysis (Figure 
5A). The molecular weight (MW) of the unmodified EPA (uEPA) 
was measured to be 68.78 kDa. The purified, glycosylated form 
of EPA (O5S.T.-EPA) had an average MW of 81.95 kDa. Fur-
thermore, low amounts of unmodified EPA were also detected 
in the O5S.T.-EPA sample, but most of the unmodified form was 
Figure 3: Analysis of the O-antigen expressed 
by Salmonella Typhimurium SL3749.
A   Proteinase K digested whole-cell samples were analyzed by Western blot, 
using an anti- S. Typhimurium O5 (O5S.T.) antibody. A bimodal distribution 
of the O-antigen chain length is seen: the long form (L) containing 16–35 
repeating units and the very long form (VL) consisting of >100 subunits. 
Deletion of wbaP in SL3749 (StGVXN1794) abolished O-antigen expression. 
B   Und-PP linked glycans were extracted from StGVXN2556 (SL3749, ǻwzy) 
and StGVXN1794 followed by 2AB labeling and separation by normal 
phase HPLC using a GlycoSep N column. The glycan structures detected  
in the O-antigen specific peaks are indicated. (white circle): hexose; (white 
right-pointing triangle): deoxyhexose;  (white upwards-pointing triangle)d: 
dideoxyhexose; Ac: acetyl. 
C   CID MS-MS spectra of the main species detected in the peak eluting  
at 24.1 min. 
D   CID MS-MS spectra of the main species detected in the 36.2 min peak.
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Figure 4: Glycosylation of EPA 
with the S. Typhimurium O5 polysaccharide. 
A   EPA was purified from S. Typhimurium SL3749 expressing PglB from 
pGVXN114 (wt) or PglBmut from pGVXN115 (mut). Purified proteins were 
analyzed by SDS-PAGE and after transfer to a nitrocellulose membrane 
visualized with antibodies directed against EPA or the S. Typhimurium O5 
polysaccharide (O5S.T.). 
B   EPA modified with the S. Typhimurium O5 polysaccharide (O5S.T.-EPA) was 
further purified using anion exchange chromatography. O5S.T.-EPA and  
the unmodified form of EPA (uEPA) were analyzed by SDS-PAGE followed by 
Coomassie blue staining or transfer to a nitrocellulose membrane and  
immunodetection with antibodies recognizing EPA, or the O5S.T. O-antigen. 
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successfully removed during anion exchange chromatography 
as previously seen in Figure 4B. No species of higher molecular 
weight were detectable in the O5S.T.-EPA sample. The difference 
in MW of the two protein samples therefore corresponds to the 
MW of the glycan moiety. By dividing the measured MW of the 
glycan by the calculated MW of an O-acetylated repeating unit of 
the S. Typhimurium O-antigen it was estimated, that the average 
length of the glycan attached to the protein consisted of around 
22 subunits. 
 Next, the purified proteins were analyzed using High Perfor-
mance Size Exclusion Chromatography (HPSEC). The chroma-
tograms of uEPA and the glycosylated O5S.T.-EPA are shown in 
Figure 5B. In HPSEC the unmodified EPA elutes as a sharp peak 
at 15.41 min, whereas the main species of the glycosylated form 
elutes at 13.16 min as a broad peak. Furthermore, the O5S.T.-
EPA displayed an additional peak eluting at 11.05 min indicating 
the presence of a larger species. Using a gel filtration standard, 
the MW of the differentially glycosylated species was determined. 
The MW of the unmodified EPA was calculated to be 70 kDa, 
whereas the O5S.T.-EPA main species had a MW of 202 kDa and 
the species eluting at 11.05 min had a MW of 548 kDa. The pres-
ence of two different species detected by HPSEC in the glycopro-
tein sample was apparently in conflict with the results obtained 
with high-mass MALDI ToF MS analysis where only a single spe-
cies with an MW of 81.95 kDa was detected. Furthermore, the 
MW of the glycoprotein determined by gel filtration was signifi-
cant higher as the one determined by MS which is mainly due to 
the rigid carbohydrate chain present in the glycoprotein, thereby 
drastically increasing its hydrodynamic volume.
 We hypothesized that the two species detected by HPSEC in 
the O5S.T.-EPA sample corresponded to the carrier protein modi-
fied with a carbohydrate polymer of a bimodal chain length distri-
bution. As seen in Figure 3A, S. Typhimurium expresses an O-an-
tigen with these characteristics: the long form (L) which consists 
of 16–35 repeating units and the very long form (VL) assembled 
of >100 subunits. 
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Figure 5: Analysis of the O5S.T.-EPA glycoprotein. 
A   High-mass MALDI ToF MS spectra of the O5S.T.-EPA and the unmodified 
EPA (uEPA). 
B   O5S.T.-EPA and uEPA were analyzed using High Performance Size  
Exclusion Chromatography (HPSEC). Two different species were detected 
in the O5S.T.-EPA sample. 
C   Analysis of the N-glycan, released from the glycoprotein by hydrazinolysis, 
followed by 2AB labeling and separation by normal phase HPLC using  
a GlycoSep N column. As a control, EPA modified with the Shigella flexneri 
2a polysaccharide 2aS.f.-EPA was used. The released N-glycan of the 2aS.f.-
EPA glycoprotein shows a modal, whereas the N-glycan of the O5S.T.- 
EPA conjugate displays a bimodal chain length distribution.
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 For characterization of the polysaccharide moiety in the gly-
coprotein the N-glycan was released by hydrazinolysis, followed 
by 2AB-labeling and separation by normal phase HPLC using a 
GlycoSep N column. In addition to the O5S.T.-EPA conjugate, a 
glycoprotein composed of EPA modified with the Shigella flexneri 
2a O-antigen (2aS.f.-EPA) was analyzed. The structure of the S. 
flexneri 2a O-antigen is seen in Figure 1. The 2aS.f.-EPA glycocon-
jugate was produced in an E. coli W3110 strain background by 
coexpression of the S. flexneri 2a O-antigen cluster together with 
PglB and EPA. In contrast to S. Typhimurium, E. coli W3110 pos-
sesses a single Wzz protein, which confers to a modal chain length 
distribution of 11–17 repeating units. The unmodified EPA was 
used as a negative control. The chromatograms of the released, 
2AB-labeled N-glycans are shown in Figure 5C. The S. flexneri 2a 
N-glycan showed a modal chain length distribution whereof gly-
cans differing in a single repeating unit could still be separated. 
In contrast, the chromatogram of the S. Typhimurium N-glycan 
displayed an additional peak eluting at around 170 min, which is 
not seen in the S. flexneri 2a N-glycan chromatogram and which 
is indicative for a bimodal distribution of O-antigen chain length. 
Therefore, PglB is able to transfer both O-antigen species differing 
in length to the carrier protein EPA.
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Discussion
The specificity of the bacterial oligosaccharyltransferase PglB 
from C. jejuni towards the glycan moiety of the LLO substrate 
was extensively studied. These studies have been conducted in vivo 
and are based on the following facts: (i) the bacterial N-linked gly-
cosylation system can be reconstituted in Escherichia coli and (ii) 
bacteria assemble a vast variety of glycan structures on the lipid 
carrier undecaprenyl pyrophosphate, thus representing potential 
substrates of the bacterial OST. The substrate specificity of PglB 
was studied in an engineered system by co-expressing a polysac-
charide biosynthetic gene cluster together with the bacterial OST 
and an acceptor protein. Especially the structural requirements of 
the reducing end saccharide, directly involved in recognition and 
catalysis, have been examined. As a result it has been postulated 
that Und-PP linked glycans containing an N-acetyl group at the 
C-2 of the reducing end saccharide solely serve as substrates for 
the bacterial OST. However, the N-linked protein glycosylation 
system reconstituted in E. coli did not reach the efficiency of gly-
cosylation observed in the natural host. Therefore, previous work 
describing the substrate specificities of PglB in vivo might be inac-
curate. 
 In this work the efficiency of glycosylation was improved pri-
or to examinations concerning the substrate specificities of PglB. 
Increasing the concentration of substrates by over-expressing the 
periplasmic acceptor protein did not improve glycosylation (re-
sults not shown). Another strategy to boost the formation of gly-
coprotein involves the increase of LLO substrate. It might well be 
that LLOs are present at sub-saturating concentrations because 
the pool of the carrier lipid Und-PP is limited. Over-expression 
of undecaprenyl pyrophosphate synthase (UPPS), which catalyzes 
the consecutive condensation reactions of farnesyl pyrophosphate 
with eight isopentenyl pyrophosphates to generate Und-PP might 
lead to higher concentrations of this key lipid. In this work we 
found that the availability of high levels of active PglB is a critical 
factor for efficient catalysis. In addition to the low copy plasmid 
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pEXT21, other plasmid backbones were tested for PglB expres-
sion. We found that the IPTG inducible tac promoter was superior 
to the arabinose inducible promoter. Furthermore, gene dosage 
constitutes an additional important factor. For example, expres-
sion of PglB encoded in the high copy plasmid pEXT20 contain-
ing the same expression cassette as pEXT21, had a contrary effect 
on glycosylation and no glycoprotein was detectable.
 This work shows that PglB is able to transfer an Und-PP linked 
glycan containing a reducing end galactose, but in case of the S. 
Typhimurium O-antigen, efficiency of glycosylation is lower com-
pared to other polysaccharides that have been tested. Around 2 % 
of the total extracted acceptor protein was glycosylated. In com-
parison, recombinant protein glycosylation with different O-anti-
gen structures containing a HexNAc at the reducing end resulted 
in modification of up to 60–70 % of the total extracted EPA. This 
study proves that the acetamido group at C-2 of the reducing end 
saccharide is not an essential requirement for PglB mediated trans-
fer. Therefore, the proposed mechanism for catalysis, where the 
C-2 N-acetyl group is involved in stabilizing the oxonium inter-
mediate after release of the pyrophosphate leaving group, is not 
plausible. However, due to the drastic difference in efficiency of 
glycosylation depending on the C-2 substitution of the reducing 
end sugar, it is likely that the acetamido group interacts with the 
OST enzyme through H-bonding. The substrate might thereby be 
bound and oriented properly in the active site for catalysis. The 
observed ability of PglB to transfer a glycan with a reducing end 
hexose opens up the possibility to engineer OST enzymes in order 
to improve the binding characteristics for such substrates. 
 Bacterial cell surface polysaccharides covalently linked to pro-
teins have been developed as vaccines. These so-called conjugate 
vaccines are amongst the most effective and safe vaccines against 
bacterial diseases and have been used in humans for over 30 years. 
For example, a dramatic reduction in invasive pneumococcal 
disease in children and infants was observed after implementing 
vaccination using a conjugate vaccine [190]. The pneumococ-
cal conjugate vaccine consists of the capsular polysaccharide of 
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Streptococcus pneumoniae (S. pneumoniae) covalently linked to the 
nontoxic diphtheria toxin CRM197. Prevnar, a pneumococcal vac-
cine developed by Wyeth (now Pfizer), is the world’s best selling 
vaccine with sales of $ 3.7 billion in 2010 (Pfizer annual report 
2010). However, the current vaccine covers only 13 of 90 different 
S. pneumoniae serotypes and an increase of infections caused by 
S. pneumoniae serotypes not covered by the 13-valent vaccine has 
been observed [191]. Novel vaccines that include new emerging 
strains are needed. The structure of most of the capsular polysac-
charides of S. pneumoniae serotypes has been elucidated. Around 
90 % of the serotypes contain a hexose at the reducing end. The 
extended substrate specificity of PglB described in this report will 
facilitate the development of novel pneumococcal vaccines.
Experimental procedures
Bacterial strains, plasmids, 
and culture conditions
All bacterial strains and plasmids used in this study are listed in 
Table I. Construction of the bacterial strains is described below. E. 
coli and S. Typhimurium strains were grown in LB medium (10 g 
tryptone, 5 g yeast extract, and 5 g NaCl per liter) or LB agar (LB 
medium with the addition of 15 g agar per liter) at 37 °C. If ap-
propriate, the media contained tetracycline (20 µg ml-1), spectino-
mycin (80 µg ml-1), trimethoprim (100 µg ml-1), chloramphenicol 
(30 µg ml-1) or ampicilin (100 µg ml-1).
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Strain Genotype or relevant description Reference
CLM24 Escherichia coli W3110; ǻwaaL [102]
SL3749 Salmonella enterica serovar Typhimurium LT2; 
pyre(+), waaL446
SGSC228*
StGVXN1794 SL3749; ǻwbaP This study
StGVXN2556 SL3749; ǻwzy This study
Plasmid Genotype or relevant description Reference
pMAF10 HA-tagged pglB cloned in pMLBAD,  
arabinose inducible, TmpR
[102]
pGVXN114 HA-tagged pglB cloned in pEXT21,  
IPTG inducible, SpR
[105]
pGVXN115 HA-tagged pglBmut encoding mutations W458A and 
D459A cloned in pEXT21, IPTG inducible, SpR
[105]
pACYC(pglmut) encodes the C. jejuni pgl cluster cloned in  
pACYC184, encoding mutations W458A and D459A 
in PglB, CmR
[101]
pGVXN64 encodes the S. dysenteriae O1 rfp and rfb gene 
clusters cloned into pLAFR1, TetR
[105]
pWA2 Soluble periplasmic His6-tagged acrA under control 
of tet promoter cloned in pBR322, AmpR
[102]
pGVXN150 Soluble periplasmic His6-tagged toxoid variant 
(L552V, ǻE553) of P. aeruginosa exotoxin A (EPA) 
containing two engineered N-glycosylation sites 
cloned in pEC415, arabinose inducible, AmpR
[105]
pKD46 Ȗ, ȕ and exo from Ȗ phage, araC-ParaB, AmpR [193]
pTOPO-DifCAT Template plasmid for inactivation of chromosomal ge-
nes, contains cat gene flanked by dif sites, KanR, ClmR
[192]
Table I
Strains and plasmids used in this study.
*  Salmonella Genetic Stock Centre,  
University of Calgary, Calgary, AL, Canada
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DNA manipulations
Restriction enzymes (Fermentas) and Phusion High-Fidelity 
DNA polymerase (Finnzyme) were used according to the manu-
facturer’s instructions. PCR products were purified using the Nu-
cleoSpin Extract II kit (Macherey-Nagel). All DNA sequencing 
was completed by Synergene Biotech GmbH (Switzerland) and 
synthetic oligonucleotides were ordered at Microsynth AG (Swit-
zerland).
Construction of bacterial strains
Deletion of the chromosomal genes wbaP and wzy in S. Typhimuri-
um LT2 strain SL3749 was done as described elsewhere [192,193]. 
Primers were designed containing 50 nucleotides of the 5’ ends 
homologous to the chromosomal regions adjacent to the gene 
targeted for deletion. In addition the primers (5’- TAATATGC-
CTATTTTATTTACATTATGCACGGTCAGAGGGTGAG-
GATTAAATCTGCAGAATTCGCCCTTACC and 5’- TTTT- 
ACGCAGGCTAATTTATACAATTATTATTCAGTAC-
TTCTCGGTAAGCAGTGTGCTGGAATTCGCCCTC 
used for wbaP deletion, 5’- TGCCTGATGGTAATATTTT-
TAATACTAAGCATTTTTTCTAAAGGCTCTATATCT-
GCAGAATTCGCCCTTACC and 5’- ATTTTTACGCTTCA-
GAGCCAAATAAAACGGCGGCATTGCCGCCGTATAA-
CAGTGTGCTGGAATTCGCCCTC used for wzy deletion) 
contained the underlined nucleotides that annealed to the template 
DNA from pTOPO-DifCAT, which carries a chloramphenicol 
resistance gene cat, flanked by dif (Xer recombinase recognition) 
sites. PCR products were purified, digested with DpnI, repuri-
fied and suspended in 5 mM Tris pH 8.5 prior to further usage. 
SL3749 was first transformed with plasmid pKD46, which pro-
vides the Ȝ Red gene functions for protection and integration of 
linear DNA placed under the control of the arabinose-inducible 
promoter PBAD. Transformants carrying pKD46 were grown over-
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night in 5 ml LB medium cultures with ampicillin at 30 °C in the 
shaker incubator. The overnight culture was diluted to an A600 of 
0.05 in 50 ml LB medium containing ampicillin and L-arabinose 
(0.2 % w/v). At an A600 of 0.6 the cells were harvested and then 
made competent by washing once in 50 ml, twice in 25 ml and once 
in 1 ml ice cold ddH2O. Finally, the cells were suspended in 200 µl 
of 10 % ice cold glycerol and the purified PCR products were in-
troduced by electroporation. Chloramphenicol resistant colonies 
were screened by PCR with primers annealing to regions outside 
of the mutated gene and tested for ampicillin sensitivity to test for 
loss of the helper plasmid pKD46. The cat gene was excised from 
the chromosome by culturing the integrants in 50 ml LB medium 
without chloramphenicol. After periods of 24 hours, dilution se-
ries were plated on LB agar and the culture was inoculated into 
fresh LB medium. Single colonies were tested for chloramphenicol 
sensitivity and excision of the cat gene was verified by PCR with 
primers annealing to regions outside of the deleted gene. Further-
more, the PCR product of the region containing the deleted gene 
was sequenced.
Analysis of undecaprenyl 
pyrophosphate (Und-PP) linked 
O-antigen glycans
By Western blot: Cells of an over night culture equivalent to an A600 
of 1 were collected, resuspended in 100 µl of 1x sample buffer ac-
cording to Laemmli and boiled at 95 °C for 10 min. Proteinase K 
(Fermentas) was added to a final concentration of 200 µg ml-1 
and the sample was incubated at 60 °C for 1 h. The LPS molecu-
lar species from the proteinase K digested whole cell lysates were 
separated by SDS-PAGE using a 12 % BisTris NuPAGE gel from 
Invitrogen and MES running buffer according to manufacturer’s 
instructions. Immunological properties of O-antigens were ana-
lyzed by western blot using standard methods. Anti- S. Typhimu-
rium O5 sera was purchased from the Statens Serum Institute 
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(SSI, Copenhagen, Denmark) and used in a 1:100 dilution.
 By 2AB labeling: The O-antigen glycans were analyzed in 
StGVXN2556 containing a chromosomal deletion in the O-antigen 
polymerase wzy and a mutation in the O-antigen ligase waaL. The 
O-antigen glycan deficient strain StGVXN1794 (SL3749, ǻwbaP) 
was used as a negative control to identify O-antigen specific sig-
nals. Starting cultures were grown overnight in a shake flask. The 
overnight cultures were diluted to an A600 of 0.05 in 400 ml LB 
medium. At an A600 of 1.0, cells were harvested and washed once 
with 0.9 % NaCl. The washed cell pellets were lyophilized. Lipids 
were extracted from the dried cells with 95 % methanol (MeOH) 
by repeated rounds of vortexing and incubation on ice for 10 min. 
The suspension was converted into 85 % MeOH by the addition 
of ddH2O and further incubated for 10 min on ice while regularly 
vortexing. After centrifugation, the supernatant was collected and 
the extract was dried under N2. The dried lipids were dissolved 
in 1:1 methanol/water (M/W) and subjected to a C18 SepPak car-
tridge (Waters). The cartridge was conditioned with 10 ml MeOH, 
followed by equilibration with 10 ml 10 mM TBAP in 1:1 M/W. Af-
ter loading of the sample, the cartridge was washed with 10 ml 10 
mM TBAP in 1:1 M/W and eluted with 5 ml MeOH followed by 
5 ml 10:10:3 chloroform/methanol/water (C/M/W). The combined 
elutions were dried under N2.
 The lipid sample were hydrolyzed according to Glover et al. 
[166] by dissolving the dried samples in 2 ml 1 M trifluoroacetic 
acid (TFA) in 50 % n-propanol and heating to 50 °C for 15 min. 
The hydrolyzed sample was dried under N2, dissolved in 4 ml 
3:48:47 C/M/W and subjected to a C18 SepPak cartridge (Waters) 
to separate the lipids from the hydrolyzed glycans. The cartridge 
was conditioned with 10 ml MeOH, followed by equilibration with 
10 ml 3:48:47 C/M/W. The sample was applied to the cartridge 
and the flow through was collected. The cartridge was washed with 
4 ml 3:48:47 C/M/W and the combined flow throughs were dried 
using a SpeedVac.
 The dried samples were labeled with 2-aminobenzamide (2AB) 
according to Bigge et al. [167]. The glycan cleanup was performed 
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using the paper disk method as described in Merry et al. [168]. 
The separation of 2AB labeled glycans was performed by HPLC 
using a GlycoSep N normal phase column according to Royle et 
al. [169], but modified to a three solvent system. Solvent A: 10 mM 
ammonium formate pH 4.4 in 80 % acetonitrile. Solvent B: 30 mM 
ammonium formate pH 4.4 in 40 % acetonitrile. Solvent C: 0.5 % 
formic acid. The column temperature was 30 °C and 2AB labeled 
glycans were detected by fluorescence (Ȝex= 330 nm, Ȝem= 420 
nm). Gradient conditions: A linear gradient of 100 % A to 100 % 
B over 160 min at a flow rate of 0.4 ml min-1, followed by 2 min 
100 % B to 100 % C, returing to 100 % A over 2 min and running 
for 15 min at 100 % A at a flow rate of 1 ml min-1, then returning 
the flow rate to 0.4 ml min-1 for 5 min. samples were injected in 
ddH2O.
 The O-antigen specific peaks were collected and 2AB glycans 
were analyzed on a MALDI SYNAPT HDMS Q-TOF system 
(Waters Corp., Milford, MA). Samples were dissolved in 5:95 ace-
tonitrile/water and spotted 1:1 with 20 mg ml-1 2,5-dihydroxyben-
zoic acid (DHB) in 80:20 methanol/water. Calibration was done 
with PEG (Ready mixed solution, Waters Corp., Milford, MA), 
spotted with 1:3 with 5 mg ml-1 Į-cyano-4-hydroxycinnamic acid 
(CHCA, Sigma-Aldrich) in 60:40:0.1 acetonitrile/water/trifluoro-
acetic acid. The instrument was equipped with 200 Hz solid state 
UV laser. Mass spectra were recorded in positive ion mode. For 
MSMS: laser energy was fixed at 240 at a firing rate of 200Hz, 
collision gas was argon, a collision energy profile was used to ramp 
collision energy depending on the m/z. All spectra were combined, 
background subtracted, smoothed (Savitzsky Golay) and centred 
using MassLynx v4.0 software (Waters Corp., Milford, MA).
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Production and purification 
of glycosylated AcrA
Production of glycoprotein was achieved by coexpressing acrA 
(pWA2), a gene cluster producing undecaprenyl-pyrophosphate 
(Und-PP) linked glycans (pACYC(pglmut) or pGVXN64), and 
the Campylobacter jejeuni oligosaccharyltransferase pglB (pMAF10 
or pGVXN114) in E. coli CLM24 cells. Cells were cultured in LB 
medium supplemented with antibiotics at 37 °C in the shaker incu-
bator (180 rpm). Shake flask expression cultures were inoculated 
from an uninduced overnight culture to an A600 of 0.05. Expres-
sion of PglB was induced at an A600 of 0.4–0.6 by the addition 
of either L-arabinose (0.2 % w/v in pMAF10 containing cells) or 
IPTG (1 mM in pGVXN114 containing cells). After induction 
at 37 °C for 4 h the cells were harvested by centrifugation and 
periplasmic proteins were extracted by osmotic shock extraction. 
Therefore, pellets were washed with 0.9 % NaCl and suspended in 
resuspension buffer (25 % sucrose, 10 mM EDTA, 200 mM Tris 
HCl pH 8.0) at a concentration equivalent to an A600 of 50. The 
cell suspension was incubated on a shaker for 20 min at 4 °C. After 
centrifugation the cell pellet was resuspended in the same volume 
of osmotic shock buffer (10 mM Tris HCl pH 8.0). The suspen-
sion was incubated on a shaker for 30 min at 4 °C and centrifuged 
at 10’000 g for 20 min to remove the spheroblasts. The superna-
tant containing the periplasmic proteins was collected and the hex-
ahistidine-tagged AcrA was purified by affinity chromatography. 
The periplasmic protein extract was diluted with 5x HT binding 
buffer (2.5 M NaCl, 150 mM Tris HCl pH 8.0, 50 mM imidazole) 
to optimize the binding conditions and MgCl2 was added to a final 
concentration of 50 mM. The extract was sterile filtered and ap-
plied to the HisTrap crude FF column equilibrated with 1x HT 
binding buffer and washed with the same buffer containing 20 
mM imidazole to remove unbound proteins. Proteins were eluted 
from the column with HT elution buffer (HT binding buffer con-
taining 0.5 M imidazole).
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Production and purification 
of EPA glycosylated with 
the S. Typhimurium O-antigen
pGVXN114 (encoding PglB) and pGVXN150 (encoding hexa-
histidine-tagged EPA) were co-transformed into S. Typhimurium 
LT2 strain SL3749. Cells were cultured in LB medium supple-
mented with antibiotics at 37 °C in the shaker incubator (180 
rpm). Shake flask expression cultures were inoculated from an 
uninduced overnight culture to an A600 of 0.05. The expression of 
pglB and epa was induced at an A600 of 0.4–0.6 by IPTG (1 mM) 
and L-arabinose (0.02 % w/v). Four hours after the first induction 
a second pulse of L-arabinose (0.02 % w/v) was added. Cells were 
harvested after overnight incubation (total induction time of 19-22 
h). The periplasmic proteins were extracted by osmotic shock ex-
traction and the hexahistidine-tagged EPA was purified by affinity 
chromatography as described above.
 After purification of EPA, the glycoprotein was separated from 
the unglycosylated form using a Resource Q column (GE Health-
care). The HisTrap elution fractions containing EPA were pooled 
and diluted 10x with RQ binding buffer (20 mM Tris HCl pH 
8.0). The diluted EPA sample was applied to the anion exchange 
column equilibrated with RQ binding buffer. The column was 
eluted with a linear gradient from 0 % to 32.5 % of RQ elution 
buffer (RQ binding buffer containing 1 M NaCl) in 25 column 
volumes and 0.5 ml fractions were collected using an Äkta FPLC 
(Amersham Biosciences). The fractions were analyzed by SDS-
PAGE and proteins were stained with Coomassie blue. Fractions 
containing glycoprotein were pooled and buffer was exchanged 
to 1x phosphate buffered saline, pH 7.5 (PBS) using an Amicon 
Ultra-4 centrifugal filter unit with a 30 kDa membrane (Millipore) 
by performing several concentration and dilution steps according 
to manufacturer’s instructions. The concentration of the final pu-
rified protein sample was adjusted to 1 mg ml-1 and was used for 
analytics.
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Western blotting
Western blotting was performed using standard methods. Anti-
AcrA antibodies are described in [8]. Antiserum against S. Ty-
phimurium O5 was obtained from Statens Serum Institute (SSI, 
Sopenhagen, Denmark) and used in a 1:100 dilution. Antiserum 
against EPA was obtained from Sigma (Switzerland, P2318). 
Anti-HA-tag antibodies were obtained from Sigma (Switzerland, 
H6908).
High-mass MALDI ToF MS 
analysis
Mass spectrometry of intact proteins was performed by CovalX 
(Zurich, Switzerland). The high mass measurements were per-
formed using a Reflex IV MALDI ToF mass spectrometer (Bruk-
er, Bremen, Germany) equipped with CovalX’s HM2 high-mass 
detector system. 
 Several dilutions of the protein were mixed 1:1 with a sinap-
inic acid matrix (10 mg ml-1, in acetonitrile/ water 1:1, 0.1 % trif-
luoracetic acid). 1 µl of each sample was spotted on the MALDI 
plate (SCOUT 384, AnchorChip). After cristallization at room 
temperature the plate was introduced in the MALDI mass spec-
trometer. The high mass MALDI ToF MS analysis has been per-
formed using the standard nitrogen laser and focusing on different 
ranges from 0 to 1200 kDa. Mass spectra were recorded in linear 
and positive mode. For the analysis the following parameters have 
been applied for the mass spectrometer: Ion source 1: 20 kV; Ion 
source 2: 17 kV; Lens: 12 kV; Pulse ion extraction: 400 ns. Cali-
bration was done with clusters of insulin, BSA and IgG. For each 
sample, 3 spots were analyzed (200 laser shots per spot). The pre-
sented spectrum corresponds to the sum of 200 laser shots. MS 
data were analyzed using Complex Tracker 2.0 analysis software.
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Molecular size determination 
of proteins by High Performance 
Size Exclusion Chromatography 
(HPSEC)
The molecular size of proteins was determined using a HPLC 
LaChrome Elite (Hitachi) equipped with a UV-VIS detec-
tor (L-2420). Samples were separated on a Supelco TSK-Gel 
G3000SWXL (Sigma/Supelco 808541) with a Supelco TSK-Gel 
SWXL (Sigma/Supelco 808543) guard column and detected by 
UV at 215 nm. The protein samples were diluted with 1x PBS, pH 
7.5 to a concentration of 100 µg ml-1 and 50 µl were injected. The 
column oven temperature was adjusted to 25 °C, and the sample 
was run at a flow rate of 0.6 ml min-1, isocratic in PBS, pH 7.5. 
To determine the void volume of the column the DNA molecular 
weight marker II (Roche, 102 3625 0001) was used and the reten-
tion time of the 23’130 bp fragment was measured. For determina-
tion of the inclusion volume the retention time of the sodium azide 
(Sigma, 71289) peak was measured. As a molecular size standard 
the MWGF1000 (29–669 kDa, Sigma, MWGF1000-1KT) di-
luted to 1.333 mg ml-1 in 1x PBS was used. 
Release of N-linked glycans 
by hydrazinolysis
N-glycans were released using the Ludger Liberate Hydrazinoly-
sis Glycan Release Kit (Ludger Ltd, LL-HYDRAZ-A2) accord-
ing to manufacturer’s instructions. The dried glycan samples were 
labeled with 2-aminobenzamide (2AB) according to Bigge et al. 
[167]. The glycan cleanup was performed using the paper disk 
method as described in Merry et al. [168]. The separation of 2AB 
labeled glycans was performed by HPLC using a GlycoSep N nor-
mal phase column as described above.
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General Discussion
The production of novel glycoconjugates using the bacterial N-
glycosylation system would enable the development of novel, cost 
efficient vaccines against diverse bacterial infections. In this thesis 
the feasibility of using this novel in vivo conjugation process for 
production of vaccines against Salmonella spp. infections was ex-
plored. As outlined in the introduction section, the antigenic cell 
surface polysaccharide structures of Salmonella are composed of 
the O and Vi antigens. Expression of O antigens is common to all 
Salmonella serovars, whereas expression of the Vi antigen, a capsu-
lar polysaccharide, is largely restricted to S. enterica serovar Typhi, 
the causative agent of typhoid fever. The O antigen structures of S. 
enterica serovars causing typhoidal and nontyphoidal salmonellosis 
in humans are closely related and share a common backbone. Even 
though these antigenic cell surface structures are validated targets 
for vaccine development, no commercial available conjugate vac-
cines exist to date. However, various conjugate vaccine candidates 
have been successfully tested in clinical trials and have been shown 
to be safe, immunogenic and effective [77-83,92,93,96,97]. 
 For the development of conjugate vaccines using the bacte-
rial N-glycosylation system, accessibility of these immunogenic 
cell surface polysaccharide structures to the bacterial oligosac-
charyltransferase PglB, the key enzyme forming the N-glycosidic 
linkeage, is fundamental. For being a glycan substrate for PglB 
several requirements have to be fulfilled: (i) the glycan has to be 
assembled on the lipid carrier undecaprenyl pyrophosphate (Und-
PP), (ii) during the biosynthetic pathway of the antigenic cell sur-
face polysaccharide structure a Und-PP linked glycan precursor 
has to be localized in the periplasmic leaflet of the bacterial inner 
cell membrane and (iii) the dogma exists that the reducing end 
saccharide of the Und-PP-linked glycan structure must contain 
an acetamido group at the C-2 position, thought to be crucial for 
catalysis [103].
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 The first part of this thesis deals with the development of a 
conjugate vaccine against typhoid fever. Such a vaccine is com-
posed of the Vi antigen bound to a carrier protein. The major-
ity of publications that deal with the Vi capsule focus on regula-
tion of expression during the different stages of infection and its 
contribution to the onset of typhoid fever. Little is known about 
the biosynthesis of the Vi capsule. Key aspects including initia-
tion, elongation, export and cell surface retention of this important 
polysaccharide structure remain equivocal and its accessibility to 
the bacterial OST is unresolved. Therefore, a molecular charac-
terization of the viaB locus encoding the biosynthetic machinery 
for Vi capsule formation has been done using E. coli as a surrogate 
system. The study provides a comprehensive phenotypic analysis 
of single gene transposon insertion mutants using diverse micro-
scopic and biochemical techniques. The work shows that despite 
sharing the basic mechanism also found for E. coli group 2 capsule 
assembly, biosynthesis of the Vi capsule displays features uniquely 
found in this cell surface polysaccharide structure. The viaB locus 
encodes a gene, vexE, containing an acyltransferase domain. Inac-
tivation of vexE resulted in a cell, which exports the polysaccharide 
to the outside but once translocated, the Vi is not retained at the 
cell surface and no capsule is formed. This phenotype has not yet 
been described for E. coli group 2 capsules nor do E. coli group 2 
capsular gene clusters encode genes with homologous functions. 
However, E. coli group 2 capsular gene clusters encode genes that 
are believed to be involved in CMP-Kdo synthesis and the specu-
lative addition of a diacylglycerophosphate-Kdo to the CPS. The 
presence of non-homologous genes encoded in the respective cap-
sular gene clusters might reflect a different mechanism of poly-
saccharide lipidation, resulting in a different structure that links 
the glycan to the cell surface. Identification of this lipid anchor is 
important in elucidating the biosynthetic pathway of this class of 
polysaccharides. A possible strategy to identify such a lipid modi-
fication, which is most likely present at the reducing end of the gly-
can polymer, involves the enzymatic degradation of purified Vi. A 
source for such enzymes might be found in phages using the Vi as 
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receptor. Analysis of the enzymatically degraded capsular polysac-
charide using mass spectrometry might result in the identification 
of the modified reducing end saccharide.
 Another important aspect of Vi biosynthesis is the initiation 
mechanism, i.e. the starting structure that is elongated. It remains 
equivocal if expression of the Vi antigen is dependent on genes en-
coded outside of the viaB locus. This seems to be a common char-
acteristic in bacterial glycan biosynthetic pathways as for example 
expression of the O antigen in E. coli strains is dependent on the 
initiating glycosyltransferase WecA, encoded in the enterobacterial 
common antigen (ECA) gene cluster. It might well be, that the 
biosynthetic machinery for Vi assembly is dependent on interme-
diates formed by other biosynthetic pathways. During this thesis, 
the viaB locus was expressed in several E. coli strains containing 
deletions in different cell surface glycan gene clusters, e.g. ECA lo-
cus, O antigen locus, colanic acid gene cluster. It was found that in 
all these mutant strains the Vi is expressed and that Vi expression 
is independent of all known initiating glycosyltrasferases resulting 
in Und-PP-linked sugars (results not shown). 
 Another approach to identify genes involved in Vi expression, 
which are encoded outside of the viaB locus, was based on a satu-
rating whole genome mutagenesis screen to detect S. Typhi genes 
that when inactivated by transposon insertion resulted in escape 
from killing by the lytic Vi bacteriophage, which binds to the Vi 
for initiating infection. The location of transposon insertions that 
resulted in escape from killing was determined by transposon di-
rected insertion site sequencing (TraDIS) (Pickard D, et al. manu-
script in preparation). The Vi phage based screening of a S. Typhi 
library resulted in the identification of several genes involved in 
Vi biosynthesis and cell surface localization of the capsular poly-
saccharide, a number of genes encoding regulators, and genes of 
unknown function. However, genes involved in Vi biosynthesis and 
cell surface localization were identified exclusively within the viaB 
locus and no additional genes with glycan metabolic functions 
were identified outside the viaB locus. This implies that either all 
of the necessary genes are encoded within the viaB locus or that 
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  essential or duplicated genes, which cannot be identified using this 
screening method, contribute to Vi capsule assembly. For instance 
it might be possible that the Vi biosynthetic machinery assembles 
the Vi polymer on the glycolipid intermediate undecaprenyl phos-
phate (Und-P)-glucose. Und-P-glucose is formed by GtrB, which 
is part of a prophage-encoded system involved in glucosylation 
of the O antigen and it is found in many other species like E. coli 
[112]. The gene product is proposed to catalyze the transfer of 
glucose from UDP-glucose to undecaprenyl phosphate (Und-P) 
at the cytosolic side of the inner membrane, resulting in the forma-
tion of Und-P-glucose [113,114]. The S. Typhi genome encodes 
two copies of gtrB and therefore it might not be identified as be-
ing involved in Vi biosynthesis by the whole genome mutagenesis 
approach. Interestingly, oxyR, which has been identified with the 
whole genome high-density mutagenesis screen, encodes a regula-
tor not only involved in Vi locus down regulation, but also in the 
down regulation of the gtr loci (Pickard D, personal communica-
tion).
 As outlined above, there are no indications that the Vi polymer 
is assembled on the lipid carrier Und-PP. Furthermore microscop-
ic studies of cells containing mutations in different parts of the Vi 
translocation machinery did not show periplasmic accumulations 
of the polysaccharide. Because these points are not fulfilled for 
the Vi antigen, it is not thought to be a substrate for PglB. There-
fore a different strategy was implemented for the development of 
a typhoid vaccine candidate using the bacterial N-glycosylation 
system by searching for Und-PP-linked glycan structures that con-
tained Vi epitopes. Such a structure was found in the O antigen of 
E. coli O121 [158,159]. It could be shown that a mutant variant of 
the O121 O antigen is recognized by anti Vi antibodies and there-
fore is cross-reactive with Vi. The glycoconjugate induced good 
antibody titers against wild type E. coli O121 O antigen. However 
the mutant O antigen, which cross-reacts with Vi, was not able to 
induce a significant anti Vi response. These results indicate that 
antigenic cross-reactivity might not be sufficient for the induc-
tion of a specific and functional antibody response against a na-
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tive virulence factor. The observation that the same animal, which 
did not induce anti E. coli O121 antibodies mounted an anti Vi 
response, might indicate that a very specific epitope (not cross-
reacting with O121 O antigen) must be presented to the immune 
system to drive the response against Vi. In order to improve an 
anti Vi immune response, the cross-reactive structure should be 
further optimized. For example by additionally deleting the gly-
cosyltransferase adding the Qui4NAcGly residue to the repeating 
unit of the O antigen (see Figure 1, page 91). This would result in a 
trisaccharide mimicking the Vi and containing fewer O121 specific 
epitopes. Furthermore this lipid-linked glycan intermediate might 
represent a starting structure for the processive glycosyltransferase 
encoded within the viaB locus, which might elongate the trisac-
charide resulting in an Und-PP-linked Vi antigen. Once the engi-
neered Vi antigen is flipped to the periplasm it would be accessible 
to the oligosaccharyltransferase.
 In the second part of this thesis the in vivo production of gly-
coconjugates consisting of the S. enterica O antigen bound to a 
protein carrier was investigated. In contrast to the Vi antigen, the 
biosynthetic pathway of O antigen assembly has been elucidated 
[110]. This class of cell surface glycan structures is assembled on 
Und-PP and periplasmic intermediates exist. However, a com-
monality of the O antigens expressed by different important S. 
enterica serovars causing human illnesses is a galactose at the re-
ducing end of the O antigen subunit. It has been reported that 
glycan structures containing a hexose at the reducing end are not 
transferred by the bacterial OST due to the lack of the acetamido 
group at C-2, which was thought to be essential for catalysis [103]. 
Nonetheless, it was shown in this work that the O antigen of S. 
Typhimurium was transferred to acceptor proteins upon optimi-
zation of recombinant PglB expression. Therefore, the acetamido 
group at C-2 of the reducing end saccharide is not an essential 
requirement for PglB mediated transfer. This important observa-
tion creates the opportunity to develop novel conjugate vaccines 
against several S. enterica serovars expressing closely related O spe-
cific polysaccharide structures, e.g. S. Paratyphi A. As outlined in 
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the introduction, the lack of effective vaccines against S. Paratyphi 
A is of great concern because this serotype appears to be respon-
sible for a growing proportion of enteric fever. Implementation 
of vaccination against S. Typhi aggravated this trend and it raised 
concerns whether the introduction of a vaccine against S. Typhi, 
in the absence of a vaccine against S. Paratyphi A, has any impact 
at all on enteric fever. Conjugate vaccine candidates consisting of 
the S. Paratyphi A O antigen bound to tetanus toxoid were shown 
to be safe and immunogenic in humans [92,93]. Production of 
conjugate vaccines consisting of the O antigen bound to carrier 
proteins is a complex process due to the additional detoxification 
step of the LPS prior to chemical coupling. Additionally, the S. 
Paratyphi A O antigen contains immunodominant O-acetyls that 
might be lost during chemical conjugation. The in vivo conjugation 
technology could overcome these difficulties, making S. Paratyphi 
A the ideal candidate for vaccine development.
 Even though the lack of a N-acetyl group at the reducing end 
of the glycan substrate does not make PglB mediated catalysis 
impossible, it has a dramatic effect on transfer efficiency. There-
fore it is crucial to improve the transfer efficiency of this class of 
glycan structures first prior to vaccine development. This might 
be achieved by optimizing the fermentation conditions of the gly-
coconjugate production strain. Different parameters have to be 
screened that improve optimal expression of all components of the 
in vivo conjugation process. Additionally, due to the fact that the 
acetamido group at C-2 is not essential for the catalytic mecha-
nism, PglB could be optimized for transferring this class of gly-
can structures by a directed evolution approach. Therefore a high 
throughput screening method has to be implemented. Improving 
the glycosylation efficiency would enable the further optimization 
of immunogenic glycoconjugates.
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